As
filed with the Securities and Exchange Commission on May 2, 2018
Registration
No. 333-
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
S-4
REGISTRATION
STATEMENT
UNDER
THE
SECURITIES ACT OF 1933
CARDAX,
INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
2834
|
|
45-4484428
|
(State
of
incorporation)
|
|
(Primary
Standard Industrial
Classification Code Number)
|
|
(I.R.S.
Employer
Identification Number)
|
2800
Woodlawn Drive, Suite 129
Honolulu,
Hawaii 96822
(808)
457-1400
(Address,
including zip code, and telephone number, including area code, of registrant’s principal executive offices)
David
G. Watumull
President and Chief Executive Officer
Cardax,
Inc.
2800
Woodlawn Drive, Suite 129
Honolulu,
Hawaii 96822
(808)
457-1400
(Name,
address, including zip code, and telephone number, including area code, of agent for service)
Copies
to:
Richard
M. Morris, Esq.
Herrick,
Feinstein LLP
2 Park Avenue
New
York, New York 10016
(212)
592-1400
Approximate
date of commencement of proposed sale to the public:
As soon as practicable after the effective date of this Registration
Statement.
If
the securities being registered on this Form are being offered in connection with the formation of a holding company and there
is compliance with General Instruction G, check the following box. [ ]
If
this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the
following box and list the Securities Act registration statement number of the earlier effective registration statement for the
same offering. [ ]
If
this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list
the Securities Act registration statement number of the earlier effective registration statement for the same offering. [ ]
Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,”
“smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
|
Large
accelerated filer [ ]
|
Accelerated
filer [ ]
|
|
Non-accelerated
filer [ ] (Do not check if a smaller reporting company)
|
Smaller
reporting company [X]
|
|
Emerging
growth company [X]
|
|
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act
[ ]
If
applicable, place an X in the box to designate the appropriate rule provision relied upon in conducting this transaction:
|
Exchange
Act Rule 13e-4(i) (Cross-Border Issuer Tender Offer) [ ]
|
|
Exchange
Act Rule 14d-1(d) (Cross-Border Third-Party Tender Offer) [ ]
|
CALCULATION
OF REGISTRATION FEE
Title
of each class of securities to be registered
|
|
Amount
to be
Registered
(1)
|
|
|
Proposed
maximum
offering price
per
share
(2)
|
|
|
Proposed
maximum
aggregate
offering
price
(3)
|
|
|
Amount
of
registration fee
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common
Stock, $0.001 par value per share, to be issued in the exchange offer
(4)
|
|
|
27,705,782
shs.
|
|
|
$
|
0.31
|
|
|
$
|
8,630,351.09
|
|
|
$
|
1,074.48
|
|
(1)
|
Pursuant
to Rule 416 under the Securities Act of 1933, this registration statement will cover
such indeterminate number of shares of our common stock, par value $0.001 per share (“
common
stock
”), that may be issued with respect to stock splits, stock dividends,
and similar transactions.
|
|
|
(2)
|
Estimated
solely for purposes of computing the amount of the registration fee pursuant to Rule
457(c) under the Securities Act of 1933, computed based upon the average of the bid
and ask price per share of our common stock on May 1, 2018 on the
OTCQB.
|
|
|
(3)
|
This
amount represents the maximum aggregate value of the Exchange Shares.
|
|
|
(4)
|
Represents
the maximum number of our common stock to be issued to holders of the registrant’s outstanding warrants pursuant to
the exchange offer described in the offer letter/prospectus to which this registration statement relates.
|
The
Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until
the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become
effective in accordance with Section 8(a) of the Securities Act of 1933 or until the Registration Statement shall become effective
on such date as the Commission, acting pursuant to said Section 8(a), may determine.
The
information in this prospectus is not complete and may be changed. We may not sell these securities until the registration statement
filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and it
is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.
Subject
to Completion
Preliminary
Prospectus May 2, 2018
P
R O S P E C T U S
Effective
date
Offer
to Exchange
Each
$0.625 Warrant to purchase shares of Common Stock
and
$0.15
in cash
for
Shares
of Common Stock
THE
OFFER WILL EXPIRE AT 5:00 P.M., NEW YORK CITY TIME, ON THE DATE THAT IS 20 BUSINESS DAYS AFTER THE EFFECTIVE DATE OF THIS REGISTRATION
STATEMENT, UNLESS THE OFFER IS EXTENDED.
We
hereby offer to exchange, upon the terms and subject to the conditions set forth in this offer to exchange and in the related
letter of transmittal, each issued and outstanding warrant that provided the holder to purchase a share of common stock at $0.625
per share (each, an “
Original Warrant
”) and payment by the holder of $0.15 in cash (the “
Exchange
Payment
”), at the election of the holder, for one share of our common stock (an “
Exchange Share
”).
We
will accept for exchange any and all Original Warrants validly tendered at any time prior to 5:00 p.m., New York City time, during
the period (the “
Exchange Period
”) beginning on the effective date of this Registration Statement, and
continuing until the date (the “
Expiration Date
”) that is 20 business days after the effective date, unless
extended by us. We will issue the Exchange Shares on a continuous basis pursuant to Rule 415 of the Securities Act of 1933 as
amended (“
Securities Act
”) during the Exchange Period.
We
will accept for exchange any Original Warrant held by any person other than the original holder if such Original Warrant is transferred
in accordance with the terms of the Original Warrant and applicable federal and state securities laws. See “General Terms
of Exchange Offer–Transfer of Original Warrants.”
We
are making this offer upon the terms and subject to the conditions described in this prospectus and in the related letter of transmittal
(which together, as they may be amended from time to time, constitute the “
Exchange Offer
”).
Our
common stock is traded on the OTCQB under the symbol CDXI. On May 1, 2018, the last reported sale price for our common
stock was $0.34 per share.
|
|
Per
New
Warrant Share
|
|
|
Total
(1)
|
|
Exchange
Payment
|
|
$
|
0.15
|
|
|
$
|
4,155,867
|
|
Financial
Advisor fee
(2)
|
|
$
|
0.00525
|
|
|
$
|
145,455
|
|
Solicitation
Agent fee
(3)
|
|
$
|
0.00645
|
|
|
$
|
178,702
|
|
Proceeds
to us, before expenses
|
|
$
|
0.1383
|
|
|
$
|
3,831,710
|
|
(1)
Assumes that all 27,705,782 Original Warrants are exchanged in the Exchange Offer.
(2)
In connection with the Exchange Offer, we have agreed to pay M.M. Dillon & Co., the Financial Advisor for this Exchange Offer,
a cash fee of 3.5% of the gross proceeds from the Exchange Offer and a 5-year common stock purchase warrant with a fair market
value equal to 3.5% of the gross proceeds from the Exchange Offer, based on a Black-Scholes valuation as of the day immediately
prior to the filing date of the initial registration statement in connection with the Exchange Offer. See “General Terms
of Exchange Offer–Fees and Expenses” and “Solicitation Agents” for a description of compensation
payable to the Financial Advisor.
(3)
In connection with the Exchange Offer, we have agreed to pay CIM Securities, the Solicitation Agent for this Exchange Offer, a
cash fee of 4.3% of the gross proceeds from the Exchange Offer and a 5-year common stock purchase warrant with a fair market value
equal to 3.5% of the gross proceeds from the Exchange Offer, based on a Black-Scholes valuation as of the day immediately prior
to the filing date of the initial registration statement in connection with the Exchange Offer. See “General Terms of Exchange
Offer–Fees and Expenses” and “Solicitation Agents” for a description of compensation payable to
the Solicitation Agent.
These
are speculative securities. Please read the “Risk Factors” section beginning on page 8 of this prospectus before
making a decision to invest in our common stock.
We
are an “emerging growth company” as defined under the federal securities laws and, as such, may elect to comply with
certain reduced public company reporting requirements for future filings.
Neither
the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or
determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
The
Financial Advisor for this Exchange Offer is
M.M.
DILLON & CO.
The
Solicitation Agent for this Exchange Offer is
CIM
SECURITIES
The
date of this prospectus is
, 2018
We
Are Not Asking You for a Proxy and You are Requested To Not Send Us a Proxy
TABLE
OF CONTENTS
BASIS
OF PRESENTATION
Unless
otherwise noted, references in this prospectus to “Cardax,” the “Company,” “we,” “our,”
or “us” means Cardax, Inc., the registrant, and, unless the context otherwise requires, together with its wholly-owned
subsidiary, Cardax Pharma, Inc., a Delaware corporation (“
Pharma
”), and Pharma’s predecessor, Cardax
Pharmaceuticals, Inc., a Delaware corporation (“
Holdings
”), which merged with and into Cardax, Inc. on December
30, 2015.
FORWARD-LOOKING
STATEMENTS
There
are statements in this prospectus that are not historical facts. These “forward-looking statements” can be identified
by use of terminology such as “anticipate,” “believe,” “estimate,” “expect,” “hope,”
“intend,” “may,” “plan,” “positioned,” “project,” “propose,”
“should,” “strategy,” “will,” or any similar expressions. You should be aware that these forward-looking
statements are subject to risks and uncertainties that are beyond our control. For a discussion of these risks, you should read
this entire prospectus carefully, especially the risks discussed under the section entitled “Risk Factors.” Although
we believe that our assumptions underlying such forward-looking statements are reasonable, we do not guarantee our future performance,
and our actual results may differ materially from those contemplated by these forward-looking statements. Our assumptions used
for the purposes of the forward-looking statements specified in the following information represent estimates of future events
and are subject to uncertainty as to possible changes in economic, legislative, industry, and other circumstances, including the
development, acceptance and sales of our products and our ability to raise additional funding sufficient to implement our strategy.
As a result, the identification and interpretation of data and other information and their use in developing and selecting assumptions
from and among reasonable alternatives require the exercise of judgment. In light of these numerous risks and uncertainties, we
cannot provide any assurance that the results and events contemplated by our forward-looking statements contained in this prospectus
will in fact transpire.
These forward-looking statements are not guarantees of future performance. You are cautioned to not
place undue reliance on these forward-looking statements, which speak only as of their dates.
We do not undertake any obligation
to update or revise any forward-looking statements, except as required by law.
CAUTIONARY
NOTE REGARDING INDUSTRY DATA
Unless
otherwise indicated, information contained in this prospectus concerning our company, our business, the services we provide and
intend to provide, our industry and our general expectations concerning our industry are based on management estimates. Such estimates
are derived from publicly available information released by third party sources, as well as data from our internal research, and
reflect assumptions made by us based on such data and our knowledge of the industry, which we believe to be reasonable.
This
document incorporates by reference important business and financial information about the Company from documents that are not
included in or delivered with this prospectus. These documents are available without charge to security holders of the Company
upon written or oral request at the address and telephone number listed below:
David
G. Watumull
c/o
Cardax, Inc.
2800
Woodlawn Drive, Suite 129
Honolulu,
Hawaii 96822
(808)
457-1400
Please
be sure to include your complete name and address in your request. Please see “Where You Can Find Additional Information”
to find out where you can find more information about Cardax, Inc.
Prospectus
Summary
This
summary highlights information contained elsewhere in this prospectus. This summary may not contain all of the information that
may be important to you. You should read the entire prospectus carefully together with our financial statements and the related
notes appearing elsewhere in this prospectus before you decide to invest in our common stock. This prospectus contains forward-looking
statements, which involve risks and uncertainties. Our actual results could differ materially from those anticipated in such forward-looking
statements as a result of certain factors, including those discussed under the heading “Risk Factors” and other sections
of this prospectus.
Our
Business and Strategy
Overview
We
are a life sciences company engaged in the development, marketing, and distribution of consumer health products and we are a smaller
reporting company as defined by applicable federal securities regulations.
We
were incorporated on January 30, 2012, as a Delaware corporation, under the name “Koffee Korner Inc., and later changed
our name to Cardax, Inc. in a February 7, 2014 reverse merger (the “
Merger
”) that acquired the life sciences
business of Pharma. On the effective date of the Merger, we divested our coffee business and now exclusively continue Pharma’s
life sciences business. On December 30, 2015, our former principal stockholder, Holdings, merged with and into us.
Our
Business
We
are a life sciences company engaged in the development, marketing, and distribution of consumer health products. We believe we
are well positioned for significant and sustained growth via the commercialization of consumer health products utilizing synthetically
manufactured astaxanthin and related xanthophyll carotenoids, which support health and longevity by reducing inflammation at the
cellular and mitochondrial level without inhibiting normal function. We may also pursue the development of astaxanthin and related
xanthophyll carotenoids for pharmaceutical applications. The safety and efficacy of our products have not been directly evaluated
in clinical trials or confirmed by the U.S. Food and Drug Administration (the “FDA”).
Our
Products
ZanthoSyn®
is marketed as a novel astaxanthin dietary supplement with superior absorption and purity. Astaxanthin is a naturally occurring
molecule with safe anti-inflammatory activity that supports joint health, cardiovascular health, metabolic health, liver health,
and longevity. The form of astaxanthin utilized in ZanthoSyn® has demonstrated excellent safety in peer-reviewed published
studies and is Generally Recognized as Safe (“GRAS”) according to FDA regulations.
We
sell ZanthoSyn® primarily through e-commerce and wholesale channels. We launched our e-commerce channel in August 2016 and
began selling to General Nutrition Corporation (“GNC”) stores in Hawaii on January 25, 2017 and GNC corporate stores
across the United States on August 10, 2017. ZanthoSyn® is currently available at over three thousand GNC corporate stores
in the United States. ZanthoSyn® was the top selling product at GNC stores in Hawaii during the fourth quarter of 2017. We
have also sold ZanthoSyn® on a wholesale basis to Health Elite Club Limited, a Hong Kong-based company.
Our
ZanthoSyn® product manufacturing process relies on certain third-party suppliers and this dependence creates several risks,
including limited control over pricing, availability, quality, and delivery schedules. In addition, any supply interruption could
materially harm our ability to manufacture ZanthoSyn® until a new source of supply is obtained on acceptable terms. We may
be unable to find such other sources in a reasonable time period or on commercially reasonable terms, if at all, which would have
an adverse effect on our business, financial condition and results of operations.
We
market ZanthoSyn® primarily through a two-pronged approach:
|
●
|
Physician
outreach and education, where ZanthoSyn
®
is positioned as the first safe, physician friendly, anti-inflammatory
for health and longevity, and GNC serves as a convenient and credible distribution channel for physicians recommending ZanthoSyn
®
|
|
|
|
|
●
|
GNC
store outreach, education, and in-store sales support, building on the ability to utilize ZanthoSyn
®
as a foundation
of health, wellness, and performance regimens
|
Our
sales and marketing program was initially launched in Hawaii, where robust physician outreach and education coupled with GNC store
outreach, education, and in-store sales support increased consumer awareness and catalyzed strong sales growth. We have also launched
this program in major markets in California and expect to extend this program nationally as resources permit. To support these
efforts, we have hired additional sales and marketing personnel.
We
may also conduct human clinical trials with astaxanthin and are currently evaluating various opportunities. While the FDA
does not require human clinical trials for consumer health products, we believe that positive results from human clinical trials
would promote scientific and consumer awareness of astaxanthin’s health and longevity applications.
As
a next generation ZanthoSyn® product, we are developing CDX-085, our patented astaxanthin derivative for more concentrated
astaxanthin product applications. In collaboration with the University of Hawaii, we demonstrated that astaxanthin through administration
of CDX-085 activated an important anti-aging gene in rodents. Following these results, the National Institutes of Health selected
CDX-085 for an important anti-aging research program.
Synthetic
Astaxanthin vs. Natural Astaxanthin
We
believe synthetic astaxanthin offers significant advantages compared to astaxanthin from microalgae, krill, or other sources:
|
●
|
Synthetic
astaxanthin can be formulated for superior bioavailability; in a human study comparing ZanthoSyn® (our synthetic astaxanthin
dietary supplement) to a leading microalgal astaxanthin product, the astaxanthin blood levels following administration of
ZanthoSyn® were nearly 3 times higher than the microalgal astaxanthin product at the same dose.
|
|
|
|
|
●
|
Synthetic
astaxanthin has been extensively tested in a battery of toxicity studies, including acute, subacute, subchronic, and chronic
toxicity studies, carcinogenicity studies, genotoxicity studies, and developmental and reproductive toxicity studies; whereas
to our knowledge microalgal or other sources of astaxanthin have not undergone the same amount of safety testing in such toxicity
studies.
|
|
|
|
|
●
|
Synthetic
astaxanthin is manufactured with superior purity and precision, whereas astaxanthin extracted from microalgae and krill oil
is obtained in a complex mixture, which may include many unknown marine byproducts.
|
|
|
|
|
●
|
Synthetic
manufacture of astaxanthin is scalable, whereas we believe the ability to readily scale the production and extraction of astaxanthin
from microalgae or other sources will be limited as demand for astaxanthin grows.
|
|
|
|
|
●
|
Synthetic
manufacture of astaxanthin emits fewer greenhouse gases and consumes less energy, raw material, and land than traditional
microalgal astaxanthin production.
|
Pharmaceutical
Development
We
may pursue the development of astaxanthin and related xanthophyll carotenoids for pharmaceutical applications and are currently
evaluating the feasibility of targeting rare diseases or conditions under the FDA’s orphan drug program.
Corporate
Information
Our
common stock is traded on the OTCQB under the trading symbol “CDXI”. We are a Delaware corporation that acquired our
life science business through a merger with Cardax Pharma, Inc., a Delaware corporation, on February 7, 2014.
Our
executive offices are located at 2800 Woodlawn Drive, Suite 129, Honolulu, Hawaii 96822; our telephone number is (808) 457-1400.
Our website is located at http://www.cardaxpharma.com. The information on our website is not part of this prospectus.
Emerging
Growth Company Status
We
are an “emerging growth company” as defined under the Jumpstart Our Business Startups Act, common referred to as the
“JOBS Act.” We will remain an “emerging growth company” for up to five years, or until the earliest of
(i) the last day of the fiscal year in which our total annual gross revenues exceed $1 billion, (ii) the date that we become a
“large accelerated filer” as defined I Rule 12b-2 under the Securities Exchange Act of 1934, which would occur if
the market value of our ordinary shares that is held by non-affiliates exceeds $700 million as of the last business day of our
most recently completed second fiscal quarter, or (iii) the date on which we have issued more than $1 billion in non-convertible
debt during the preceding three year period.
As
an “emerging growth company,” we may take advantage of certain exemptions from various reporting requirements that
are applicable to other public companies that are not “emerging growth companies” including, but not limited to:
|
●
|
not
being required to comply with the auditor attestation requirements of Section 404(b) of the Sarbanes-Oxley Act (we will also
not be subject to the auditor attestation requirements of Section 404(b) as long as we are a “smaller reporting company,”
which includes issuers that had a public float of less than $75 million as of the last business day of their most recently
completed second fiscal quarter);
|
|
|
|
|
●
|
reduced
disclosure obligations regarding executive compensation in our periodic reports and proxy statements; and
|
|
|
|
|
●
|
exemptions
from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden
parachute payments not previously approved.
|
In
addition, Section 107 of the JOBS Act provides that an “emerging growth company” can take advantage of the extended
transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards.
Under this provision, an “emerging growth company” can delay the adoption of certain accounting standards until those
standards would otherwise apply to private companies. However, we are choosing to “opt out” of such extended transition
period, and as a result, we will comply with new or revised accounting standards on the relevant dates on which adoption of such
standards is required for non-emerging growth companies. Section 107 of the JOBS Act provides that our decision to opt out of
the extended transition period for complying with new or revised accounting standards is irrevocable.
Summary
of Risk Factors
Our
business is subject to numerous risks, as more fully described in the section entitled “Risk Factors” immediately
following this prospectus summary. You should read these risks before you invest in our common stock. In particular, our risks
include, but are not limited to, the following:
|
●
|
We
have a history of operating losses and have received a going concern opinion from our auditors.
|
|
|
|
|
●
|
We
have limited experience as a commercial company.
|
|
|
|
|
●
|
We
are dependent upon the success of our lead astaxanthin technologies, which may not be successfully commercialized.
|
|
|
|
|
●
|
We
operate in highly competitive industries, and our failure to compete effectively could adversely affect our market share,
financial condition and growth prospects. If competitors are better able to develop and market products that are more effective,
or gain greater acceptance in the marketplace than our products, our commercial opportunities may be reduced or eliminated.
|
|
●
|
If
we fail to comply with FDA regulations our business could suffer.
|
|
|
|
|
●
|
We
may rely on third-party distributors for sales, marketing and distribution activities.
|
|
|
|
|
●
|
We
may be subject to product liability claims. Our insurance may not be sufficient to cover these claims, or we may be required
to recall our products.
|
|
|
|
|
●
|
If
we are unable to obtain and maintain protection of our intellectual property, the value of our products may be adversely affected.
|
|
|
|
|
●
|
Our
operating results may fluctuate, which may result in volatility of our share price.
|
|
|
|
|
●
|
If
we are unable to manage our expected growth, our future revenue and operating results may be adversely affected.
|
|
|
|
|
●
|
We
are highly dependent on our senior management, and if we are not able to retain them or to recruit and retain additional qualified
personnel, our business will suffer.
|
|
|
|
|
●
|
Our
ability to grow and compete in the future will be adversely affected if adequate capital is not available to us or not available
on terms favorable to us.
|
|
|
|
|
●
|
Our
common stock has a limited trading market, which could affect your ability to sell shares of our common stock and the price
you may receive for our common stock.
|
|
|
|
|
●
|
Future
sales of our common stock in the public market could lower the price of our common stock and impair our ability to raise funds
in future securities offerings.
|
|
|
|
|
●
|
We
are subject to penny stock regulations and restrictions and you may have difficulty selling shares of our common stock.
|
|
|
|
|
●
|
We
are registering an aggregate of 27,705,782 Exchange Shares which may be issued pursuant to the Exchange Offer. The sale of
such shares could depress the market price of our common stock.
|
The
Exchange Offer
We
are making the Exchange Offer primarily to raise capital from holders of our existing warrants to purchase Exchange Shares. We
believe that by allowing holders of Original Warrants to exchange such Original Warrants for Exchange Shares, the Company can
raise additional capital in an efficient and cost-effective manner.
There
are 27,705,782 Original Warrants outstanding. Each Original Warrant provides the holder the right to purchase a share of our common
stock at a price equal to $0.625 per share, subject to certain specified adjustments for changes or reclassifications to our common
stock. The Original Warrants expire February 7, 2019 (five years from the date of issuance).
The
Original Warrants were issued on February 7, 2014, as follows:
|
●
|
6,276,960
were issued upon the consummation of the Merger in connection with the private placement of shares of our common stock and
Original Warrants for aggregate gross cash proceeds of $3,923,100;
|
|
|
|
|
●
|
17,768,377
were issued upon the consummation of the Merger in connection with the conversion of unsecured promissory notes issued by
our predecessor Cardax Pharma, Inc. in the aggregate principal amount of $10,565,036 plus all accrued interest thereon into
our common stock and Original Warrants; and
|
|
|
|
|
●
|
3,660,445
were issued upon the consummation of the Merger to placement agents and other service providers.
|
The
Merger and the issuance of the Original Warrants are described in the Current Report on Form 8-K, filed by us February 10, 2014.
We
are now permitting all holders of the Original Warrants to tender their Original Warrants and receive the Exchange Shares through
this Exchange Offer, subject to a payment of $0.15. You should read the discussions under the headings “General Terms
of the Exchange Offer,” and “Description of Securities,” respectively, for more information about the Exchange
Offer, and the Exchange Shares.
The
Exchange Offer
|
|
During
the Exchange Period,
holders can tender Original Warrants and the Exchange Payment, in exchange for an Exchange Share. A holder may tender
as few or as many Original Warrants as the holder elects. All Original Warrants that are not tendered prior to the Expiration
Date, or, or for any reason, not accepted by us, will continue to be outstanding according to their terms unmodified. We
will issue the Exchange Shares on a continuous basis during the Exchange Period.
|
|
|
|
Price
|
|
The
cost to you for participating in this Exchange Offer is $0.15 per share. See “General Terms of the Exchange Offer—Fees
and Expenses”.
|
|
|
|
Expiration
Date
|
|
The
Exchange Offer will expire on the Expiration Date, which is at 5:00 p.m., New York City time, on the date that is 20 business
days after the effective date of this Registration Statement, unless extended by us at our sole discretion.
|
|
|
|
Procedure
for Participating in the Exchange Offer
|
|
In
all cases, the issuance of Exchange Shares pursuant to the Exchange Offer will be made
only after timely receipt by the Exchange Agent of the Original Warrants and the Letter
of Transmittal properly completed and duly executed and any required signature guarantees
and other documents required by the Letter of Transmittal, and timely receipt by the
Company of the Exchange Payment.
By
signing or agreeing to be bound by the Letter of Transmittal and other required documents, you will represent to us that,
among other things:
|
|
●
|
any
Exchange Shares that you receive will be acquired in the ordinary course of your business or for your own personal investment;
|
|
|
|
|
●
|
you
have no arrangement or understanding with any person to participate in the distribution of the Exchange Shares;
|
|
|
|
|
●
|
you
are not our “affiliate,” as defined in Rule 405 under the Securities Act;
|
|
|
|
|
●
|
if
you are not a broker-dealer, you are not engaged in and do not intend to engage in the distribution of the Exchange Shares;
and
|
|
|
|
|
●
|
if
you are a broker-dealer, that you will receive Exchange Shares for your own account in exchange for Original Warrants that
were acquired as a result of market-making activities or other trading activities and that you will deliver a prospectus in
connection with any resale of such Exchange Shares.
|
Procedures
for Tendering Original Warrants Through a Custodian
|
|
If
you are a beneficial owner of Original Warrants, but the holder of such Original Warrants is a custodial entity such as a
bank, broker, dealer, trust company or other nominee, and you seek to tender your Original Warrants pursuant to the Exchange
Offer, you must provide appropriate instructions to such holder of the Original Warrants.
|
|
|
|
Return
of Original Warrants
|
|
If
we do not accept any Original Warrants tendered in the Exchange Offer for any reason described in the terms and conditions
of the Exchange Offer, we will return such Original Warrants without expense to the exercising holder.
|
|
|
|
Conditions
to the Exchange Offer
|
|
The
Exchange Offer is subject to certain customary conditions, which we may amend or waive.
We have the right, in our sole discretion, to terminate or withdraw the Exchange Offer
if any of the conditions described in this prospectus are not satisfied or waived.
See
“General Terms of the Exchange Offer — Conditions to the Exchange Offer.”
|
|
|
|
United
States Federal Income Tax Considerations
|
|
We
recommend that you consult with your own tax advisor with regard to the possibility of any federal, state, local, or other
tax consequences of the Exchange Offer. See “Certain United States Federal Income Tax Considerations” for a discussion
of the material U.S. Federal Income Tax Consequences of participating in the Exchange Offer.
|
|
|
|
Use
of Proceeds
|
|
We
intend to use the net proceeds from the Exchange Offer for general corporate purposes. See “Use of Proceeds”.
|
|
|
|
Solicitation
Agent
|
|
CIM
Securities, LLC (“
CIM Securities
”) is serving as the Solicitation Agent in connection with the Exchange
Offer. Questions, requests for assistance, or requests for additional copies of the Exchange Offer documents, Letter of Transmittal,
or other materials should be directed to: CIM Securities, LLC, Attn: Andrew Daniels, Managing Director, 509 Madison
Avenue, 9th Floor, New York, NY 10022; Andrew.Daniels@brooklinecm.com; 646-603-6717.
|
|
|
|
Exchange
Agent
|
|
VStock
Transfer, LLC is serving as the Exchange Agent in connection with the Exchange Offer. See “Exchange Agent.”
|
|
|
|
Registration
|
|
The
Exchange Shares issued at the closing will be registered pursuant to this registration statement. See “Description of
Securities.”
|
|
|
|
Risk
Factors
|
|
See
“Risk Factors” and other information included in this prospectus for a discussion of factors you should consider
carefully before investing pursuant to the terms of this prospectus.
|
Background
and Purpose of the Exchange Offer
Through
a series of discussions with M.M. Dillon & Co. Group LLC (“
M.M. Dillon & Co.
”) and other prospective
financial advisors, we determined that, on the basis of the price of our common stock and other potential sources of capital,
the Exchange Offer provided the best alternative to raise capital.
By
undertaking the Exchange Offer, we are trying raise capital which will be used for general corporate purposes.
Approval
of the Exchange Offer
Our
Board and our Audit Committee met telephonically on October 16, 2017 to discuss the potential Exchange Offer. At this meeting,
David G. Watumull initially discussed the financial purposes for eliminating the Original Warrants and the reasons why the Exchange
Offer would be the best means available at present to raise capital. Mr. Watumull next presented the terms of engaging M.M. Dillon
& Co. to act as the Financial Advisor and CIM Securities as the Solicitation Agent in connection with the Exchange Offer.
Mr. Bickerstaff recused himself from each meeting and did not submit a vote on the engagement of M.M. Dillon & Co. and CIM
Securities due to his affiliation as a managing director of M.M. Dillon & Co. Our Board and our Audit Committee (with Mr.
Bickerstaff abstaining) resolved to proceed with the engagement of M.M. Dillon & Co. and CIM Securities, on the terms as presented
by management for such purpose.
On
October 18, 2017, representatives of the law firms of Herrick, Feinstein LLP met with representative of M.M. Dillon & Co.
and representatives from CIM Securities in person to discuss the Exchange Offer and the SEC filings related to the Exchange
Offer. The current status of the proposed exchange transaction was discussed as well as the merits of the Exchange Offer and existing
market conditions.
On
May 2, 2018, the terms of M.M. Dillon & Co.’s engagement were modified, and such modifications were approved
by our Board (with Mr. Bickerstaff abstaining) on April 30, 2018.
Our
Board met telephonically on April 30, 2018 to discuss approving the proposed structure for the exchange of the Original
Warrants and the SEC filings related to the Exchange Offer. Mr. Watumull reviewed the current status of the proposed exchange
transaction previously circulated to the Board, noting that the Company will file with the SEC all information required for this
exchange offer and related Offer Letter to all holders of Original Warrants to exchange Original Warrants and the Exchange Payment
for Exchange Shares. The members of the Board asked questions of management and Herrick, Feinstein LLP on the Exchange Offer and
the documents. The Board discussed the interests of the Company and its stockholders, the consequences of not pursuing the Exchange
Offer and resolved to approve the final Exchange Offer terms and related documents reviewed at the meeting. The Board also determined
and approved the price of the Exchange Offer based on the discount to the quoted price of the common stock and the Board’s
valuation of the Original Warrants based on the Black-Scholes valuation model.
Interests
of Directors in the Exchange Offer
None
of the directors, officers or their affiliates beneficially owns any of the Existing Warrants and, therefore will not participate
in the Exchange Offer. See “Certain Relationships and Related Party Transactions— Financial Advisor”, for other
interests of a director in the Exchange Offer.
Risk
Factors
Prospective
participants in the Exchange Offer should carefully consider all of the information contained in this prospectus. An investment
in our common stock, any warrants to purchase our common stock, or any other security that may be issued by us involves a high
degree of risk. You should carefully consider the risks described below, together with all of the other information included elsewhere
in this prospectus, before making an investment decision. If any of the following risks actually occur, our business, financial
condition or results of operations could suffer. In that case, the trading price of our shares of common stock could decline,
and you may lose all or part of your investment. You should read the section entitled “Forward-Looking Statements”
above for a discussion of what types of statements are forward-looking statements, as well as the significance of such statements
in the context of this prospectus.
Risks
Related to the Exchange Offer
Your
tender of Original Warrants in exchange for the issuance of Exchange Shares will not be accepted if you fail to follow the Exchange
Offer procedures.
We
will issue you Exchange Shares pursuant to the Exchange Offer only after a timely receipt of your Original Warrants, Exchange
Payment, and a properly completed and duly executed Letter of Transmittal, and all other required documents. Therefore, if you
want to tender your Original Warrants in connection with the Exchange Offer, please allow sufficient time to ensure timely processing
of your exchange. If we do not receive your Original Warrants, Exchange Payment, Letter of Transmittal, and other required documents
by the Expiration Date, we will not accept your Original Warrants in exchange for the issuance of Exchange Shares. We are generally
under no duty to give notification of defects or irregularities with respect to the delivery of your Original Warrants, Exchange
Payment, Letter of Transmittal, and other required documents pursuant to the terms of the Exchange Offer. If there are defects
or irregularities with respect to your tender of Original Warrants, we may not accept your tender of Original Warrants pursuant
to the terms of the Exchange Offer.
If
holders of Original Warrants have claims against us resulting from their acquisition or ownership of the Original Warrants, they
will give up those claims if they tender their Original Warrants in the Exchange Offer.
By
tendering the Original Warrants in the Exchange Offer, upon closing of the Exchange Offer, holders of the Original Warrants will
be deemed to have released and waived any and all claims they, their successors and their assigns have or may have had against
us, our affiliates and their stockholders, and our directors, officers, employees, attorneys, accountants, advisors, agents, and
representatives, in each case whether current or former, as well as the directors, officers, employees, attorneys, accountants,
advisors, agents, and representatives of our affiliates and our stockholders, arising from, related to, or in connection with
their acquisition or ownership of the Original Warrants, unless those claims arise under federal or state securities laws.
Because
it is not possible to estimate the likelihood of their success in pursuing any legal claims or the magnitude of any recovery to
which they ultimately might be entitled, it is possible that the consideration that the holders of Original Warrants receive in
the Exchange Offer will have a value less than what they own today. Moreover, holders who do not tender their Original Warrants
in the Exchange Offer will continue to have the right to prosecute any claims against us.
Income
tax consequences of participation in this Exchange Offer.
We
have not obtained and do not intend to obtain a ruling from the Internal Revenue Service, or IRS, regarding the U.S. federal income
tax consequences of the tender of Original Warrants pursuant to the Exchange Offer. You should consult with your own tax advisor
with regard to the possibility of any federal, state, local, or other tax consequences of this Exchange Offer. See “Certain
United States Federal Income Tax Considerations”.
Risks
Related to Our Business, Industry, and Financial Condition
We
have a history of operating losses and have received a going concern opinion from our auditors.
We
have incurred substantial net losses since our inception and may continue to incur losses for the foreseeable future, as we continue
our product development activities. As a result of our limited operating history, we have limited historical financial data that
can be used in evaluating our business and our prospects and in projecting our future operating results. Through December 31,
2017, we have accumulated a total deficit of $57,919,096.
Additionally,
we have received a “going concern” opinion from our independent registered public accounting firm. The Company expects
that its marketing program for ZanthoSyn® will continue to focus on outreach to physicians, healthcare professionals, retail
personnel, and consumers, and anticipates further losses in the development of its business. As a result of these and other factors,
management has determined there is substantial doubt about the Company’s ability to continue as a going concern. Our ability
to continue as a going concern is dependent upon our ability to raise additional capital and implement our business plan. If we
are unable to achieve or sustain profitability or to secure additional financing on acceptable terms, we may not be able to meet
our obligations as they come due, raising substantial doubts as to our ability to continue as a going concern. Any such inability
to continue as a going concern may result in our common stock holders losing their entire investment. There is no guarantee that
we will become profitable or secure additional financing on acceptable terms. Our consolidated financial statements contemplate
that we will continue as a going concern and do not contain any adjustments that might result if we were unable to continue as
a going concern. Changes in our operating plans, our existing and anticipated working capital needs, the acceleration or modification
of our expansion plans, increased expenses, potential acquisitions or other events will all affect our ability to continue as
a going concern.
We
have limited experience as a commercial company.
In
2016, we launched our first commercial product, ZanthoSyn® and we have limited sales to date. As such, we have limited historical
financial data upon which to base our projected revenue, planned operating expenses or upon which to evaluate our company and
our commercial prospects. Based on our limited experience in developing and marketing new products, we may not be able to effectively:
|
●
|
drive
adoption of our current and future products, including ZanthoSyn®;
|
|
|
|
|
●
|
attract
and retain customers for our products;
|
|
|
|
|
●
|
provide
appropriate levels of customer support for our products;
|
|
|
|
|
●
|
implement
an effective marketing strategy to promote awareness of our products;
|
|
|
|
|
●
|
develop,
manufacture and commercialize new products or achieve an acceptable return on our research and development efforts and expenses;
|
|
|
|
|
●
|
comply
with regulatory requirements applicable to our products;
|
|
|
|
|
●
|
anticipate
and adapt to changes in our market;
|
|
|
|
|
●
|
maintain
and develop strategic relationships with vendors and manufacturers to acquire necessary materials for the production of our
existing or future products;
|
|
●
|
scale
our manufacturing activities to meet potential demand at a reasonable cost;
|
|
|
|
|
●
|
avoid
infringement and misappropriation of third-party intellectual property;
|
|
|
|
|
●
|
obtain
any necessary licenses to third-party intellectual property on commercially reasonable terms;
|
|
|
|
|
●
|
obtain
valid and enforceable patents that give us a competitive advantage;
|
|
|
|
|
●
|
protect
our proprietary technology; and
|
|
|
|
|
●
|
attract,
retain and motivate qualified personnel.
|
In
addition, a high percentage of our expenses is and will continue to be fixed. Accordingly, if we do not generate revenue as and
when anticipated, our losses may be greater than expected and our operating results will suffer
We
are dependent upon the success of our lead astaxanthin technologies, which may not be successfully commercialized.
While
the FDA does not require clinical trials for consumer health products such as dietary ingredients/supplements and food additives,
we may conduct clinical trials to demonstrate the safety and efficacy of our product(s) in humans. A failure of any clinical trial
can occur at any stage of testing. The results of initial clinical testing of this product may not necessarily indicate the results
that will be obtained from later or more extensive testing. Additionally, any observations made with respect to blinded clinical
data are inherently uncertain as we cannot know which set of data come from patients treated with an active drug versus the placebo
vehicle. Investors are cautioned not to rely on observations coming from blinded data and not to rely on initial clinical trial
results as necessarily indicative of results that will be obtained in subsequent clinical trials.
Additionally,
our products will be subject to a variety of FDA and other food and drug regulatory regimes. The extent of regulations applicable
to our products, and the designations our products may receive from regulatory agencies such as the FDA, are dependent upon the
nature and development of our future products and how such products are ultimately commercialized and marketed.
A
number of different factors could prevent us from conducting a clinical trial or commercializing our product candidates on a timely
basis, or at all.
We,
the FDA, other applicable regulatory authorities or an institutional review board, or IRB, may suspend clinical trials of a product
candidate at any time for various reasons, including if we or they believe the subjects or patients participating in such trials
are being exposed to unacceptable health risks. Among other reasons, adverse side effects of a product candidate on subjects or
patients in a clinical trial could result in the FDA or other regulatory authorities suspending or terminating the trial and refusing
to approve a particular product candidate for any or all indications of use.
Clinical
trials of a product require the enrollment of a sufficient number of patients, including patients who are suffering from the disease
or condition the product candidate is intended to treat and who meet other eligibility criteria. Rates of patient enrollment are
affected by many factors, and delays in patient enrollment can result in increased costs and longer development times.
Clinical
trials also require the review and oversight of IRBs, which approve and continually review clinical investigations and protect
the rights and welfare of human subjects. An inability or delay in obtaining IRB approval could prevent or delay the initiation
and completion of clinical trials, and the FDA may decide not to consider any data or information derived from a clinical investigation
not subject to initial and continuing IRB review and approval.
Numerous
factors could affect the timing, cost or outcome of our drug development efforts, including the following:
|
●
|
delays
in filing or acceptance of investigational drug applications for our product candidates;
|
|
|
|
|
●
|
difficulty
in securing centers to conduct clinical trials;
|
|
|
|
|
●
|
conditions
imposed on us by the FDA or comparable foreign authorities that are applicable to our business regarding the scope or design
of our clinical trials;
|
|
|
|
|
●
|
problems
in engaging IRBs to oversee trials or problems in obtaining or maintaining IRB approval of studies;
|
|
|
|
|
●
|
difficulty
in enrolling patients in conformity with required protocols or projected timelines;
|
|
|
|
|
●
|
third-party
contractors failing to comply with regulatory requirements or to meet their contractual obligations to us in a timely manner;
|
|
|
|
|
●
|
our
product candidates having unexpected and different chemical and pharmacological properties in humans than in laboratory testing
and interacting with human biological systems in unforeseen, ineffective or harmful ways;
|
|
|
|
|
●
|
the
need to suspend or terminate clinical trials if the participants are being exposed to unacceptable health risks;
|
|
|
|
|
●
|
insufficient
or inadequate supply or quality of our product candidates or other materials necessary to conduct our clinical trials;
|
|
|
|
|
●
|
effects
of our product candidates not being the desired effects or including undesirable side effects or the product candidates having
other unexpected characteristics;
|
|
|
|
|
●
|
the
cost of our clinical trials being greater than we anticipate;
|
|
|
|
|
●
|
negative
or inconclusive results from our clinical trials or the clinical trials of others for similar product candidates or inability
to generate statistically significant data confirming the efficacy of the product being tested;
|
|
|
|
|
●
|
changes
in the FDA’s requirements for testing during the course of that testing;
|
|
|
|
|
●
|
reallocation
of our limited financial and other resources to other programs; and
|
|
|
|
|
●
|
adverse
results obtained by other companies developing similar products.
|
It
is possible that none of our future product candidates that we may develop will obtain the appropriate regulatory approvals necessary
to begin selling them or that any regulatory approval to market a product may be subject to limitations on the indicated uses
for which we may market the product. The time required to obtain FDA and other approvals is unpredictable, but often can take
years following the commencement of clinical trials, depending upon the complexity of the product candidate. Any analysis we perform
of data from clinical activities is subject to confirmation and interpretation by regulatory authorities, which could delay, limit
or prevent regulatory approval. Any delay or failure in obtaining required approvals could have a material adverse effect on our
ability to generate revenue from the particular product candidate.
We
also must comply with clinical trial and post-approval safety and adverse event reporting requirements. Adverse events related
to our products must be reported to the FDA in accordance with regulatory timelines based on their severity and expectedness.
Failure to make timely safety reports and to establish and maintain related records could result in withdrawal of marketing authorization.
We
may also become subject to numerous foreign regulatory requirements governing the conduct of clinical trials, manufacturing and
marketing authorization, pricing and third-party reimbursement. The foreign regulatory approval process includes all of the risks
associated with the FDA approval described above as well as risks attributable to the satisfaction of local regulations in foreign
jurisdictions. Approval by the FDA does not assure approval by regulatory authorities outside of the United States.
We
have limited experience in managing communications with regulatory agencies, including filing investigational new drug applications,
filing new drug applications, submitting promotional materials, and generally directing the regulatory processes in all territories.
We
may be responsible for managing communications with regulatory agencies, including filing investigational new drug (“IND”)
applications, filing new drug applications (“NDAs”), submitting promotional materials, and generally directing
the regulatory processes in all territories. We have limited experience directing such activities and may not be successful with
our planned development strategies, on the planned timelines, or at all. Even if any of our product candidates are designated
for “fast track” or “priority review” status or if we seek approval under accelerated approval (Subpart
H) regulations, such designation or approval pathway does not necessarily mean a faster development process or regulatory review
process or necessarily confer any advantage with respect to approval compared to conventional FDA procedures. Accelerated development
and approval procedures will only be available if the indications for which we are developing products remain unmet medical needs
and if our clinical trial results support use of surrogate endpoints, respectively. Even if these accelerated development or approval
mechanisms are available to us, depending on the results of clinical trials, we may elect to follow the more traditional approval
processes for strategic and marketing reasons, since drugs approved under accelerated approval procedures are more likely to be
subjected to post-approval requirements for clinical studies to provide confirmatory evidence that the drugs are safe and effective.
If we fail to conduct any such required post-approval studies or if the studies fail to verify that any of our product candidates
are safe and effective, our FDA approval could be revoked. It can be difficult, time-consuming and expensive to enroll patients
in such clinical trials because physicians and patients are less likely to participate in a clinical trial to receive a drug that
is already commercially available. Drugs approved under accelerated approval procedures also require regulatory pre-approval of
promotional materials that may delay or otherwise hinder commercialization efforts.
We
operate in highly competitive industries, and our failure to compete effectively could adversely affect our market share, financial
condition and growth prospects. If competitors are better able to develop and market products that are more effective, or gain
greater acceptance in the marketplace than our products, our commercial opportunities may be reduced or eliminated.
The
consumer health and pharmaceutical industries are constantly evolving, and scientific advances are expected to continue at a rapid
pace. This results in intense competition among companies operating in the industry. Other, larger companies may have, or may
be developing, products that compete with our products and may significantly limit the market acceptance of our products or render
them obsolete. Our technical and/or business competitors would include major pharmaceutical companies, biotechnology companies,
consumer health companies, universities and nonprofit research institutions and foundations. Most of these competitors have significantly
greater research and development capabilities than we have, as well as substantial marketing, financial and managerial resources.
ZanthoSyn®, our lead product, primarily competes against consumer health and pharmaceutical products that provide anti-inflammatory
health benefits. In addition, there are several other companies, both public and private, that service the same markets as we
do, all of which compete to some degree with us.
The
primary competitive factors facing us include safety, efficacy, price, quality, breadth of product line, manufacturing quality
and capacity, service, marketing and distribution capabilities. Our current and future competitors may have greater resources,
more widely accepted and innovative products and stronger name recognition than we do. Our ability to compete is affected by our
ability to:
|
●
|
develop
or acquire new products and innovative technologies;
|
|
|
|
|
●
|
obtain
regulatory clearance and compliance for our products;
|
|
|
|
|
●
|
manufacture
and sell our products cost-effectively;
|
|
●
|
meet
all relevant quality standards for our products in their particular markets;
|
|
|
|
|
●
|
respond
to competitive pressures specific to each of our geographic and product markets;
|
|
|
|
|
●
|
protect
the proprietary technology of our products and avoid infringement of the proprietary rights of others;
|
|
|
|
|
●
|
market
our products;
|
|
|
|
|
●
|
attract
and retain skilled employees, including sales representatives;
|
|
|
|
|
●
|
maintain
and establish distribution relationships; and
|
|
|
|
|
●
|
engage
in acquisitions, joint ventures or other collaborations.
|
Competitors
could develop products that are more effective, achieve favorable reimbursement status from third-party payors, cost less or are
ready for commercial introduction before our products. If our competitors are better able to develop and patent products earlier
than we can, or develop more effective and/or less expensive products that render our products obsolete or non-competitive, our
business will be harmed and our commercial opportunities will be reduced or eliminated.
In
addition, competitors and other parties may also seek to impact regulatory status of our products through the filing of citizen
petitions or other similar documents. For example, allegations were made by the Natural Algae Astaxanthin Association (“NAXA”),
a small trade group with four members, each of which markets natural astaxanthin products, in a citizen petition that it filed
with FDA, which we believed to be false and baseless. Responding to any such actions, even if false and baseless, will use our
limited time and resources.
We
believe that the market in which we compete in is also highly sensitive to the introduction of new products, including various
prescription drugs, which may rapidly capture a significant share of the market. In the United States, we expect to also compete
for sales with heavily advertised national brands manufactured by large pharmaceutical, biotechnology, and consumer health companies,
as well as other retailers.
As
some products gain market acceptance, we may experience increased competition for those products as more participants enter the
market. Currently, we are not a manufacturer. To the extent that we engage third-party manufacturers or use strategic alliances
to produce our products, our manufacturing capabilities may not be adequate or sufficient to compete with large scale, direct
or third-party manufacturers. Certain of our potential competitors are larger than us and have longer operating histories, customer
bases, greater brand recognition and greater resources for marketing, advertising and product promotion. They may be able to secure
inventory from vendors on more favorable terms, operate with a lower cost structure or adopt more aggressive pricing policies.
In addition, our potential competitors may be more effective and efficient in introducing new products. We may not be able to
compete effectively, and our attempt to do so may require us to increase marketing and/or reduce our prices, which may result
in lower margins. Failure to effectively compete could adversely affect our market share, financial condition and growth prospects.
Market
acceptance of ZanthoSyn® and any future products are vital to our future success.
The
commercial success of ZanthoSyn® and any future products is dependent upon the acceptance of such products. ZanthoSyn®
and any future products may not gain and maintain any significant degree of market acceptance among potential consumers, retailers,
healthcare providers, or acceptance by third-party payors, such as health insurance companies. The health applications for ZanthoSyn®
and any future products can also be addressed by other products or techniques. The medical community widely accepts alternative
treatments, and certain of these other treatments have a long history of use. We cannot be certain that our proposed products
and the procedures in which they are used will be able to replace those established treatments or that users will accept and utilize
our products or any other medical products that we may market.
Market
acceptance will depend upon numerous factors, many of which are not under our control, including:
|
●
|
the
safety and efficacy of our products;
|
|
|
|
|
●
|
favorable
regulatory approval and product labeling;
|
|
|
|
|
●
|
the
availability, safety, efficacy and ease of use of alternative products or treatments;
|
|
|
|
|
●
|
our
ability to educate potential users on the advantages of our products;
|
|
|
|
|
●
|
the
price of our products relative to alternative technologies; and
|
|
|
|
|
●
|
the
availability of third-party reimbursement.
|
If
our proposed products do not achieve significant market acceptance, our future revenues and profitability would be adversely affected.
The
pharmaceutical and consumer health industries are subject to extensive and complex healthcare regulation. Any determination that
we have violated federal or state laws applicable to us that regulate healthcare would have a material adverse effect on our business,
prospects and financial condition.
Federal
and state laws regulating healthcare are extensive and complex. The laws applicable to our business are subject to evolving interpretations,
and therefore we cannot be sure that a review of our operations by federal or state courts or regulatory authorities will not
result in a determination that we have violated one or more provisions of federal or state law. Any such determination could have
a material adverse effect on our business, prospects and financial condition.
If
we fail to comply with FDA regulations our business could suffer.
The
manufacture and marketing of pharmaceutical and consumer health products are subject to extensive regulation by the FDA and foreign
and state regulatory authorities. In the United States, pharmaceutical and consumer health companies such as ours must comply
with laws and regulations promulgated by the FDA. These laws and regulations require various authorizations prior to a product
being marketed in the United States. Manufacturing facilities and practices are also subject to FDA regulations. The FDA regulates
the clinical testing, manufacture, labeling, sale, distribution and promotion of pharmaceutical and consumer health products in
the United States. Our failure to comply with regulatory requirements, including any future changes to such requirements, could
have a material adverse effect on our business, prospects, financial condition and results of operations.
Even
after clearance or approval of a product, we are subject to continuing regulation by the FDA, including the requirements of registering
our facilities and listing our products with the FDA. We are subject to reporting regulations. These regulations require us to
report to the FDA if any of our products may have caused or contributed to a death or serious injury and such product or a similar
product that we market would likely cause or contribute to a death or serious injury. Unless an exemption applies, we must report
corrections and removals to the FDA where the correction or removal was initiated to reduce a risk to health posed by the product
or to remedy a violation of the Food, Drug and Cosmetic Act. The FDA also requires that we maintain records of corrections or
removals, regardless of whether such corrections and removals are required to be reported to the FDA. In addition, the FDA closely
regulates promotion and advertising, and our promotional and advertising activities could come under scrutiny by the FDA.
The
FDA also requires that manufacturing be in compliance with its Quality System Regulation, or QSR. The QSR covers the methods and
documentation of the design, testing, control, manufacturing, labeling, quality assurance, packaging, storage and shipping of
our products. Our failure to maintain compliance with the QSR requirements could result in the shutdown of, or restrictions on,
our manufacturing operations, to the extent we have any, and the recall or seizure of our products, which would have a material
adverse effect on our business. In the event that one of our suppliers fails to maintain compliance with our quality requirements,
we may have to qualify a new supplier and could experience manufacturing delays as a result.
The
FDA has broad enforcement powers. If we violate applicable regulatory requirements, the FDA may bring enforcement actions against
us, which could have a material adverse effect on our business, prospects, financial condition and results of operations. Violations
of regulatory requirements, at any stage, including after approval, may result in various adverse consequences, including the
delay by a regulatory agency in approving or refusal to approve a product, withdrawal or recall of an approved product from the
market, other voluntary agency-initiated action that could delay further development or marketing, as well as the imposition of
criminal penalties against the manufacturer and NDA holder.
The
extent of FDA regulations applicable to us, and whether our products are ultimately designated as drugs (including active pharmaceutical
ingredients) or dietary supplements (including dietary ingredients), will depend upon how our products are ultimately commercialized.
Because we are currently evaluating the extent of our pharmaceutical program, we are unable to determine the extent of FDA regulations
applicable to our product candidates. Furthermore, our products may be commercialized by us or by other parties through licensing
arrangements, joint ventures, or other alliances, and our burden of complying with any regulations applicable to our product candidates
will depend upon the nature and extent of any relationships with such partners. While consumer health products are not as extensively
regulated as pharmaceutical products, the extent of any other regulatory regimes to which we may be subject will depend upon the
specific products we ultimately produce.
We
may seek orphan drug designation for current or future product candidates, but any orphan drug designations we receive may not
confer marketing exclusivity or other expected benefits.
Under
the Orphan Drug Act of 1983 (the “
Orphan Drug Act
”), the FDA may grant orphan drug designation to a drug intended
to treat a rare disease or condition that (i) affects less than 200,000 persons in the United States, or (ii) affects more than
200,000 in the United States and for which there is no reasonable expectation that the cost of developing and making available
in the United States a drug for such disease or condition will be recovered from sales in the United States of such drug. The
Orphan Drug Act mainly provides incentives intended to make the development of orphan drugs financially viable but does not provide
for separate regulatory standards for orphan drugs. Drugs that receive an orphan drug designation do not require prescription
drug user fees at the time of marketing application, may qualify the drug development sponsor for certain tax credits, and can
be marketed without generic competition for seven years.
We
may seek orphan drug designation for current or future product candidates that we believe may qualify for orphan drug designation;
however, there can be no assurance that we will request an orphan product designation for any product candidate, or if requested,
that will receive such orphan drug designation. If we are unable to secure orphan drug designation, our regulatory and commercial
prospects may be negatively impacted. Even if we obtain orphan drug designation for a current or future product candidate, we
may not be able to obtain or maintain orphan drug exclusivity for that product candidate. We may not be the first to obtain marketing
approval of any product candidate for which we have obtained orphan drug designation for the orphan-designated indication due
to the uncertainties associated with developing pharmaceutical products. In addition, exclusive marketing rights in the United
States may be limited if we seek approval for an indication broader than the orphan-designated indication or may be lost if the
FDA later determines that the request for designation was materially defective or if we are unable to assure sufficient quantities
of the product to meet the needs of patients with the rare disease or condition. Further, even if we obtain orphan drug exclusivity
for a product, that exclusivity may not effectively protect the product from competition because different drugs with different
active moieties may be approved for the same condition. Even after an orphan drug is approved, the FDA can subsequently approve
the same drug with the same active moiety for the same condition if the FDA concludes that the later drug is clinically superior
in that it is shown to be safer, more effective, or makes a major contribution to patient care, or the manufacturer of the product
with orphan exclusivity is unable to maintain sufficient product quantity. Orphan drug designation may not shorten the development
time or regulatory review time of a drug or give the drug any advantage in the regulatory review or approval process, nor does
it prevent competitors from obtaining approval of the same product candidate as ours for indications other than those in which
we have been granted orphan drug designation.
Healthcare
and insurance legislation may increase the difficulty and cost for us to commercialize our product candidates and affect the prices
we may obtain.
The
United States and many foreign jurisdictions have enacted or proposed legislative and regulatory changes affecting the healthcare
system that could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities
and affect our ability to profitably sell any product candidate for which we obtain marketing approval.
In
the United States, the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, or Medicare Modernization Act,
changed the way Medicare covers and pays for pharmaceutical products. The legislation expanded Medicare coverage for drug purchases
by the elderly by establishing Medicare Part D and introduced a new reimbursement methodology based on average sales prices for
physician-administered drugs under Medicare Part B. In addition, this legislation provided authority for limiting the number of
drugs that Medicare will cover in any therapeutic class under the new Medicare Part D program. Cost reduction initiatives and
other provisions of this legislation could decrease the coverage and reimbursement rate that we receive for any of our approved
products. While the Medicare Modernization Act applies only to drug benefits for Medicare beneficiaries, private payors often
follow Medicare coverage policy and payment limitations in setting their own reimbursement rates. Therefore, any reduction in
reimbursement that results from the Medicare Modernization Act may result in a similar reduction in payments from private payors.
In
March 2010, former President Obama signed into law the Patient Protection and Affordable Care Act, as amended by the Health Care
and Education Reconciliation Act of 2010, or, collectively, the Affordable Care Act, a law intended to broaden access to health
insurance, reduce or constrain the growth of healthcare spending, enhance remedies against healthcare fraud and abuse, add new
transparency requirements for healthcare and health insurance industries, impose new taxes and fees on pharmaceutical and medical
device manufacturers and impose additional health policy reforms. Among other things, the Affordable Care Act expanded manufacturers’
rebate liability under the Medicaid Drug Rebate Program by increasing the minimum rebate for both branded and generic drugs, effective
the first quarter of 2010, and revising the definition of “average manufacturer price,” or AMP, for reporting purposes,
which could increase the amount of Medicaid drug rebates manufacturers are required to pay to states. The legislation also extended
Medicaid drug rebates, previously due only on fee-for-service utilization, to Medicaid managed care utilization, and created an
alternative rebate formula for certain new formulations of certain existing products that is intended to increase the amount of
rebates due on those drugs. The Centers for Medicare and Medicaid Services, which administers the Medicaid Drug Rebate Program,
also has proposed to expand Medicaid drug rebates to the utilization that occurs in the United States territories, such as Puerto
Rico and the Virgin Islands. Also effective in 2010, the Affordable Care Act expanded the types of entities eligible to receive
discounted 340B pricing, although, with the exception of children’s hospitals, these newly eligible entities will not be
eligible to receive discounted 340B pricing on orphan drugs. In addition, because 340B pricing is determined based on AMP and
Medicaid drug rebate data, the revisions to the Medicaid rebate formula and AMP definition described above could cause the required
340B discounts to increase. Furthermore, as of 2011, the new law imposes a significant annual fee on companies that manufacture
or import branded prescription drug products and requires manufacturers to provide a 50% discount off the negotiated price of
prescriptions filled by beneficiaries in the Medicare Part D coverage gap, referred to as the “donut hole.” Substantial
new provisions affecting compliance have also been enacted, which may affect our business practices with healthcare practitioners.
Notably, a significant number of provisions are not yet, or have only recently become, effective. Although it is too early to
determine the full effect of the Affordable Care Act, the new law appears likely to continue the downward pressure on pharmaceutical
pricing, especially under the Medicare program, and may also increase our regulatory burdens and operating costs.
In
addition, other legislative changes have been proposed and adopted since the Affordable Care Act was enacted. In August 2011,
the former President signed into law the Budget Control Act of 2011, which, among other things, created the Joint Select Committee
on Deficit Reduction to recommend to Congress proposals in spending reductions. The Joint Select Committee on Deficit Reduction
did not achieve a targeted deficit reduction of at least $1.2 trillion for fiscal years 2012 through 2021, triggering the legislation’s
automatic reduction to several government programs. This includes aggregate reductions to Medicare payments to providers of up
to 2% per fiscal year.
We
expect that the Affordable Care Act, as well as other healthcare reform measures that have and may be adopted in the future, may
result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved product,
and could seriously harm our future revenues. Any reduction in reimbursement from Medicare or other government programs may result
in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms
may prevent us from being able to generate revenue, attain profitability or commercialize our products.
The
impact of continued health care reform efforts with respect to the Affordable Care Act is currently unknown, and may adversely
affect our business model.
Since
its enactment, there have been judicial and Congressional challenges to numerous provisions of the Affordable Care Act. In January
2017, Congress voted to adopt a budget resolution for fiscal year 2017, or the Budget Resolution, that authorizes the implementation
of legislation that would repeal portions of the Affordable Care Act. The Budget Resolution is not a law, but it is widely viewed
as the first step toward the passage of legislation that would repeal certain aspects of the Affordable Care Act. On January 20,
2017, President Trump signed an Executive Order directing federal agencies with authorities and responsibilities under the Affordable
Care Act to waive, defer, grant exemptions from, or delay the implementation of any provision of the Affordable Care Act that
would impose a fiscal or regulatory burden on states, individuals, healthcare providers, health insurers, or manufacturers of
pharmaceuticals or medical devices. Additionally, on October 12, 2017, President Trump issued another executive order requiring
the Secretaries of the Departments of Health and Human Services (“HHS”), Labor and the Treasury to consider proposing
regulations or revising existing guidance to allow more employers to form association health plans that would be allowed to provide
coverage across state lines, increase the availability of short-term, limited duration health insurance plans, which are generally
not subject to the requirements of the Affordable Care Act, and increase the availability and permitted use of health reimbursement
arrangements. On October 13, 2017, the Department of Justice announced that HHS was immediately stopping its cost sharing reduction
payments to insurance companies based on the determination that those payments had not been appropriated by Congress. Furthermore,
on December 22, 2017, President Trump signed tax reform legislation into law that, in addition to overhauling the federal tax
system, also, effective as of January 1, 2019, repeals the penalties associated with the individual mandate. Congress or the President
of the United States may also consider subsequent legislation or executive action to replace or eliminate elements of the Affordable
Care Act. We will continue to evaluate the effect that the Affordable Care Act and any future measures to modify, repeal or replace
the Affordable Care Act have on our business. We are not able to provide any assurance that the continued healthcare reform debate
will not result in legislation, regulation, or executive action by the President of the United States that is adverse to
our business.
We
cannot predict the effect the recent U.S. tax reform will have on us.
On
December 22, 2017, President Trump signed the Tax Act into law, resulting in sweeping changes to the tax code. The Tax Act,
inter
alia,
reduced the corporate tax rate to 21%, reduced interest expense deductibility, increased capitalization amounts for
deferred acquisition costs, eliminated the corporate alternative minimum tax, and reduced the dividend received deduction. Most
of the changes in the Tax Act are effective as of January 1, 2018. We are currently unable to predict whether this legislation
would have a cumulative positive or negative impact on us.
We
rely on third parties to supply and manufacture our proposed products. If these third parties do not perform as expected or if
our agreements with them are terminated, our business, prospects, financial condition and results of operations would be materially
adversely affected.
We
outsource our manufacturing to third parties. Our reliance on contract manufacturers and suppliers exposes us to risks, including
the following:
|
●
|
We
rely on our suppliers and manufacturers to provide us with the needed products or components in a timely fashion and of an
acceptable quality. An uncorrected defect or supplier’s variation in a component could harm our or our third-party manufacturers’
ability to manufacture, and our ability to sell, products and may subject us to product liability claims.
|
|
|
|
|
●
|
The
facilities of our third-party manufacturers must satisfy production and quality standards set by applicable regulatory authorities.
Regulatory authorities periodically inspect manufacturing facilities to determine compliance with these standards. If we or
our third-party manufacturers fail to satisfy these requirements, the facilities could be shut down.
|
|
|
|
|
●
|
These
manufacturing operations could also be disrupted or delayed by fire, earthquake or other natural disaster, a work stoppage
or other labor-related disruption, failure in supply or other logistical channels, electrical outages or other reasons. If
there was any such disruption to any of these manufacturing facilities, our third-party manufacturers would potentially be
unable to manufacture our products.
|
|
|
|
|
●
|
A
third-party manufacturer or supplier could decide to terminate our manufacturing or supply arrangement, including due to a
disagreement between us and such third-party manufacturer, if the third-party manufacturer determines not to further manufacture
our products, or if we fail to comply with our obligations under such arrangements.
|
|
|
|
|
●
|
If
any third-party manufacturer makes improvements in the manufacturing process for our products, we may not own, or may have
to share, the intellectual property rights to the innovation.
|
We
currently rely on a limited number of suppliers to provide key components for our products. If these or other suppliers become
unable to provide components in the volumes needed or at an acceptable price or quality, we would have to identify and qualify
acceptable replacements from alternative suppliers. We may experience stoppages in the future. We may not be able to find a sufficient
alternative supplier in a reasonable time period, or on commercially reasonable terms, if at all, and our ability to produce and
supply our products could be impaired.
To
the extent we are able to identify alternative suppliers, qualifying suppliers is a lengthy process. There are a limited number
of manufacturers and suppliers that may satisfy applicable requirements. In addition, FDA regulations may require additional testing
of any components from new suppliers prior to our use of these materials or components, which testing could delay or prevent the
supply of components. Moreover, a new manufacturer would have to be educated in, or develop substantially equivalent processes
for, production of our products, which could take a significant period of time.
Each
of these risks could delay the development or commercialization of our products or result in higher costs or deprive us of potential
product revenues. Furthermore, delays or interruptions in the manufacturing process could limit or curtail our ability to meet
demand for our products and/or make commercial sales, unless and until the manufacturing capability at the facilities are restored
and re-qualified or alternative manufacturing facilities are developed or brought on-line and “scaled up.” Any such
delay or interruption could have a material adverse effect on our business, prospects, financial condition and results of operations.
An
unexpected interruption or shortage in the supply or significant increase in the cost of components could limit our ability to
manufacture any products, which could reduce our sales and margins.
To
the extent we engage in relationships with contract manufacturers in the future, an unexpected interruption of supply or a significant
increase in the cost of components, whether to us or to our contract manufacturers for any reason, such as regulatory requirements,
import restrictions, loss of certifications, disruption of distribution channels as a result of weather, terrorism or acts of
war, or other events, could result in significant cost increases and/or shortages of our products. Our inability to obtain a sufficient
amount of products or to pass through higher cost of products we offer could have a material adverse effect on our business, financial
condition or results of operations.
We
have limited experience in marketing our products and services.
We
have undertaken limited marketing efforts for ZanthoSyn® and any future products and services. Our sales and marketing teams
compete against the experienced and well-funded sales organizations of competitors. Our future revenues and ability to achieve
profitability will depend largely on the effectiveness of our sales and marketing team, and we will face significant challenges
and risks related to marketing our services, including, but not limited to, the following:
|
●
|
the
ability of sales representatives to obtain access to or persuade adequate numbers of healthcare providers to promote and/or
purchase and use our products and services;
|
|
|
|
|
●
|
the
ability to recruit, properly motivate, retain, and train adequate numbers of qualified sales and marketing personnel;
|
|
|
|
|
●
|
the
costs associated with hiring, training, maintaining, and expanding an effective sales and marketing team; and
|
|
|
|
|
●
|
assuring
compliance with government regulatory requirements affecting the healthcare industry in general and our products in particular.
|
We
may seek to establish a network of distributors in selected markets to market, sell and distribute our products. If we fail to
select or use appropriate distributors, or if the sales and marketing strategies of such distributors prove ineffective in generating
sales of our products, our future revenues would be adversely affected and we might never become profitable.
We
may rely on third-party distributors for sales, marketing and distribution activities.
We
may rely on third-party distributors to sell, market, and distribute ZanthoSyn® and any future products. Because we may rely
on third-party distributors for sales, marketing and distribution activities, we may be subject to a number of risks associated
with our dependence on these third-party distributors, including:
|
●
|
lack
of day-to-day control over the activities of third-party distributors;
|
|
|
|
|
●
|
third-party
distributors may not fulfill their obligations to us or otherwise meet our expectations;
|
|
|
|
|
●
|
third-party
distributors may terminate their arrangements with us on limited or no notice or may change the terms of these arrangements
in a manner unfavorable to us for reasons outside of our control; and
|
|
|
|
|
●
|
disagreements
with our distributors could require or result in costly and time-consuming litigation or arbitration.
|
If
we fail to establish and maintain satisfactory relationships with third-party distributors, we may be unable to sell, market and
distribute our products, our future revenues and market share may not grow as anticipated, and we could be subject to unexpected
costs which would harm our results of operations and financial condition. There is no assurance that our sales through GNC stores
will continue on terms that are favorable to us or at all.
The
loss of our largest customer would substantially reduce revenues.
Our
customers are material to our success. If we are unable to maintain good relationships with our existing customers, our business
could suffer. We currently sell ZanthoSyn® to GNC under an exclusive sales contract for the “brick and mortar”
retail channel in the United States. GNC has the ability to terminate the exclusive nature of this agreement. The loss of GNC
as the exclusive seller or the reduction of increasing sales through GNC would have a material adverse effect on the Company.
Commercialization
of our products and services will require us to build and maintain sophisticated sales and marketing teams.
We
have limited prior experience with commercializing our products. To successfully commercialize our products and services, we will
need to establish and maintain sophisticated sales and marketing teams. While we intend to use current Company employees and service
providers to lead our marketing efforts, we may choose to expand our marketing and sales team. Experienced sales representatives
may be difficult to locate and retain, and all new sales representatives will need to undergo extensive training. There is no
assurance that we will be able to recruit and retain sufficiently skilled sales representatives, or that any new sales representatives
will ultimately become productive. If we are unable to recruit and retain qualified and productive sales personnel, our ability
to commercialize our products and to generate revenues will be impaired, and our business will be harmed.
We
may not be able to establish or maintain the third-party relationships that are necessary to develop or potentially commercialize
some or all of our product candidates.
We
expect to depend on collaborators, partners, licensees, contract research organizations, contract manufacturing organizations,
clinical research organizations and other third parties to support our discovery efforts, to formulate product candidates, to
manufacture our product candidates and to conduct clinical trials for some or all of our product candidates. We cannot guarantee
that we will be able to successfully negotiate agreements for or maintain relationships with collaborators, partners, licensees,
contractors, clinical investigators, vendors and other third parties on favorable terms, if at all. Our ability to successfully
negotiate such agreements will depend on, among other things, potential partners’ evaluation of the superiority of our technology
over competing technologies, the quality of the preclinical and clinical data that we have generated and the perceived risks specific
to developing our product candidates. If we are unable to obtain or maintain these agreements, we may not be able to clinically
develop, formulate, manufacture, obtain regulatory approvals for or commercialize our future product candidates. We cannot necessarily
control the amount or timing of resources that our contract partners will devote to our research and development programs, product
candidates or potential product candidates, and we cannot guarantee that these parties will fulfill their obligations to us under
these arrangements in a timely fashion. We may not be able to readily terminate any such agreements with contract partners even
if such contract partners do not fulfill their obligations to us. We may experience stoppages in the future. We may not be able
to find a sufficient alternative provider in a reasonable time period, or on commercially reasonable terms, if at all, and our
ability to produce and supply our products could be impaired.
We
expect to continue to incur significant research and development expenses, which may make it difficult for us to attain profitability.
We
expend substantial funds to develop our proprietary technologies, and additional substantial funds will be required for further
research and development, including preclinical testing and clinical trials of any product candidates, and to manufacture and
market any products that are approved for commercial sale. Because the successful development of our products is uncertain, we
are unable to precisely estimate the actual funds we will require to develop and potentially commercialize them. In addition,
we may not be able to generate enough revenue, even if we are able to commercialize any of our product candidates, to become profitable.
We
may be subject to product liability claims. Our insurance may not be sufficient to cover these claims, or we may be required to
recall our products.
Our
business is to develop and commercialize, among other things, pharmaceutical and consumer health products that provide anti-inflammatory
benefits. As a result, we will face an inherent risk of product liability claims. The pharmaceutical industry has been historically
litigious. Since our products are to be used in the human body, manufacturing errors, design defects or packaging defects could
result in injury or death to the patient. This could result in a recall of one or more of our products and substantial monetary
damages. Any product liability claim brought against us, with or without merit, could result in a diversion of our resources,
an increase in our product liability insurance premiums and/or an inability to secure coverage in the future. We may also have
to pay any amount awarded by a court in excess of our policy limits. In addition, any recall of our products, whether initiated
by us or by a regulatory agency, may result in adverse publicity for us that could have a material adverse effect on our business,
prospects, financial condition and results of operations. Our product liability insurance policies have various exclusions; therefore,
we may be subject to a product liability claim or recall for which we have no insurance coverage. In such a case, we may have
to pay the entire amount of the award or costs of the recall. Finally, product liability insurance supplements or renewals may
be expensive and may not be available in the future on acceptable terms, or at all.
If
we experience product recalls, we may incur significant and unexpected costs and damage to our reputation and, therefore, could
have a material adverse effect on our business, financial condition or results of operations.
We
may be subject to product recalls, withdrawals or seizures if any of our products are believed to cause injury or illness or if
we are alleged to have violated governmental regulations in the manufacture, labeling, promotion, sale or distribution of our
products. A recall, withdrawal or seizure of any of our products could materially and adversely affect consumer confidence in
our brands and lead to decreased demand for our products. In addition, a recall, withdrawal or seizure of any of our products
would require significant management attention, would likely result in substantial and unexpected expenditures and could materially
and adversely affect our business, financial condition or results of operations.
If
we are unable to obtain and maintain protection of our intellectual property, the value of our products may be adversely affected.
Our
business is dependent in part upon our ability to use intellectual property rights to protect our products from competition. To
protect our products, we rely on a combination of patent and other intellectual property laws, employment, confidentiality and
invention assignment agreements with our employees and contractors, and confidentiality agreements and protective contractual
provisions with our partners, licensors and other third parties. These methods, however, afford us only limited protection against
competition from other products.
We
attempt to protect our intellectual property position, in part, by filing patent applications related to our proprietary technology,
inventions and improvements that are important to our business. However, our patent position is not likely by itself to prevent
others from commercializing products that compete directly with our products. Moreover, we do not have patent protection for certain
components of our products and our patent applications can be challenged. In addition, we may fail to receive any patent for which
we have applied, and any patent owned by us or issued to us could be challenged, invalidated, or held to be unenforceable. We
also note that any patent granted may not provide a competitive advantage to us. Our competitors may independently develop technologies
that are substantially similar or superior to our technologies. Further, third parties may design around our patented or proprietary
products and technologies.
We
rely on certain trade secrets and we may not be able to adequately protect our trade secrets even with contracts with our personnel
and third parties. Also, any third party could independently develop and have the right to use, our trade secret, know-how and
other proprietary information. If we are unable to protect our intellectual property rights, our business, prospects, financial
condition and results of operations could suffer materially.
Our
ability to market our products may be impaired by the intellectual property rights of third parties.
Our
success depends in part on our products not infringing on the patents and proprietary rights of other parties. For instance, in
the United States, patent applications filed in recent years are confidential for 18 months, while older applications are not
published until the patent issues. As a result, there may be patents and patent applications of which we are unaware, and avoiding
patent infringement may be difficult.
Our
industry is characterized by a large number of patents, patent applications and frequent litigation based on allegations of patent
infringement. Competitors may own patents or proprietary rights, or have filed patent applications, related to products that are
similar to ours. We may not be aware of all of the patents and pending applications potentially adverse to our interests that
may have been issued to others. Moreover, since there may be unpublished patent applications that could result in patents with
claims relating to our products, we cannot be sure that our current products will not infringe any patents that might be issued
or filed in the future. Based on the litigious nature of our industry and the fact that we may pose a competitive threat to some
companies who own or control various patents, we believe it is possible that one or more third parties may assert a patent infringement
claim seeking damages or enjoining us from the manufacture or marketing of one or more of our products. Such a lawsuit may have
already been filed against us without our knowledge, or may be filed in the near future. If any future claim of infringement against
us was successful, we may be required to pay substantial damages, cease the infringing activity or obtain the requisite licenses
or rights to use the technology, which may not be available to us on acceptable terms, if at all. Even if we were able to obtain
rights to a third party’s intellectual property rights, these rights may be non-exclusive, thereby giving our competitors
potential access to the same rights and weakening our market position. Moreover, regardless of the outcome, patent litigation
could significantly disrupt our business, divert our management’s attention and consume our financial resources. We cannot
predict if or when any third-party patent holder will file suit for patent infringement.
We
may be involved in lawsuits or proceedings to protect or enforce our intellectual property rights or to defend against infringement
claims, which could be expensive and time consuming.
Litigation
may be necessary to enforce our intellectual property rights, protect our trade secrets or determine the validity and scope of
the proprietary rights of others. Interference proceedings conducted by a patent and trademark office may be necessary to determine
the priority of inventions with respect to our patent applications. Litigation or interference proceedings could result in substantial
costs and diversion of resources and management attention. In addition, in an infringement proceeding, a court may decide that
a patent of ours is not valid or is unenforceable or may refuse to stop the other party from using the technology at issue on
the grounds that our patents do not cover the technology. An adverse determination of any litigation or defense proceedings could
put one or more of our patents at risk of being invalidated or interpreted narrowly and could put our patent applications at risk
of not issuing. In addition, we may be enjoined from marketing one or more of our products if a court finds that such products
infringe the intellectual property rights of a third party.
During
litigation, we may not be able to prevent the confidentiality of certain of our proprietary rights because of the substantial
amount of discovery required in connection with intellectual property litigation. In addition, during the course of litigation,
there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If investors
or customers perceive these results to be negative, it could have a material adverse effect on our business, prospects, financial
condition and results of operations.
Our
insurance liability coverage is limited and may not be adequate to cover potential losses.
In
the ordinary course of business, we purchase insurance coverage (e.g., liability coverage) to protect us against claims made by
third parties and employees for property damage or personal injuries. However, the protection provided by such insurance is limited
in significant respects and, in some instances, we have no coverage and certain of our insurance policies have substantial “deductibles”
or have limits on the maximum amounts that may be recovered. Insurers have also introduced new exclusions or limitations of coverage
for claims related to certain perils including, but not limited to, mold and terrorism. If a series of losses occurred, such as
from a series of lawsuits in the ordinary course of business each of which were subject to the deductible amount, or if the maximum
limit of the available insurance was substantially exceeded, we could incur losses in amounts that would have a material adverse
effect on our results of operations and financial condition. We do not presently have any product liability insurance that would
provide coverage for any allegation of product defects or related claims. We will review our ability to obtain such insurance
coverage later, but there cannot be any assurance that such insurance coverage will be available on acceptable terms.
Our
operating results may fluctuate, which may result in volatility of our share price.
Our
operating results, including components of operating results, can be expected to fluctuate from time to time in the future. Some
of the factors that may cause these fluctuations include:
|
●
|
the
impact of acquisitions;
|
|
|
|
|
●
|
market
acceptance of our existing products, as well as products in development;
|
|
|
|
|
●
|
the
timing of regulatory approvals;
|
|
|
|
|
●
|
our
ability or the ability of third-party distributors to sell, market, and distribute our products;
|
|
|
|
|
●
|
our
ability or the ability of our contract manufacturers to manufacture our products efficiently; and
|
|
|
|
|
●
|
the
timing of our research and development expenditures.
|
If
we are unable to manage our expected growth, our future revenue and operating results may be adversely affected.
Our
anticipated growth is expected to place a significant strain on our management, operational and financial resources. Our current
and planned personnel, systems, procedures and controls may not be adequate to support our anticipated growth. To manage our growth,
we will be required to improve existing, and implement new, operational and financial systems, procedures and controls and expand,
train and manage our growing employee base. We expect that we may need to increase our management personnel to oversee our expanding
operations. Recruiting and retaining qualified individuals can be difficult. If we are unable to manage our growth effectively,
or are unsuccessful in recruiting qualified management personnel, our business, prospects, financial condition and results of
operations could be harmed.
We
are highly dependent on our senior management, and if we are not able to retain them or to recruit and retain additional qualified
personnel, our business will suffer.
We
are highly dependent upon our senior management, including David G. Watumull, our President and Chief Executive Officer, Gilbert
M. Rishton, our Chief Science Officer, Timothy J. King, our Vice President, Research, John B. Russell, our Chief Financial Officer,
and David M. Watumull, our Chief Operating Officer. The loss of services of David G. Watumull or any other member of our senior
management could have a material adverse effect on our business, prospects, financial condition and results of operations. We
carry $1 million “key person” life insurance policies on David G. Watumull and David M. Watumull but do not carry
similar insurance for any of our other senior executives.
We
may choose to increase our management personnel. For example, we will need to obtain certain additional functional capability,
including regulatory, sales, quality assurance and control, either by hiring additional personnel or by outsourcing these functions
to qualified third parties. We may not be able to engage these third parties on terms favorable to us. Also, we may not be able
to attract and retain qualified personnel on acceptable terms given the competition for such personnel among companies that operate
in our markets. The trend in the pharmaceutical industry of requiring sales and other personnel to enter into non-competition
agreements prior to starting employment exacerbates this problem, since personnel who have made such a commitment to their current
employers are more difficult to recruit. If we fail to identify, attract, retain and motivate these highly skilled personnel,
or if we lose current employees, our business, prospects, financial conditions and results of operations could be adversely affected.
Our
ability to grow and compete in the future will be adversely affected if adequate capital is not available to us or not available
on terms favorable to us.
The
ability of our business to grow and compete depends on the availability of adequate capital, which in turn depends in large part
on our cash flow from operations and the availability of equity and debt financing. We cannot assure you that our cash flow from
operations will be sufficient or that we will be able to obtain equity or debt financing on acceptable terms or at all to implement
our growth strategy. As a result, we cannot assure you that adequate capital will be available to finance our current growth plans,
take advantage of business opportunities or respond to competitive pressures, any of which could harm our business. Additionally,
if adequate additional financing is not available on acceptable terms, we may not be able to continue our business operations.
Any additional capital, investment or financing of our business may result in dilution of our stockholders or be on terms and
conditions that impair our ability to profitably conduct our business.
You
may have limited access to information regarding our Company because we are a limited reporting company exempt from many regulatory
requirements.
As
a filer subject to Section 15(d) of the Exchange Act, the Company is not required to prepare proxy or information statements;
our common stock is not subject to the protection of the going private regulations; the Company is subject to only limited portions
of the tender offer rules; our officers, directors, and more than ten (10%) percent stockholders are not required to file beneficial
ownership reports about their holdings in our Company; such persons are not subject to the short-swing profit recovery provisions
of the Exchange Act; and stockholders of more than five percent (5%) are not required to report information about their ownership
positions in the securities. As a result, investors will have reduced visibility as to the Company and its financial condition.
Risks
Related to Ownership of Our Common Stock
Our
common stock has a limited trading market, which could affect your ability to sell shares of our common stock and the price you
may receive for our common stock.
Our
common stock is currently traded in the over-the-counter market and “bid” and “asked” quotations regularly
appear on the OTCQB maintained by OTC Markets, Inc. under the symbol “CDXI”. There is only limited trading activity
in our securities. We have a relatively small public float compared to the number of our shares outstanding. Accordingly, we cannot
predict the extent to which investors’ interest in our common stock will provide an active and liquid trading market, which
could depress the trading price of our common stock and could have a long-term adverse impact on our ability to raise capital
in the future. Due to our limited public float, we may be vulnerable to investors taking a “short position” in our
common stock, which would likely have a depressing effect on the price of our common stock and add increased volatility to our
trading market. The volatility of the market for our common stock could have a material adverse effect on our business, results
of operations and financial condition. There cannot be any guarantee that an active trading market for our securities will develop
or, if such a market does develop, will be sustained. Accordingly, investors must be able to bear the financial risk of losing
their entire investment in our common stock.
We
may voluntarily file for deregistration of our common stock with the Commission.
Compliance
with the periodic reporting requirements required by the Securities and Exchange Commission (the “
Commission
”
or “
SEC
”) consumes a considerable amount of both internal, as well external, resources and represents a significant
cost for us. Our senior management team has relatively limited experience managing a company subject to the reporting requirements
of the Exchange Act, and the regulations promulgated thereunder. Our management will be required to design and implement appropriate
programs and policies in responding to increased legal, regulatory compliance and reporting requirements, and any failure to do
so could lead to the imposition of fines and penalties and harm our business. In addition, if we are unable to continue to devote
adequate funding and the resources needed to maintain such compliance, while continuing our operations, we may be in non-compliance
with applicable SEC rules or the securities laws, and be delisted from the OTCQB or other market we may be listed on, which would
result in a decrease in or absence of liquidity in our common stock, and potentially subject us and our officers and directors
to civil, criminal and/or administrative proceedings and cause us to voluntarily file for deregistration of our common stock with
the Commission.
Future
sales of our common stock in the public market could lower the price of our common stock and impair our ability to raise funds
in future securities offerings.
We
intend to raise additional capital through the sale of our securities. Future sales of a substantial number of shares of our common
stock in the public market, or the perception that such sales may occur, could adversely affect the then prevailing market price
of our common stock and could make it more difficult for us to raise funds in the future through the sale of our securities.
We
may issue shares of preferred stock that subordinate your rights and dilute your equity interests.
We
believe that for us to successfully execute our business strategy we will need to raise investment capital and it may be preferable
or necessary to issue preferred stock to investors. Preferred stock may grant the holders certain preferential rights in voting,
dividends, liquidation or other rights in preference over a company’s common stock.
The
issuance by us of preferred stock could dilute both the equity interests and the earnings per share of existing holders of our
common stock. Such dilution may be substantial, depending upon the number of shares issued. The newly authorized shares of preferred
stock could also have voting rights superior to our common stock, and in such event, would have a dilutive effect on the voting
power of our existing stockholders.
Any
issuance of preferred stock with voting rights could, under certain circumstances, have the effect of delaying or preventing a
change in control of us by increasing the number of outstanding shares entitled to vote and by increasing the number of votes
required to approve a change in control of us. Shares of voting or convertible preferred stock could be issued, or rights to purchase
such shares could be issued, to render more difficult or discourage an attempt to obtain control of us by means of a tender offer,
proxy contest, merger or otherwise. Such issuances could therefore deprive our stockholders of benefits that could result from
such an attempt, such as the realization of a premium over the market price that such an attempt could cause. Moreover, the issuance
of such shares of preferred stock to persons friendly to our Board of Directors could make it more difficult to remove incumbent
managers and directors from office even if such change were to be favorable to stockholders generally.
The
market price of our common stock may be volatile and may be affected by market conditions beyond our control.
The
market for our common shares is characterized by significant price volatility when compared to seasoned issuers, and we expect
that our share price will continue to be more volatile than a seasoned issuer for the indefinite future. The volatility in our
share price is attributable to a number of factors. First, our shares of common stock are sporadically and thinly traded. As a
consequence of this lack of liquidity, the trading of relatively small quantities of shares by our stockholders may disproportionately
influence the price of those shares in either direction. The price for our shares could, for example, decline precipitously in
the event that a large number of shares of our common stock are sold on the market without commensurate demand, as compared to
a seasoned issuer which could better absorb those sales without adverse impact on its share price. Second, we are a speculative
or “risky” investment due to our limited operating history and lack of profits to date, and uncertainty of future
market acceptance for our potential products. As a consequence of this enhanced risk, more risk-averse investors may, under the
fear of losing all or most of their investment in the event of negative news or lack of progress, be more inclined to sell their
shares on the market more quickly and at greater discounts than would be the case with the stock of a seasoned issuer. Many of
these factors are beyond our control and may decrease the market price of our common stock, regardless of our operating performance.
We cannot make any predictions or projections as to what the prevailing market price for our common stock will be at any time,
including as to whether our common stock will sustain its current market price, or as to what effect the sale of shares or the
availability of common stock for sale at any time will have on the prevailing market price.
The
market price of our common stock is subject to significant fluctuations in response to, among other factors:
|
●
|
changes
in our financial performance or a change in financial estimates or recommendations by securities analysts;
|
|
|
|
|
●
|
announcements
of innovations or new products or services by us or our competitors;
|
|
●
|
the
emergence of new competitors or success of our existing competitors;
|
|
|
|
|
●
|
operating
and market price performance of other companies that investors deem comparable;
|
|
|
|
|
●
|
changes
in our Board of Directors or management;
|
|
|
|
|
●
|
sales
or purchases of our common stock by insiders;
|
|
|
|
|
●
|
commencement
of, or involvement in, litigation;
|
|
|
|
|
●
|
changes
in governmental regulations; and
|
|
|
|
|
●
|
general
economic conditions and slow or negative growth of related markets.
|
In
addition, if the market for stock in our industry, or the stock market in general, experiences a loss of investor confidence,
the market price of our common stock could decline for reasons unrelated to our business, financial condition or results of operations.
If any of the foregoing occurs, it could cause the price of our common stock to fall and may expose us to lawsuits that, even
if unsuccessful, could be costly to defend and distract our Board of Directors and management.
We
do not intend to pay dividends for the foreseeable future, and you must rely on increases in the market prices of our common stock
for returns on your investment.
For
the foreseeable future, we intend to retain any earnings to finance the development and expansion of our business, and we do not
anticipate paying any cash dividends on our common stock. Accordingly, investors must be prepared to rely on sales of their common
stock after price appreciation to earn an investment return, which may never occur. Investors seeking cash dividends should not
purchase our common stock. Any determination to pay dividends in the future will be made at the discretion of our Board of Directors
and will depend on our results of operations, financial condition, contractual restrictions, restrictions imposed by applicable
law and other factors our Board of Directors deems relevant.
We
are subject to penny stock regulations and restrictions and you may have difficulty selling shares of our common stock.
The
Commission has adopted regulations which generally define so-called “penny stocks” as an equity security that has
a market price of less than $5.00 per share or an exercise price of less than $5.00 per share, subject to certain exemptions.
Our common stock is a “penny stock”, and we are subject to Rule 15g-9 under the Exchange Act, or the Penny Stock Rule.
This rule imposes additional sales practice requirements on broker-dealers that sell such securities to persons other than established
customers and “accredited investors” (generally, individuals with a net worth in excess of $1,000,000 or annual income
exceeding $200,000, or $300,000 together with their spouses). For transactions covered by Rule 15g-9, a broker-dealer must make
a special suitability determination for the purchaser and receive the purchaser’s written consent to the transaction prior
to sale. As a result, this rule affects the ability of broker-dealers to sell our securities and affects the ability of purchasers
to sell any of our securities in the secondary market.
For
any transaction involving a penny stock, unless exempt, the rules require delivery, prior to any transaction in a penny stock,
of a disclosure schedule prepared by the Commission relating to the penny stock market. Disclosure is also required to be made
about sales commissions payable to both the broker-dealer and the registered representative and current quotations for the securities.
Finally, monthly statements are required to be sent disclosing recent price information for the penny stock held in the account
and information on the limited market in penny stock.
There
can be no assurance that our shares of common stock will qualify for exemption from the Penny Stock Rule. In any event, even if
our common stock were exempt from the Penny Stock Rule, we would remain subject to Section 15(b)(6) of the Exchange Act, which
gives the Commission the authority to restrict any person from participating in a distribution of penny stock if the Commission
finds that such a restriction would be in the public interest.
In
addition to the “penny stock” rules described above, the Financial Industry Regulatory Authority (“
FINRA
”)
has adopted similar rules that may also limit a stockholder’s ability to buy and sell our common stock. FINRA rules require
that in recommending an investment to a customer, a broker-dealer must have reasonable grounds for believing that the investment
is suitable for such customer. Prior to recommending speculative low priced securities to their non-institutional customers, broker-dealers
must make reasonable efforts to obtain information about the customer’s financial status, tax status, investment objectives
and other information. Under interpretations of these rules, FINRA believes that there is a high probability that speculative
low priced securities will not be suitable for at least some customers. The FINRA requirements make it more difficult for broker-dealers
to recommend that their customers buy our common stock, which may limit your ability to buy and sell our stock and have an adverse
effect on the market for our shares.
We
are an “emerging growth company,” and we cannot be certain if the reduced reporting requirements applicable to emerging
growth companies will make our common stock less attractive to investors.
We
are an “emerging growth company,” as defined in the Jumpstart Our Business Startups Act, or the JOBS Act, which was
enacted in April 2012. For as long as we continue to be an emerging growth company, we may take advantage of exemptions from various
reporting requirements that are applicable to other public companies that are not emerging growth companies, including not being
required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley
Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements and exemptions
from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute
payments not previously approved. We could be an emerging growth company for up to five years, although circumstances could cause
us to lose that status earlier. We will remain an emerging growth company until the earlier of (1) the last day of the fiscal
year following the fifth anniversary of the completion of the IPO, (2) the last day of the fiscal year in which we have total
annual gross revenue of at least $1.0 billion, (3) the date on which we are deemed to be a large accelerated filer, which means
the market value of our common stock that is held by non-affiliates exceeds $700.0 million as of the prior June 30th, and (4)
the date on which we have issued more than $1.0 billion in non-convertible debt securities during the prior three-year period.
We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors
find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock
price may suffer or be more volatile.
Under
the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment
of the JOBS Act until such time as those standards apply to private companies. We have elected to use the extended transition
period for complying with new or revised accounting standards that have different effective dates for public and private companies
until the earlier of the date we (i) are no longer an emerging growth company or (ii) affirmatively and irrevocably opt out of
the extended transition period under the JOBS Act.
Provisions
in our corporate charter documents and under Delaware law could make an acquisition of us more difficult and may prevent attempts
by our stockholders to replace or remove our current management.
Provisions
in our corporate charter and our bylaws may discourage, delay, or prevent a merger, acquisition, or other change in control of
us that stockholders may consider favorable, including transactions in which stockholders might otherwise receive a premium for
their shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of our
common stock, thereby depressing the market price of our common stock. In addition, these provisions may frustrate or prevent
any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace
members of our board of directors. Because our board of directors is responsible for appointing the members of our management
team, these provisions could in turn affect any attempt by our stockholders to replace current members of our management team.
Among others, these provisions include the following:
|
●
|
our
board of directors will have the right to elect directors to fill a vacancy created by the expansion of our board of directors
or the resignation, death, or removal of a director, which will prevent stockholders from being able to fill vacancies on
our board of directors;
|
|
|
|
|
●
|
our
stockholders will not be able to act by written consent or call special stockholders’ meetings; as a result, a holder,
or holders, controlling a majority of our capital stock would not be able to take certain actions other than at annual stockholders’
meetings or special stockholders’ meetings called by our board of directors, the chairman of our board, the chief executive
officer, or the president;
|
|
|
|
|
●
|
our
certificate of incorporation will prohibit cumulative voting in the election of directors, which limits the ability of minority
stockholders to elect director candidates;
|
|
|
|
|
●
|
our
stockholders will be required to provide advance notice and additional disclosures in order to nominate individuals for election
to our board of directors or to propose matters that can be acted upon at a stockholders’ meeting, which may discourage
or deter a potential acquiror from conducting a solicitation of proxies to elect the acquiror’s own slate of directors
or otherwise attempting to obtain control of our company; and
|
|
|
|
|
●
|
our
board of directors will be able to issue, without stockholder approval, shares of undesignated preferred stock, which makes
it possible for our board of directors to issue preferred stock with voting or other rights or preferences that could impede
the success of any attempt to acquire us.
|
Moreover,
because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation
Law, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for
a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting
stock, unless the merger or combination is approved in a prescribed manner.
Risks
Related To Market Conditions
We
are registering an aggregate of 27,705,782 Exchange Shares, some or all of which, may be issued pursuant to the Exchange Offer.
The sale of such shares could depress the market price of our common stock.
We
are registering an aggregate of 27,705,782 Exchange Shares, some or all of which, may be issued pursuant to the Exchange Offer.
The 27,705,782 Exchange Shares will represent approximately 18% of our shares outstanding. Our common stock is thinly traded.
The sale of these shares into the public market may result in a greater number of shares being available for trading than the
market can absorb and therefore, could depress the market price of our common stock.
The
sale of material amounts of common stock could encourage short sales by third parties and further depress the price of our common
stock. As a result, you may lose all or part of your investment.
The
significant downward pressure on our common stock price caused by the sale of a significant number of shares could cause our common
stock price to decline, thus allowing short sellers of our common stock an opportunity to take advantage of any decrease in the
value of our common stock. The presence of short sellers in our common stock may further depress the price of our common stock.
USE
OF PROCEEDS
We
estimate that the net proceeds we will receive from the Exchange Offer will be approximately $3,800,000, after deducting
estimated offering expenses payable by us. The receipt of $3,800,000 in net proceeds assumes that all of the Original Warrants
are tendered. We have no ability to know with certainty the number of Original Warrants that will be tendered, if any, and thus,
the receipt of the $3,800,000 of net proceeds and the use of those proceeds outlined below should be read in the context
of this uncertainty.
We
anticipate that the net proceeds from this offering will be used for general corporate purposes, including to continue to fund
our ZanthoSyn® sales and marketing program. We may also fund human clinical trials with ZanthoSyn® to promote scientific
and consumer awareness and advance the development of next generation products for consumer health and pharmaceutical applications,
including seeking orphan drug designation for current or future product candidates. This expected use of the net proceeds
from this offering represents our intentions based upon our current plans and business conditions. As a result, our management
will retain broad discretion over the allocation of the net proceeds from this offering.
PRICE
RANGE OF COMMON STOCK AND DIVIDEND POLICY
Market
Information
Our
shares of common stock are quoted on the OTCQB under the symbol “CDXI.” The high and low bid quotations for our shares
of common stock for each full quarterly period within the two most recent fiscal years and the current fiscal year are:
Quarter
Ended
|
|
High
|
|
|
Low
|
|
|
|
|
|
|
|
|
March
31, 2016
|
|
$
|
0.28
|
|
|
$
|
0.03
|
|
June
30, 2016
|
|
$
|
0.18
|
|
|
$
|
0.05
|
|
September
30, 2016
|
|
$
|
0.20
|
|
|
$
|
0.07
|
|
December
31, 2016
|
|
$
|
0.15
|
|
|
$
|
0.03
|
|
|
|
|
|
|
|
|
|
|
March
31, 2017
|
|
$
|
0.27
|
|
|
$
|
0.09
|
|
June
30, 2017
|
|
$
|
0.23
|
|
|
$
|
0.12
|
|
September
30, 2017
|
|
$
|
0.59
|
|
|
$
|
0.16
|
|
December
31, 2017
|
|
$
|
0.49
|
|
|
$
|
0.07
|
|
|
|
|
|
|
|
|
|
|
March
31, 2018
|
|
$
|
0.44
|
|
|
$
|
0.13
|
|
Such
quotations reflect inter-dealer prices, without retail mark-up, mark-down or commission and do not necessarily represent actual
transactions.
As
of May 1, 2018, there were approximately 470 stockholders of record of our common stock. The number of stockholders
does not include beneficial owners holding shares through nominee names.
As
of May 1, 2018, the last reported sale price of our common stock on the OTCQB was $0.34.
Dividends
We
have never paid any cash dividends and intend, for the foreseeable future, to retain any future earnings for the development of
our business. Our future dividend policy will be determined by our Board of Directors on the basis of various factors, including
our results of operations, financial condition, capital requirements and investment opportunities.
Securities
Authorized for Issuance under Equity Compensation Plans
We
adopted, and our stockholders approved, the Cardax, Inc. 2014 Equity Compensation Plan (the “
2014 Plan
”), effective
as of February 7, 2014. Under such plan, we may grant equity-based incentive awards, including options, restricted stock, and
other stock-based awards, to any directors, employees, advisors, and consultants that provide services to us or any of our subsidiaries
on terms and conditions that are from time to time determined by us. An aggregate of 45,420,148 shares of our common stock are
reserved for issuance under the 2014 Plan. Options for the purchase of 43,365,083 shares of our common stock have been granted,
options for the purchase of 916,357 shares of our common stock have been exercised, and options for the purchase of 3,851,965
shares of our common stock have been forfeited; options for the purchase of 38,596,761 shares of our common stock are outstanding
as of May 1, 2018. In addition, an aggregate of 2,881,386 shares of our common stock have been granted under the 2014 Plan.
The purpose of the 2014 Plan is to provide financial incentives for selected directors, employees, advisors, and consultants of
Cardax and/or its subsidiaries, thereby promoting the long-term growth and financial success of the Company.
Equity
Compensation Plan Information
The
following table summarizes information as of May 1, 2018 about our outstanding stock options and shares of common stock
reserved for future issuance under our existing equity compensation plans.
Plan
category
|
|
Number
of securities to be
issued upon exercise of
outstanding options,
warrants and rights
|
|
|
Weighted-
average
exercise price
of
outstanding
options,
warrants and
rights
|
|
|
Number
of securities
remaining available for future issuance under equity compensation
plans
|
|
Equity
compensation plans approved by security holders
|
|
|
38,596,761
|
|
|
$
|
0.41
|
|
|
|
3,189,727
|
|
Equity
compensation plans not approved by security holders
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
Total
|
|
|
38,596,761
|
|
|
$
|
0.41
|
|
|
|
3,189,727
|
|
Penny
Stock Regulations
The
Commission has adopted regulations which generally define so-called “penny stocks” as an equity security that has
a market price of less than $5.00 per share or an exercise price of less than $5.00 per share, subject to certain exemptions.
Our common stock is a “penny stock”, and we are subject to Rule 15g-9 under the Exchange Act, or the Penny Stock Rule.
This rule imposes additional sales practice requirements on broker-dealers that sell such securities to persons other than established
customers and “accredited investors” (generally, individuals with a net worth in excess of $1,000,000 or annual income
exceeding $200,000, or $300,000 together with their spouses). For transactions covered by Rule 15g-9, a broker-dealer must make
a special suitability determination for the purchaser and receive the purchaser’s written consent to the transaction prior
to sale. As a result, this rule affects the ability of broker-dealers to sell our securities and affects the ability of purchasers
to sell any of our securities in the secondary market.
For
any transaction involving a penny stock, unless exempt, the rules require delivery, prior to any transaction in a penny stock,
of a disclosure schedule prepared by the Commission relating to the penny stock market. Disclosure is also required to be made
about sales commissions payable to both the broker-dealer and the registered representative and current quotations for the securities.
Finally, monthly statements are required to be sent disclosing recent price information for the penny stock held in the account
and information on the limited market in penny stock.
There
can be no assurance that our shares of common stock will qualify for exemption from the Penny Stock Rule. In any event, even if
our common stock were exempt from the Penny Stock Rule, we would remain subject to Section 15(b)(6) of the Exchange Act, which
gives the Commission the authority to restrict any person from participating in a distribution of penny stock if the Commission
finds that such a restriction would be in the public interest.
In
addition to the “penny stock” rules described above, the FINRA has adopted similar rules that may also limit a stockholder’s
ability to buy and sell our common stock. FINRA rules require that in recommending an investment to a customer, a broker-dealer
must have reasonable grounds for believing that the investment is suitable for such customer. Prior to recommending speculative
low priced securities to their non-institutional customers, broker-dealers must make reasonable efforts to obtain information
about the customer’s financial status, tax status, investment objectives and other information. Under interpretations of
these rules, FINRA believes that there is a high probability that speculative low priced securities will not be suitable for at
least some customers. The FINRA requirements make it more difficult for broker-dealers to recommend that their customers buy our
common stock, which may limit the ability of our stockholders to sell their shares and have an adverse effect on the market for
our shares.
Management’s
Discussion and Analysis of Financial Condition and Results of Operations
The
financial data discussed below is derived from our audited consolidated financial statements for the fiscal years ended December
31, 2017 and 2016, which are found elsewhere in this prospectus. Our consolidated financial statements are prepared and presented
in accordance with generally accepted accounting principles in the United States. The financial data discussed below is only a
summary and investors should read the following discussion and analysis of our financial condition and results of our operations
in conjunction with our consolidated financial statements and the related notes to those statements included elsewhere in this
prospectus. This discussion contains forward-looking statements reflecting our current expectations that involve risks and uncertainties.
Our actual results and the timing of events may differ materially from those contained in these forward-looking statements
due to a number of factors, including those discussed in the section entitled “Risk Factors,” and elsewhere in this
prospectus.
Corporate
Overview and History
We
were incorporated on January 30, 2012, as a Delaware corporation, under the name “Koffee Korner Inc., and later changed
our name to Cardax, Inc. in a February 7, 2014 reverse merger (the “
Merger
”) that acquired the life sciences
business of Pharma. Prior to the February 7, 2014, our business was limited to a single location retailer of specialty coffee
located in Houston, Texas. On the effective date of the Merger, we divested our coffee business and now exclusively continue Pharma’s
life sciences business. On December 30, 2015, our former principal stockholder, Holdings, merged with and into us.
We
are devoting substantially all of our present efforts to establishing our business related to the development and commercialization
of consumer health products. Our first commercial product, ZanthoSyn®, is a physician recommended anti-inflammatory supplement
for health and longevity that features astaxanthin with optimal absorption and purity. The form of astaxanthin utilized in ZanthoSyn®
has demonstrated excellent safety in peer-reviewed published studies and is designated as GRAS (Generally Recognized as Safe)
according to FDA regulations. We sell ZanthoSyn® primarily through e-commerce and wholesale channels and expect that our marketing
program will continue to focus on education of physicians, healthcare professionals, retail personnel, and consumers. As a next
generation product, we are developing CDX-085, our patented astaxanthin derivative for more concentrated astaxanthin product applications.
We may also pursue pharmaceutical applications of astaxanthin and related compounds. The safety and efficacy of our products have
not been directly evaluated in clinical trials or confirmed by the FDA.
At
present we are not able to estimate if or when we will be able to generate sustained revenues. Our financial statements have been
prepared assuming that we will continue as a going concern; however, given our recurring losses from operations, our independent
registered public accounting firm has determined there is substantial doubt about our ability to continue as a going concern.
Results
of Operations
Results
of Operations for the Years Ended December 31, 2017 and 2016:
The
following table reflects our operating results for the years ended December 31, 2017 and 2016:
Operating
Summary
|
|
Year
ended
December 31, 2017
|
|
|
Year
ended
December 31, 2016
|
|
|
Change
|
|
Revenues,
net
|
|
$
|
610,323
|
|
|
$
|
35,258
|
|
|
$
|
575,065
|
|
Cost
of Goods Sold
|
|
|
(274,707
|
)
|
|
|
(14,580
|
)
|
|
|
(260,127
|
)
|
Gross
Profit
|
|
|
335,616
|
|
|
|
20,678
|
|
|
|
314,938
|
|
Operating
Expenses
|
|
|
(2,337,886
|
)
|
|
|
(1,850,902
|
)
|
|
|
(486,984
|
)
|
Net
Operating Loss
|
|
|
(2,002,270
|
)
|
|
|
(1,830,224
|
)
|
|
|
(172,046
|
)
|
Other
Income
|
|
|
17,036
|
|
|
|
46,519
|
|
|
|
(29,483
|
)
|
Net
Loss
|
|
$
|
(1,985,234
|
)
|
|
$
|
(1,783,705
|
)
|
|
$
|
(201,529
|
)
|
Operating
Summary
We
sell ZanthoSyn® primarily through e-commerce and wholesale channels. We launched our e-commerce channel in August 2016 and
began selling to GNC stores in Hawaii on January 25, 2017 and GNC corporate stores across the United States on August 10, 2017.
As a result, revenues were $610,323 and $35,258 for the years ended December 31, 2017 and 2016, respectively. Cost of goods sold
were $274,707 and $14,580 for the years ended December 31, 2017 and 2016, respectively, and included costs of the product, shipping
and handling, sales taxes, merchant fees, and other costs incurred on the sale of goods. Gross profits were $335,616 and $20,678
for the years ended December 31, 2017 and 2016, which represented gross profit margins of 55% and 59%, respectively.
Operating
expenses were $2,337,886 and $1,850,902, for the years ended December 31, 2017 and 2016, respectively. Operating expenses primarily
consisted of services provided to the Company, including payroll and consultation, for research and development, administration,
and sales and marketing. These expenses were paid in accordance with agreements entered into with each consultant, employee, or
service provider. Included in operating expenses were $242,146 and $525,062 in stock based compensation for the years ended December
31, 2017 and 2016, respectively.
Other
income was $17,036 and $46,519, for the years ended December 31, 2017 and 2016, respectively. For the years ended December 31,
2017 and 2016, other income primarily consisted of a State of Hawaii refundable research and development credit of $17,253 and
$47,082.
Assets
and Liabilities
Assets
were $3,156,685 and $750,580 as of December 31, 2017 and 2016, respectively. The increase was primarily due to an increase in
cash. At December 31, 2017, cash totaled $2,236,837. Negative working capital of $1,833,988 as of December 31, 2017, was primarily
due to accrued payroll and paid time off of $3,490,225, accrued Board of Director fees and related consultation of $418,546, and
accounts payable of $603,391, less cash of $2,236,837. The accrual of payroll and Board of Director fees and related consultation,
which occurred from January 2008 to December 2013, was due to significant capital constraints, and was selected in favor of layoffs
or furloughs in order to maximize employee and director retention. In 2013 and 2014, the Company initiated repayment on these
accrued amounts, utilizing approximately 5% to 10% of proceeds from various financings and plans to continue a structured repayment
of the outstanding amounts over time as resources permit.
Liquidity
and Capital Resources
Since
our inception, we have sustained operating losses and have used cash raised by issuing securities in our operations. During the
years ended December 31, 2017 and 2016, we used cash in operating activities of $2,080,623 and $1,256,771, respectively, and incurred
a net loss of $1,985,234 and $1,783,705, respectively.
As
of December 31, 2017, we had a U.S. federal income tax net operating loss carryforward of $33,345,946. The net operating losses
may be available to offset our future taxable income to the extent permitted under the Internal Revenue Code.
We
require additional financing in order to continue to fund our operations and to pay existing and future liabilities and other
obligations.
In
addition to the $4,138,435 raised during the year ended December 31, 2017, we intend to raise additional capital that would fund
our operations through at least December 31, 2018. We may continue to obtain additional financing from investors through the private
placement of our common stock and warrants to purchase our common stock. Any financing transaction could also, or in the alternative,
include the issuance of our debt or convertible debt securities. There can be no assurance that a financing transaction would
be available to us on terms and conditions that we determined are acceptable. We may also access capital under the previously
reported equity purchase agreement, pursuant to which we have the right, but not the obligation, to sell shares of our common
stock, as described in our Registration Statement on Form S-1 (333-214049) filed on February 8, 2017.
We
cannot give any assurance that we will in the future be able to achieve a level of profitability from the sale of existing or
future products or otherwise to sustain our operations. These conditions raise substantial doubt about our ability to continue
as a going concern. The accompanying financial statements do not include any adjustments to reflect the possible future effects
on recoverability and reclassification of assets or the amounts and classification of liabilities that may result from the outcome
of this uncertainty.
Any
inability to obtain additional financing on acceptable terms will materially and adversely affect us, including requiring us to
significantly further curtail or cease business operations altogether.
Our
working capital and capital requirements at any given time depend upon numerous factors, including, but not limited to:
|
●
|
revenues
from the sale of any products or licenses;
|
|
|
|
|
●
|
costs
of production, marketing and sales capabilities, or other operating expenses; and
|
|
|
|
|
●
|
costs
of research, development, and commercialization of our technologies.
|
We
have funded our research, development, and commercialization primarily by issuing convertible debt and equity securities in several
separate private placements of securities.
Upon
the consummation of the Merger, the outstanding principal amount of the senior secured convertible promissory notes issued by
Pharma in 2013, consisting of (a) the aggregate principal amount of approximately $3,648,244 for notes exchanged with Holdings
on May 31, 2013, and (b) the aggregate principal amount of $4,840,792 for notes issued by Pharma during the year ended December
31, 2013, together in the aggregate principal amount of $8,489,036, plus all accrued interest thereon, was automatically converted
into an aggregate number of 14,446,777 shares of our common stock and warrants, issued by Cardax, to purchase an aggregate of
14,446,777 shares of our common stock at an exercise price equal to $0.625 that expire on February 7, 2019.
Upon
the consummation of the Merger, the outstanding principal amount of the convertible unsecured promissory notes issued by Pharma
in 2014, consisting of the aggregate principal amount of $2,076,000 plus all accrued interest thereon, was automatically converted
into an aggregate number of 3,353,437 shares of our common stock and warrants to purchase an aggregate of 3,321,600 shares of
our common stock at an exercise price equal to $0.625 that expire on February 7, 2019.
Upon
the consummation of the Merger we issued and sold an aggregate of 6,276,960 shares of our common stock and warrants, that expire
on February 7, 2019, to purchase an aggregate of 6,276,960 shares of our common stock at a price per share equal to $0.625, for
aggregate gross cash proceeds of $3,923,100.
During
the year ended December 31, 2015, we sold securities in a self-directed offering in the aggregate amount of $1,806,222 at $0.30
per unit, which included the conversion of a $30,000 note issued on January 28, 2015 and $222 in accrued interest. Each unit consisted
of one share of our common stock, two Class D warrants, each to purchase one share of our common stock at $0.10 per share, which
expire March 31, 2020, and one Class E warrant to purchase three-fourths of one share of our common stock at $0.1667 per share,
which expires March 31, 2020. In aggregate, we issued 6,020,725 shares of our common stock, Class D warrants to purchase 12,041,450
shares of our common stock, and Class E warrants to purchase 4,515,554 shares of our common stock.
During
the year ended December 31, 2016 and the first quarter of 2017, we sold securities in a self-directed offering in the aggregate
amount of $1,300,000 at $0.08 per unit. Each unit consisted of (i) one share of our common stock, (ii) a five-year warrant to
purchase one share of our common stock at $0.08, (iii) a five-year warrant to purchase one share of our common stock at $0.12,
and (iv) a five-year warrant to purchase one share of our common stock at $0.16. In aggregate, we issued (i) 16,250,000 shares
of our common stock, (ii) warrants to purchase 16,250,000 shares of our common stock at $0.08 per share, (iii) warrants to purchase
16,250,000 shares of our common stock at $0.12 per share, and (iv) warrants to purchase 16,250,000 shares of our common stock
at $0.16 per share.
During
the year ended December 31, 2017, we sold securities in a self-directed offering in the aggregate amount of $3,774,456 at $0.12
per unit. Each unit consisted of (i) one share of our common stock, and (ii) a five-year warrant to purchase one share of our
common stock at $0.12. In aggregate, we issued (i) 31,453,788 shares of our common stock, and (ii) warrants to purchase 31,453,788
shares of our common stock at $0.12 per share.
During
the year ended December 31, 2017, we sold securities in a self-directed offering in the aggregate amount of $124,979 at $0.30
per unit. Each unit consisted of (i) one share of our common stock, and (ii) a five-year warrant to purchase one share of our
common stock at $0.30. In aggregate, we issued (i) 416,595 shares of our common stock, and (ii) warrants to purchase 416,595 shares
of our common stock at $0.30 per share.
On
July 13, 2016, we entered into an Equity Purchase Agreement with Southridge. Pursuant to the Equity Purchase Agreement, Southridge
shall commit to purchase up to $5,000,000 of our common stock over the course of twenty-four (24) months commencing on February
9, 2017, the effective date of our registration statement pursuant to the registration rights agreement. The price that we may
specify in any exercise of a Put Right will be determined by calculating a 12% discount to the lowest closing bid price—subject
to a pre-designated floor—during a ten trading day period following delivery of a notice of the exercise of our Put Right
to Southridge.
As
a result of the foregoing, management believes that that the Company should have sufficient sources of liquidity to satisfy its
obligations for at least the next 12 months. To the extent our cash and cash equivalents, cash flow from operating activities,
and net proceeds from the issuance of our common stock pursuant to the Equity Purchase Agreement are insufficient to fund our
future activities, we may need to raise additional funds through bank credit arrangements or public or private equity or debt
financings. We also may need to raise additional funds in the event we determine in the future to effect one or more acquisitions
of, or investments in, businesses, services or technologies. If additional funding is required, we may not be able to obtain bank
credit arrangements or to effect an equity or debt financing on terms acceptable to us or at all.
We
will incur ongoing recurring expenses associated with professional fees for accounting, legal, and other expenses for annual reports,
quarterly reports, proxy statements and other filings under the Exchange Act. We estimate that these costs will likely be in excess
of $250,000 per year for the next few years. These obligations will reduce our ability and resources to fund other aspects of
our business. We hope to be able to use our status as a public company to increase our ability to use non-cash means of settling
obligations and compensate certain independent contractors who provide professional services to us, although there can be no assurances
that we will be successful in any of those efforts.
The
following is a summary of our cash flows provided by (used in) operating, investing, and financing activities during the periods
indicated:
Cash
Flow Summary
|
|
Year
ended
December 31, 2017
|
|
|
Year
ended
December 31, 2016
|
|
Net
Cash Used in Operating Activities
|
|
$
|
(2,080,623
|
)
|
|
$
|
(1,256,771
|
)
|
Net
Cash Used in Investing Activities
|
|
|
(19,408
|
)
|
|
|
(29,206
|
)
|
Net
Cash Provided by Financing Activities
|
|
|
4,178,435
|
|
|
|
1,121,000
|
|
Net
Cash Increase (Decrease) for Period
|
|
|
2,078,404
|
|
|
|
(164,977
|
)
|
Cash
at Beginning of Year
|
|
|
158,433
|
|
|
|
323,410
|
|
Cash
at End of Year
|
|
$
|
2,236,837
|
|
|
$
|
158,433
|
|
Cash
Flows from Operating Activities
During
the years ended December 31, 2017 and 2016, our operating activities primarily consisted of payments or accruals for employees,
directors, and consultants for services related to research and development, administration, and sales and marketing.
Cash
Flows from Investing Activities
During
the years ended December 31, 2017 and 2016, our investing activities were primarily related to the capitalization of patent costs.
Cash
Flows from Financing Activities
During
the years ended December 31, 2017 and 2016, our financing activities primarily consisted of various transactions in which we raised
proceeds through the issuance of common stock.
Our
existing liquidity is not sufficient to fund our operations, anticipated capital expenditures, working capital and other financing
requirements for the foreseeable future. We will need to seek to obtain additional debt or equity financing, especially if we
experience downturns or cyclical fluctuations in our business that are more severe or longer than anticipated, or if we experience
significant increases in the cost of components and manufacturing, or increases in our expense levels resulting from being a publicly-traded
company. If we attempt to obtain additional debt or equity financing, we cannot assure you that such financing will be available
to us on favorable terms, or at all.
Recently
Issued Accounting Pronouncements
In
May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”)
No. 2014-09,
Revenue from Contracts with Customers
, related to revenue recognition. The underlying principle of this ASU
is that a business or other organization will recognize revenue to depict the transfer of promised goods or services to customers
in an amount that reflects what it expects in exchange for the goods or services. This ASU also requires more detailed disclosures
and provides additional guidance for transactions that were not addressed completely in prior accounting guidance. ASU No. 2014-09
provides alternative methods of initial adoption. The Company is currently assessing the impact of this ASU on the Company’s
consolidated financial statements. In August 2015, the FASB issued ASU No. 2015-14,
Revenue from Contracts with Customers (Topic
606): Deferral of the Effective Date
, which defers the effective date of ASU No. 2014-09 by one year to fiscal years beginning
after December 15, 2017, including interim periods within those years and permitted early adoption of the standard, but not before
the original effective date. The Company has assessed the impact of these ASUs and does not believe that they will have a material
effect on the Company’s consolidated financial statements.
The
FASB issued four additional ASUs in 2016 that affect the guidance in ASU No. 2014-09,
Revenue from Contracts with Customers
,
and are effective upon adoption of ASU No. 2014-09.
The
Company has assessed the impact of these ASUs and does not believe that they will have a material effect on the Company’s
consolidated financial statements, including the following ASUs:
|
●
|
In
March 2016, the FASB issued ASU No. 2016-08,
Revenue from Contracts with Customers (Topic 606): Principal versus Agent
Considerations (Reporting Revenue Gross versus Net)
. This ASU clarifies the implementation guidance on principal versus
agent considerations. The guidance includes indicators to assist an entity in determining whether it controls a specified
good or service before it is transferred to the customers.
|
|
●
|
In
April 2016, the FASB issued ASU No. 2016-10,
Identifying Performance Obligations and Licensing
. This ASU clarifies
the following two aspects of ASU No. 2014-09: identifying performance obligations and licensing implementation guidance. The
amendment requires revenue recognition to depict the transfer of goods or services to customers in an amount that reflects
the consideration that a company expects to be entitled to in exchange for the goods or services. To achieve this principle,
a company must apply five steps including identifying the contract with a customer, identifying the performance obligations
in the contract, determining the transaction price, allocating the transaction price to the performance obligations, and recognizing
revenue when (or as) the company satisfies the performance obligations. Additional quantitative and qualitative disclosures
to enhance the understanding about the nature, amount, timing, and uncertainty of revenue and cash flows are also required.
|
|
●
|
In
May 2016, the FASB issued ASU No. 2016-12,
Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements
and Practical Expedients
. This ASU makes narrow-scope amendments to ASU No. 2014-09,
Revenue from Contracts with Customers
,
and provides practical expedients to simplify the transition to the new standard and to clarify certain aspects of the standard.
|
|
●
|
In
December 2016, the FASB issued ASU 2016-20,
Technical Corrections and Improvements to Topic 606, Revenue from Contracts
with Customers (Topic 606)
. This ASU addresses technical corrections and improvements to clarify the codification and
to correct unintended application of guidance. Those items generally are not expected to have a significant effect on current
accounting practice or create a significant administrative cost for most entities. The amendments in this Update are of a
similar nature to the items typically addressed in the Technical Corrections and Improvements project.
|
In
February 2016, the FASB issued ASU No. 2016-02,
Leases
. This ASU requires management to recognize lease assets and lease
liabilities for all leases. ASU No. 2016-02 retains a distinction between finance leases and operating leases. The classification
criteria for distinguishing between finance leases and operating leases are substantially similar to the classification criteria
for distinguishing between capital leases and operating leases in the previous leases guidance. The result of retaining a distinction
between finance leases and operating leases is that under the lessee accounting model, the effect of leases in the statement of
comprehensive income and the statement of cash flows is largely unchanged from previous U.S. GAAP. The guidance in ASU No. 2016-02
is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company
is currently assessing the impact of this ASU on the Company’s consolidated financial statements.
In
March 2016, the FASB issued ASU No. 2016-09,
Compensation - Stock Compensation
. This ASU was issued as part of the FASB’s
simplification initiative focused on improving areas of U.S. GAAP for which cost and complexity may be reduced while maintaining
or improving the usefulness of information disclosed within the financial statements. The amendments focused on simplification
specifically with regard to share-based payment transactions, including income tax consequences, classification of awards as equity
or liabilities, and classification on the statement of cash flows. The guidance in ASU No. 2016-09 is effective for fiscal years
beginning after December 15, 2016, including interim periods within those fiscal years. Early adoption is permitted. The amendments
in this ASU should be applied prospectively to an award modified on or after the adoption date. The Company has assessed the impact
of this ASU and does not believe that this update has a significant impact on its consolidated financial statements.
In
November 2016, the FASB issued ASU 2016-18,
Statement of Cash Flows (Topic 23)
. The amendments of ASU No. 2016-18 require
that a statement of cash flow explain the change during a period in the total of cash, cash equivalents, and amounts generally
described as restricted cash or restricted cash equivalents. The guidance of ASU No. 2016-18 is effective for years beginning
after December 15, 2017, including interim periods within those years. The Company has assessed the impact of this ASU and does
not believe that this update has a significant impact on its consolidated financial statements.
In
May 2017, the FASB issued ASU No. 2017-09,
Compensation-Stock Compensation: Scope of Modification Accounting
. The amendments
of ASU No. 2017-09 provide guidance about which changes to the terms or conditions of a share-based payment award require an entity
to apply modification accounting. The guidance of ASU No. 2017-09 is effective for years beginning after December 15, 2017, including
interim periods within those years. The Company has assessed the impact of this ASU and does not believe that this update has
a significant impact on its consolidated financial statements.
We
do not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material
effect on the consolidated financial statements.
Off-Balance
Sheet Arrangements
There
are no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition,
changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.
Our
Business
Overview
We
are a life sciences company engaged in the development, marketing, and distribution of consumer health products and we are a smaller
reporting company as defined by applicable federal securities regulations.
We
were incorporated on January 30, 2012, as a Delaware corporation, under the name “Koffee Korner Inc., and later changed
our name to Cardax, Inc. in a February 7, 2014 reverse merger (the “
Merger
”) that acquired the life sciences
business of Pharma. On the effective date of the Merger, we divested our coffee business and now exclusively continue Pharma’s
life sciences business. On December 30, 2015, our former principal stockholder, Holdings, merged with and into us.
Our
executive offices are located at 2800 Woodlawn Drive, Suite 129, Honolulu, Hawaii 96822; our telephone number is (808) 457-1400.
Our website is located at https://www.cardaxpharma.com. The information on our website is not part of this prospectus.
Our
Business
We
are a life sciences company engaged in the development, marketing, and distribution of consumer health products. We believe we
are well positioned for significant and sustained growth via the commercialization of consumer health products utilizing synthetically
manufactured astaxanthin and related xanthophyll carotenoids, which support health and longevity by reducing inflammation at the
cellular and mitochondrial level without inhibiting normal function. We may also pursue the development of astaxanthin and related
xanthophyll carotenoids for pharmaceutical applications. The safety and efficacy of our products have not been directly evaluated
in clinical trials or confirmed by the U.S. Food and Drug Administration (the “FDA”).
Our
Products
ZanthoSyn®
is marketed as a novel astaxanthin dietary supplement with superior absorption and purity. Astaxanthin is a naturally occurring
molecule with safe anti-inflammatory activity that supports joint health, cardiovascular health, metabolic health, liver health,
and longevity. The form of astaxanthin utilized in ZanthoSyn® has demonstrated excellent safety in peer-reviewed published
studies and is Generally Recognized as Safe (“GRAS”) according to FDA regulations.
We
sell ZanthoSyn® primarily through e-commerce and wholesale channels. We launched our e-commerce channel in August 2016 and
began selling to General Nutrition Corporation (“GNC”) stores in Hawaii on January 25, 2017 and GNC corporate stores
across the United States on August 10, 2017. ZanthoSyn® is currently available at over three thousand GNC corporate stores
in the United States. ZanthoSyn® was the top selling product at GNC stores in Hawaii during the fourth quarter of 2017. We
have also sold ZanthoSyn® on a wholesale basis to Health Elite Club Limited, a Hong Kong-based company.
Our
ZanthoSyn® product manufacturing process relies on certain third-party suppliers and this dependence creates several risks,
including limited control over pricing, availability, quality, and delivery schedules. In addition, any supply interruption could
materially harm our ability to manufacture ZanthoSyn® until a new source of supply is obtained on acceptable terms. We may
be unable to find such other sources in a reasonable time period or on commercially reasonable terms, if at all, which would have
an adverse effect on our business, financial condition and results of operations.
We
market ZanthoSyn® primarily through a two-pronged approach:
|
●
|
Physician
outreach and education, where ZanthoSyn
®
is positioned as the first safe, physician friendly, anti-inflammatory
for health and longevity, and GNC serves as a convenient and credible distribution channel for physicians recommending ZanthoSyn
®
|
|
|
|
|
●
|
GNC
store outreach, education, and in-store sales support, building on the ability to utilize ZanthoSyn
®
as a foundation
of health, wellness, and performance regimens
|
Our
sales and marketing program was initially launched in Hawaii, where robust physician outreach and education coupled with GNC store
outreach, education, and in-store sales support increased consumer awareness and catalyzed strong sales growth. We have also launched
this program in major markets in California and expect to extend this program nationally as resources permit. To support these
efforts, we have hired additional sales and marketing personnel.
We
may also conduct human clinical trials with astaxanthin and are currently evaluating various opportunities. While the FDA
does not require human clinical trials for consumer health products, we believe that positive results from human clinical trials
would promote scientific and consumer awareness of astaxanthin’s health and longevity applications.
As
a next generation ZanthoSyn® product, we are developing CDX-085, our patented astaxanthin derivative for more concentrated
astaxanthin product applications. In collaboration with the University of Hawaii, we demonstrated that astaxanthin through administration
of CDX-085 activated an important anti-aging gene in rodents. Following these results, the National Institutes of Health selected
CDX-085 for an important anti-aging research program.
Synthetic
Astaxanthin vs. Natural Astaxanthin
We
believe synthetic astaxanthin offers significant advantages compared to astaxanthin from microalgae, krill, or other sources:
|
●
|
Synthetic
astaxanthin can be formulated for superior bioavailability; in a human study comparing ZanthoSyn® (our synthetic astaxanthin
dietary supplement) to a leading microalgal astaxanthin product, the astaxanthin blood levels following administration of
ZanthoSyn® were nearly 3 times higher than the microalgal astaxanthin product at the same dose.
|
|
|
|
|
●
|
Synthetic
astaxanthin has been extensively tested in a battery of toxicity studies, including acute, subacute, subchronic, and chronic
toxicity studies, carcinogenicity studies, genotoxicity studies, and developmental and reproductive toxicity studies; whereas
to our knowledge microalgal or other sources of astaxanthin have not undergone the same amount of safety testing in such toxicity
studies.
|
|
|
|
|
●
|
Synthetic
astaxanthin is manufactured with superior purity and precision, whereas astaxanthin extracted from microalgae and krill oil
is obtained in a complex mixture, which may include many unknown marine byproducts.
|
|
|
|
|
●
|
Synthetic
manufacture of astaxanthin is scalable, whereas we believe the ability to readily scale the production and extraction of astaxanthin
from microalgae or other sources will be limited as demand for astaxanthin grows.
|
|
|
|
|
●
|
Synthetic
manufacture of astaxanthin emits fewer greenhouse gases and consumes less energy, raw material, and land than traditional
microalgal astaxanthin production.
|
Pharmaceutical
Development
We
may pursue the development of astaxanthin and related xanthophyll carotenoids for pharmaceutical applications and are currently
evaluating the feasibility of targeting rare diseases or conditions under the FDA’s orphan drug program.
Research
and Development
Our
research and development program is presently comprised of employees, consultants, including regulatory, scientific, and medical
professionals, and third-party collaborators or contract organizations, including academic institutions, contract research organizations,
and contract manufacturing organizations. We utilized dedicated internal synthetic chemistry, biology, and bioanalytical chemistry
laboratories and a research and development staff to conduct discovery stage synthesis of product candidates (with transfer of
materials and/or methods for additional process development and/or testing),
in vitro
testing of product candidates and
related components to elucidate the mechanism of action, and analysis of biological samples from internal research and/or contract
organizations to detect and quantify levels of product candidates and related components following administration of product in
various studies. Our research and development staff has also worked with other professionals to identify, contract and transfer
materials and methods, and oversee research and manufacturing by contract organizations. Contract organizations provide us with
access to larger scale manufacturing, animal proof-of-concept studies, pharmacokinetics, and toxicity, and analysis that would
not otherwise be available to us without significant expense. We anticipate that the majority of our research and development
will be conducted by contract organizations with direction and oversight by our current internal research and development personnel,
including two Ph.D. scientists, two Ph.D. scientific executives, one operational executive, and one M.D. consultant.
In
addition to conducting or overseeing research and development activities, our research and development personnel analyze and interpret
other research on astaxanthin, as well as related compounds, competing products, applicable health applications, and industry
trends. In the United States National Library of Medicine’s online repository, PubMed.gov, there are more than 1,600 peer-reviewed
journal articles that reference astaxanthin in the title or abstract, over 400 of which were published in the last three years,
with the vast majority published by organizations and researchers that are not affiliated with us. This type of “open-source”
research has served to significantly advance the understanding of astaxanthin, and has also presented our research and development
personnel with the critical task of keeping up-to-date on all of the latest research and interpreting and integrating the findings
with our research and that of others in order to serve as the preeminent thought leaders on astaxanthin’s mechanism of action
and its application in biological systems.
Our
research and development expenditures totaled $460,991 and $347,885 for the years ended December 31, 2017 and 2016. These expenditures
primarily reflect the compensation of our research and development personnel and product development activities.
Government
Regulation
Most
aspects of our business are subject to some degree of government regulation. For some of our products, government regulation is
significant and, in general, there appears to be a trend toward more stringent regulation throughout the world, as well as global
harmonization of various regulatory requirements. We expect to devote significant time, effort and expense to address the extensive
government and regulatory requirements applicable to our business. We believe that we are no more or less adversely affected by
existing government regulations than our competitors.
FDA
Regulation
Life
sciences companies must comply with comprehensive regulation by the FDA and other regulatory agencies in the United States and
comparable authorities in other countries. While the FDA does not require human clinical trials for consumer health products,
we may conduct Phase I, Phase II, and/or Phase III clinical trials with our products.
We
must obtain regulatory approvals by the FDA and, to the extent we have any international distribution of our products, foreign
government agencies prior to human clinical testing and commercialization of any pharmaceutical product and for post-approval
clinical studies for additional indications in approved drugs. We anticipate that any pharmaceutical product candidate will be
subject to rigorous preclinical and clinical testing and pre-market approval procedures by the FDA and similar health authorities
in foreign countries to the extent applicable. The extent to which our products are regulated by the FDA, and the designations
applicable to our products, will depend upon the types of products we ultimately develop. We are currently evaluating other product
developments or technologies to pursue and cannot predict, during this stage of our development, the scope of FDA or other agency
regulation to which we or our products and technologies will be subject. Various federal statutes and regulations also govern
or influence the preclinical and clinical testing, record-keeping, approval, labeling, manufacture, quality, shipping, distribution,
storage, marketing and promotion, export and reimbursement of products and product candidates.
The
steps ordinarily required before a drug product may be marketed in the United States include:
|
●
|
preclinical
studies;
|
|
|
|
|
●
|
submission
to the FDA of an IND, which must become effective before human clinical trials may commence;
|
|
●
|
adequate
and well-controlled human clinical trials to establish the safety and efficacy of the product candidate in the desired indication
for use;
|
|
|
|
|
●
|
submission
of an NDA to the FDA, together with payment of a substantial user fee; and
|
|
|
|
|
●
|
FDA
approval of the NDA, including inspection and approval of the product manufacturing facility and select sites at which human
clinical trials were conducted.
|
Preclinical
trials typically involve laboratory evaluation of product candidate chemistry, formulation and stability, as well as animal studies
to assess the potential safety and efficacy of each product candidate. The results of preclinical trials are submitted to the
FDA as part of an IND and are reviewed by the FDA before the commencement of clinical trials. Unless the FDA objects to an IND,
the IND will become effective 30 days following its receipt by the FDA. Submission of an IND may not result in FDA clearance to
commence clinical trials, and the FDA’s failure to object to an IND does not guarantee FDA approval of a marketing application.
Clinical
trials involve the administration of the product candidate to humans under the supervision of a qualified principal investigator.
In the United States, clinical trials must be conducted in accordance with Good Clinical Practices under protocols submitted to
the FDA as part of the IND. In addition, each clinical trial must be approved and conducted under the auspices of an institutional
review board and with the patient’s informed consent. We would be subject to similar protocols and similar regulatory considerations
if we conduct clinical trials outside the United States.
The
goal of Phase I clinical trials is to establish initial data about safety and tolerability of the product candidate in humans.
The investigators seek to evaluate the effects of various dosages and to establish an optimal dosage level and schedule.
The
goal of Phase II clinical trials is to provide evidence about the desired therapeutic efficacy of the product candidate in limited
studies with small numbers of carefully selected subjects. Investigators also gather additional safety data.
Phase
III clinical trials consist of expanded, large-scale, multi-center studies in the target patient population. This phase further
tests the product’s effectiveness, monitors side effects, and, in some cases, compares the product’s effects to a
standard treatment, if one is already available. Phase III trials are designed to more rigorously test the efficacy of a product
candidate and are normally randomized, double-blinded, and placebo-controlled. Phase III trials are typically monitored by an
independent data monitoring committee, or DMC, which periodically reviews data as a trial progresses. A DMC may recommend that
a trial be stopped before completion for a number of reasons including safety concerns, patient benefit or futility.
Data
obtained from this development program are submitted as part of an NDA to the FDA and possibly to corresponding agencies
in other countries for review. The NDA requires agency approval prior to marketing in the relevant country. Extensive regulations
define the form, content and methods of gathering, compiling and analyzing the product candidate’s safety and efficacy data.
The
process of obtaining regulatory approval can be costly, time consuming and subject to unanticipated delays. Regulatory agencies
may refuse to approve an application if they believe that applicable regulatory criteria are not satisfied and may also require
additional testing for safety and efficacy and/or post-marketing surveillance or other ongoing requirements for post-marketing
studies. In some instances, regulatory approval may be granted with the condition that confirmatory Phase IV clinical trials are
carried out, and if these trials do not confirm the results of previous studies, regulatory approval for marketing may be withdrawn.
Moreover, each regulatory approval of a product is limited to specific indications. The FDA or other regulatory authorities may
approve only limited label information for the product. The label information describes the indications and methods of use for
which the product is authorized, may include Risk Evaluation and Mitigation Strategies and, if overly restrictive, may limit a
sponsor’s ability to successfully market the product. Regulatory agencies routinely revise or issue new regulations, which
can affect and delay regulatory approval of product candidates.
Furthermore,
pharmaceutical manufacturing processes must conform to current Good Manufacturing Practices, or cGMPs. Manufacturers, including
a drug sponsor’s third-party contract manufacturers, must expend time, money and effort in the areas of production, quality
control and quality assurance, including compliance with stringent record-keeping requirements. Manufacturing establishments are
subject to periodic inspections by the FDA or other health authorities, in order to assess, among other things, compliance with
cGMP. Before approval of the initiation of commercial manufacturing processes, the FDA will usually perform a preapproval inspection
of the facility to determine its compliance with cGMP and other rules and regulations. In addition, foreign manufacturing establishments
must also comply with cGMPs in order to supply products for use in the United States, and are subject to periodic inspection by
the FDA or by regulatory authorities in certain countries under reciprocal agreements with the FDA. Manufacturing processes and
facilities for pharmaceutical products are highly regulated. Regulatory authorities may choose not to certify or may impose restrictions,
or even shut down existing manufacturing facilities that they determine are non-compliant.
FDA
GRAS Determination
“
GRAS
”
is an acronym for the phrase “generally recognized as safe,” which the FDA utilizes to describe those substances that,
in the generally recognized opinion of the scientific community, will not be harmful to consumers, provided the substance is used
as intended. According to applicable FDA regulations, any substance that is intentionally added to food is a food additive, which
is subject to premarket review and approval by FDA, unless the substance is generally recognized, among qualified experts, as
having been adequately shown to be safe under the conditions of its intended use. Under sections 201(s) and 409 of the Federal
Food, Drug, and Cosmetic Act (the “
FD&C Act
”), and FDA’s implementing regulations in 21 CFR 170.3
and 21 CFR 170.30, the use of a food substance may be GRAS either through scientific procedures or, for a substance used in food
before 1958, through experience based on common use in food. General recognition of safety through scientific procedures requires
the same quantity and quality of scientific evidence as is required to obtain approval of the substance as a food additive and
ordinarily is based upon published studies, which may be corroborated by unpublished studies and other data and information. General
recognition of safety through experience based on common use in foods requires a substantial history of consumption for food use
by a significant number of consumers.
Manufacturers
of GRAS substances may provide the FDA with a notification of GRAS determination, which includes a description of the substance,
the applicable conditions of use, and an explanation of how the substance was determined to be safe. Upon review of such a notification,
the FDA may respond with a “no questions” position, whereby the manufacturer’s determination that a product
is GRAS for its intended purposes is affirmed. Alternatively, manufacturers may elect to “self-affirm” a given substance
as GRAS without FDA notification but should retain all applicable safety data used for GRAS determination in the case of FDA inquiry.
Synthetic
copies of naturally-occurring dietary ingredients or related components do not qualify as dietary ingredients under the FD&C
Act, but substances that have been affirmed by the FDA as GRAS, self-affirmed as GRAS, or approved as direct food additives in
the U.S. may be marketed as dietary ingredients, subject to FDA regulations for dietary ingredients.
FDA
NDI Notification
The
Dietary Supplement Health and Education Act of 1994 (the “
DSHEA
”) (Pub. L. 103-417) was signed into law on
October 25, 1994 and amended the FD&C Act by adding: (i) section 201(ff) (21 U.S.C. 321(ff)), which defines the term “dietary
supplement”, and (ii) section 413 (21 U.S.C. 350b), which defines the term “new dietary ingredient” (“
NDI
”)
and requires the manufacturer or distributor of an NDI, or of the dietary supplement that contains the NDI, to submit a premarket
notification to FDA at least 75 days before introducing/delivering the supplement into interstate commerce, unless the NDI and
any other dietary ingredients in the dietary supplement have been present in the food supply without chemical alteration (21 U.S.C.
350b(a)(1)). The NDI notification must contain applicable information, including history of use and citations to published articles,
from which the manufacturer or distributor of the NDI or dietary supplement has concluded that the dietary supplement containing
the NDI will be reasonably expected to be safe under the conditions of its intended use. NDI notifications are not required for
the marketing of approved food additives or GRAS substances as NDIs unless the dietary ingredient has been chemically altered.
FDA
Orphan Drug Designation
The
Orphan Drug Act was signed into law on January 4, 1983. The Congressional findings for the Orphan Drug Act were as follows: (i)
there are many rare diseases and conditions that affect such small numbers of individuals residing in the United States; (ii)
adequate drugs for many rare diseases and conditions have not been developed; (iii) drugs for rare diseases and conditions are
commonly referred to as "orphan drugs"; (iv) because so few individuals are affected by any one rare disease or condition,
a pharmaceutical company that develops an orphan drug may reasonably expect the drug to generate relatively small sales in comparison
to the cost of developing the drug and consequently to incur a financial loss; (v) there is reason to believe that some promising
orphan drugs will not be developed unless changes are made in the applicable Federal laws to reduce the costs of developing such
drugs and to provide financial incentives to develop such drugs; and (vi) it is in the public interest to provide such changes
and incentives for the development of orphan drugs.
Under
the Orphan Drug Act, the FDA may grant orphan drug designation to a drug intended to treat a rare disease or condition that (i)
affects less than 200,000 persons in the United States, or (ii) affects more than 200,000 in the United States and for which there
is no reasonable expectation that the cost of developing and making available in the United States a drug for such disease or
condition will be recovered from sales in the United States of such drug. Orphan drug designation must be requested before submitting
an NDA. After the FDA grants orphan drug designation, the identity of the drug and its potential orphan use are disclosed publicly
by the FDA.
In
the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards
clinical trial costs, tax advantages, and NDA user-fee waivers. In addition, if a drug receives the first FDA approval for the
indication for which it has orphan designation, the drug is entitled to orphan drug exclusivity, which means the FDA may not approve
any other application, including a full NDA, to market the same drug for the same indication for a period of seven years, except
in limited circumstances, such as a showing of clinical superiority over the drug with orphan exclusivity or where the manufacturer
with orphan exclusivity is unable to assure sufficient quantities of the approved orphan-designated drug. Competitors, however,
may receive approval of different drugs for the indication that the orphan drug has exclusivity or obtain approval for the same
drug but for a different indication for which the orphan drug has exclusivity. Orphan drug exclusivity also could block the approval
of one of our drugs for seven years if a competitor obtains approval of the same drug as defined by the FDA or if our product
candidate is determined to be contained within the competitor’s drug for the same indication or disease. If a drug designated
as an orphan drug receives marketing approval for an indication broader than what is designated, it may not be entitled to orphan
drug exclusivity. In addition, exclusive marketing rights in the United States may be lost if the FDA later determines that the
request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the drug
to meet the needs of patients with the rare disease or condition. There can be no assurance that we will request an orphan drug
designation for any current or future product candidate, or if requested, that will receive such orphan drug designation.
Other
Regulations
Pharmaceutical
companies are subject to various federal and state laws pertaining to healthcare “fraud and abuse,” including anti-kickback
and false claims laws. The Anti-Kickback Statute is a federal criminal statute that makes it illegal for any person, including
a prescription drug manufacturer, or a party acting on its behalf, to knowingly and willfully solicit, offer, receive or pay any
remuneration, directly or indirectly, in exchange for, or to induce, the referral of business, including the purchase, order or
prescription of a particular drug, for which payment may be made under federal healthcare programs such as Medicare and Medicaid.
Some of the state prohibitions apply to referral of patients for healthcare services reimbursed by any source, not only the Medicare
and Medicaid programs.
In
the course of practicing medicine, physicians may legally prescribe FDA approved drugs for an indication that has not been approved
by the FDA and which, therefore, is not described in the product’s approved labeling, so-called “off-label use.”
The FDA does not ordinarily regulate the behavior of physicians in their choice of treatments. The FDA and other governmental
agencies do, however, restrict communications on the subject of off-label use by a manufacturer or those acting on behalf of a
manufacturer. Companies may not promote FDA-approved drugs for off-label uses. The FDA and other governmental agencies do permit
a manufacturer (and those acting on its behalf) to engage in some limited, non-misleading, non-promotional exchanges of scientific
information regarding unapproved indications. The United States False Claims Act prohibits, among other things, anyone from knowingly
and willfully presenting, or causing to be presented for payment to third-party payers (including Medicare and Medicaid) claims
for reimbursed drugs or services that are false or fraudulent, claims for items or services not provided as claimed or claims
for medically unnecessary items or services. Violations of fraud and abuse laws may be punishable by criminal and/or civil sanctions,
including imprisonment, fines and civil monetary penalties, as well as possible exclusion from federal health care programs (including
Medicare and Medicaid). In addition, under this and other applicable laws, such as the Food, Drug and Cosmetic Act, there is an
ability for private individuals to bring similar actions. Further, there is an increasing number of state laws that require manufacturers
to make reports to states on pricing and marketing information. Many of these laws contain ambiguities as to what is required
to comply with the law.
We
are subject to various laws and regulations regarding laboratory practices and the experimental use of animals in connection with
our research. In each of these areas, as above, the FDA and other regulatory authorities have broad regulatory and enforcement
powers, including the ability to suspend or delay issuance of approvals, seize or recall products, withdraw approvals, enjoin
violations and institute criminal prosecution, any one or more of which could have a material adverse effect upon our business,
financial condition and results of operations.
We
must comply with regulations under the Occupational Safety and Health Act, the Environmental Protection Act, the Toxic Substances
Control Act and other federal, state and local regulations. We are subject to federal, state and local laws and regulations governing
the use, generation, manufacture, storage, air emission, effluent discharge, handling and disposal of certain hazardous or potentially
hazardous materials. We may be required to incur significant costs to comply with environmental and health and safety regulations
in the future. Our research and development involves the controlled use of hazardous materials, including, but not limited to,
certain hazardous chemicals.
Our
activities are also potentially subject to federal and state consumer protection and unfair competition laws. We are also subject
to the United States Foreign Corrupt Practices Act, or the FCPA, which prohibits companies and individuals from engaging in specified
activities to obtain or retain business or to influence a person working in an official capacity. Under the FCPA, it is illegal
to pay, offer to pay, or authorize the payment of anything of value to any foreign government official, governmental staff members,
political party or political candidate in an attempt to obtain or retain business or to otherwise influence a person working in
an official capacity. In addition, federal and state laws protect the confidentiality of certain health information, in particular,
individually identifiable information, and restrict the use and disclosure of that information. At the federal level, the Department
of Health and Human Services promulgated health information privacy and security rules under the Health Insurance Portability
and Accountability Act of 1996. In addition, many state laws apply to the use and disclosure of health information.
Competition
The
industry in which we intend to compete is subject to intense competition. We believe that our ability to compete will be dependent
in large part upon our ability to continually enhance and improve our products and technologies. In order to do so, we plan to
effectively utilize and expand our research and development capabilities. Competition is based primarily on scientific and technological
superiority, technical support, availability of patent protection, protection of trade secrets, access to adequate capital, ability
to develop, acquire and market products successfully, ability to obtain governmental approvals and ability to serve the particular
needs of customers. We intend to compete on the basis of safety, effectiveness, convenience, manufacturing superiority, intellectual
property, and where appropriate, price.
Numerous
pharmaceutical and biotechnology companies are developing or producing anti-inflammatories. These companies include, but are not
limited to: AbbVie, Amgen, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Eisai, Eli Lilly, Gilead,
GlaxoSmithKline, Johnson & Johnson, Merck, MT Pharma, Nestle/Pamlab, Novartis, Pfizer, Reata, Roche/Genentech, Sanofi-Aventis,
Servier, Takeda, and Vivus.
In
addition to competing with other anti-inflammatories in health applications, we compete with microalgal astaxanthin consumer health
products on the basis of our global-scale manufacturing capability and product purity. Leading manufacturers of microalgal astaxanthin
include Cyanotech, which produces the BioAstin brand; Fuji Health Science (parent company: Fuji Chemical), which produces the
AstaREAL brand; and Algatechnologies, which produces the AstaPure brand. Many other companies, including Valensa International
(parent company: EID Parry), acquire astaxanthin from these or other smaller manufacturers. We believe that large-scale, multi-fold
expansion of naturally produced microalgal astaxanthin would require large amounts of land, and fresh water for open pond systems
or large amounts of infrastructure and energy for closed systems, and, consequently, a significant if not overwhelming amount
of investment capital. Furthermore, microalgal astaxanthin products, which are lipophilic extracts of a commercially cultivated
microalgae, typically have relatively low astaxanthin content, with the majority of the product comprised of other lipophilic,
non-astaxanthin microalgal compounds. In contrast, our synthetically manufactured astaxanthin products have very high astaxanthin
content, with consistent purity. Higher relative astaxanthin content reduces the size/number of capsules or tablets required to
achieve equivalent circulating levels of astaxanthin. We may also face competition from other synthetic astaxanthin consumer health
products, although competitors in this space are limited by the substantial cost and technical expertise required to develop large-scale,
industrial production of astaxanthin.
Our
success will also depend in large part on our ability to obtain and maintain international and domestic patent and other legal
protections for the proprietary technology that we consider important to our business. We intend to continue to seek appropriate
patent protection for our products where applicable by filing patent applications in the United States and other selected countries.
We intend for these patent applications to cover, where applicable, claims for composition of matter, uses, processes for preparation
and formulations. Our success will also depend on our ability, and the ability of our current and/or future strategic partners
to maintain trade secrets related to proprietary production methods for products that we, or our partners, intend to market.
Raw
Materials and Components
We
utilize contract manufacturers and/or other third-party suppliers for the production of our products and product candidates. The
raw materials and supplies required for the production of our products and product candidates may be available, in some instances
from one supplier, and in other instances, from multiple suppliers. In those cases where raw materials are only available through
one supplier, such supplier may be either a sole source (the only recognized supply source available to us) or a single source
(the only approved supply source for us among other sources). We, our contract manufacturers, and/or other third-party suppliers
will adopt appropriate policies to attempt, to the extent feasible, to minimize our raw material supply risks, including maintenance
of greater levels of raw materials inventory and implementation of multiple raw materials sourcing strategies, especially for
critical raw materials. Although to date we have not experienced any significant delays in obtaining any raw materials from suppliers,
we cannot provide assurance that we, our contract manufacturers, and/or other third-party suppliers will not face shortages from
one or more of them in the future.
Customers
We
sell ZanthoSyn® primarily through e-commerce and wholesale channels. We launched our e-commerce channel in August 2016 and
began selling to GNC stores in Hawaii on January 25, 2017 and GNC corporate stores across the United States on August 10, 2017.
We have also sold ZanthoSyn® on a wholesale basis to Health Elite Club Limited, a Hong Kong-based company.
We
currently sell ZanthoSyn® to GNC under an exclusive sales contract for the “brick and mortar” retail channel in
the United States, which comprises the majority of our revenues, the loss of which would have a material adverse effect on the
Company. During the years ended December 31, 2017 and 2016, sales to GNC accounted for 74% and 0% of our revenues, respectively.
No other customer accounted for 10% or more of our revenues during these years.
Intellectual
Property
We
have obtained and are continuing to seek patent protection for compositions of matter, pharmaceutical compositions, and pharmaceutical
uses, in certain disease areas, of our various carotenoid analogs and derivatives. Such carotenoids include, but are not limited
to, astaxanthin, zeaxanthin, lutein, and/or lycophyll, and esters and other analogs and derivatives of these compounds. More specifically,
we seek to protect: (i) the composition of matter of novel carotenoid analogs and derivatives, (ii) pharmaceutical compositions
comprising synthetic or natural preparations of novel or natural occurring carotenoid analogs and derivatives, and (iii) the pharmaceutical
use of synthetic preparations of novel or naturally occurring carotenoid analogs and derivatives in specific disease areas, including,
but not limited to, the treatment of inflammation and related tissue damage, liver disease, and reperfusion injury, as well as
the pharmaceutical use of synthetic or natural preparations of novel or natural occurring carotenoid analogs and derivatives for
the reduction of platelet aggregation. We intend to enforce and defend our intellectual property rights consistent with our strategic
business objectives.
We
own 22 issued patents, including 14 in the United States and 8 others in Europe, China, India, Japan, and Hong Kong, related to
the technology described above. These patents will expire during the years of 2023 to 2028, subject to any patent term extensions
of the individual patent. We have 4 foreign patent applications pending in Europe, Canada, and Brazil, also related to the technology
described above. Of these patents and patent applications, 21 patents and 3 patent applications have coverage related to astaxanthin
analogs and derivatives; however, our proprietary technologies and business opportunities are not dependent on any single patent
or sub-set of patents—the portfolio, which includes coverage related to compositions of matter, pharmaceutical compositions,
and pharmaceutical uses, as described above, provides the comprehensive coverage that we deem material to our business.
Employees
As
of the date of this prospectus, we have 11 full-time employees and 1 part-time employee. None of our employees are subject to
a collective bargaining agreement. We believe the relations with our employees are satisfactory.
Properties
We
maintain a facility of approximately 738 square feet at 2800 Woodlawn Drive, Honolulu, Hawaii, which is leased on a month-to-month
basis. We believe that our facility is adequate for our current purposes.
Legal
Proceedings
From
time to time, we may become involved in various lawsuits and legal proceedings that arise in the ordinary course of business.
However, litigation is subject to inherent uncertainties and an adverse result in these or other matters may arise from time to
time that may harm our business. We are currently not aware of any such legal proceedings or claims that we believe will have
a material adverse effect on our business, financial condition or operating results.
Management
Set
forth below is a list of the names, ages and positions of our directors and executive officers.
Name
|
|
Age
|
|
Position(s)
|
George
W. Bickerstaff, III
|
|
62
|
|
Chairman
of the Board of Directors
|
David
G. Watumull
|
|
68
|
|
President,
Chief Executive Officer, and Director
|
Terence
A. Kelly, Ph.D.
|
|
57
|
|
Director
|
Michele
Galen
|
|
61
|
|
Director
|
John
B. Russell
|
|
45
|
|
Chief
Financial Officer and Treasurer
|
Richard
M. Morris
|
|
57
|
|
Secretary
|
David
M. Watumull
|
|
36
|
|
Chief
Operating Officer, Assistant Treasurer, and Assistant Secretary
|
Biographies
of Directors and Executive Officers
George
W. Bickerstaff, III
has served as a Director since June 16, 2014. Mr. Bickerstaff is currently a Managing Director of M.M.
Dillon & Co. Group LLC, which he joined in 2005. Prior to joining M.M. Dillon & Co. Group LLC, Mr. Bickerstaff held various
positions with Novartis International AG, a global pharmaceuticals and consumer health company, including Chief Financial Officer
of Novartis Pharma AG from October 2000 to May 2005. From December 1999 to September 2000, Mr. Bickerstaff served as Executive
Vice President and Chief Financial Officer of Workscape, Inc. a provider of employee-related information services. From July 1998
to December 1999, Mr. Bickerstaff served as Executive Vice President and Chief Financial Officer of Uniscribe Professional Services,
Inc., a nationwide provider of paper and technology-based document management solutions. From January 1998 to June 1998, Mr. Bickerstaff
served as Executive Vice President and Chief Financial Officer of Intellisource Group, Inc., a provider of information technology
solutions to the federal, state and local government and utility markets. From July 1997 to December 1997, Mr. Bickerstaff served
as Vice President of Finance of Cognizant Corporation, a global business information services company. From January 1990 to June
1997, Mr. Bickerstaff served in various senior finance roles, including Chief Financial Officer of IMS Healthcare, a global business
information services company in the healthcare and pharmaceutical industries. Prior to that, Mr. Bickerstaff held various finance,
audit and engineering positions with the Dun & Bradstreet Corporation and General Electric Company. Mr. Bickerstaff has been
a member of the board of directors of CareDx, Inc., a company that develops, markets, and delivers diagnostic surveillance solutions
for organ transplant recipients, since April 2014. Mr. Bickerstaff was a member of the board of directors of Vion Pharmaceuticals,
Inc., from June 2005 to March 2010. Mr. Bickerstaff’s nonprofit activities include serving on the board of directors of
the International Vaccine Institute, the International Centre for Missing and Exploited Children, The Center for Disease Dynamics,
Economics & Policy and The Global Alliance for Vaccines and Immunization. Mr. Bickerstaff holds a B.S. in Engineering and
a B.A. in Business Administration from Rutgers University (1978). Mr. Bickerstaff’s experience through various roles in
establishing the strategic, operational, and financial direction of numerous private and public companies, including those in
the pharmaceutical industry, will be instrumental in enabling our Board to implement our strategic plan.
David
G. Watumull
has served as our Chief Executive Officer, President, and Director since February 7, 2014. Mr. Watumull has served
as the Chief Executive Officer, President, and Director of Pharma since its inception in May 2013. Mr. Watumull also served as
the Chief Executive Officer, President, and Director of Holdings from its inception in March 2006 until it merged with us in December
2015. Mr. Watumull is a co-founder of Holdings and has over 20 years of experience as a biotechnology industry executive. From
2001 to 2006, Mr. Watumull served as President, Chief Executive Officer, and Director of Hawaii Biotech, Inc. Mr. Watumull was
Executive Vice President of Aquasearch, Inc., a public astaxanthin consumer health company, from 1998 to 2000. From 1997 to 1998
he headed his own biotech research firm, Watumull & Co. From 1994 to 1997 he was a biotech research analyst, money manager,
and investment banker at First Honolulu Securities. From 1992 to 1994 he led his own money management firm, Biovest, Inc. Prior
to that, from 1982 to 1992, Mr. Watumull worked at Paine Webber in various capacities, including as a biotech money manager and
investment executive. Mr. Watumull’s extensive background in the biotechnology industry, his operational acumen, and his
position of leadership since the founding of our business uniquely qualifies him to serve as a member of our Board.
Terence
A. Kelly, Ph.D.
has served as a Director since June 16, 2014. Dr. Kelly has over 20 years of experience as a scientist and
executive in the pharmaceutical industry starting as a medicinal chemist in 1990. Dr. Kelly is currently the President and Chief
Executive Officer of CoMentis, Inc. and a founder of Kelly Pharma Research Consulting, LLC. From 1990 to 2009, Dr. Kelly served
in various scientific and executive positions at Boehringer Ingelheim, where after a successful early career developing LFA-1
antagonists, he led its US-based medicinal chemistry department, which included 145 scientists in the high throughput screening,
computational chemistry, structural biology, combinatorial chemistry and medicinal chemistry groups. Dr. Kelly holds a B.S. degree
in Chemistry at Rensselaer Polytechnic Institute (1982) and a Ph.D. degree in Chemistry at the University of Texas at Austin (1988).
He completed postdoctoral work in natural products synthesis at Yale University (1988-1990) and holds an MBA from New York University,
Stern School of Business (1998). Dr. Kelly is the co-author of over 25 scientific publications and serves on the College of Natural
Sciences Advisory Council for the University of Texas. Dr. Kelly’s scientific training and his track record of delivering
high quality compounds into advanced clinical studies provide valuable skills and knowledge to our Board.
Michele
Galen
has served as a Director since January 4, 2017. Ms. Galen serves as a strategic advisor and board member across pharmaceuticals,
biotechnology, health start-ups and global health, drawing on her broad experience in global business, communications, law and
journalism. From June 2016 to present, Ms. Galen has led an independent consultancy, Michele Galen LLC. From April 2015 to June
2016, Ms. Galen served as Global Head, Communications and Public Affairs, for Shire plc, a biotechnology company, where she served
as the lead communications and public affairs advisor on the successful $32 billion acquisition and integration of Baxalta. From
February 2015 to March 2015, Ms. Galen led an independent consultancy, Michele Galen LLC. From May 2014 to January 2015, Ms. Galen
served as a senior advisor to Novartis AG. From February 2012 to May 2014, Ms. Galen led Global Communications for Novartis AG,
based in Basel, Switzerland. From February 2010 to February 2012, Ms. Galen served as Vice President and Global Head of Communications
& Patient Advocacy for Novartis Pharma AG. From October 2003 to February 2010, Ms. Galen served as Vice President and Global
Head, Oncology Affairs for Novartis Pharma AG. From February 2001 to October 2003, Ms. Galen served as Vice President, Corporate
Communications for Novartis Pharmaceuticals Corporation. Earlier in her career, Ms. Galen was a Managing Director in the global
public relations firm Burson-Marsteller. There, she co-founded the Organizational Change Communications practice. She is an award-winning
journalist, and worked as Legal Editor and Social Issues Editor at Business Week magazine. Ms. Galen is a member of the New York
State Bar and practiced law at Stroock, Stroock & Lavan LLP, and Skadden, Arps, Slate, Meagher & Flom LLP. Ms. Galen currently
serves on the inaugural board of directors of Global Oncology, and on the advisory board of MK&A, a global healthcare consultancy
firm. Formerly, she served as a pro bono advisor to the UNICEF Office of Public Advocacy, and on the boards of the Global Health
Council and Stupid Cancer. Ms. Galen received a B.A. from George Washington University, M.S. from the Columbia University Graduate
School of Journalism, and J.D. from New York University School of Law. She also completed the External Executive Coaching Intensive
at Columbia University. Ms. Galen’s broad pharmaceutical, biotechnology, and healthcare background provide valuable skills
and knowledge to our Board.
John
B. Russell, CPA,
has served as our Chief Financial Officer and Treasurer since February 7, 2014. Mr. Russell has served as
the Chief Financial Officer and Treasurer of Pharma since July 2013. Mr. Russell also served as the Chief Financial Officer and
Treasurer of Holdings from July 2013 until it merged with us in December 2015. Mr. Russell is the founder of JBR Business Solutions,
LLC and has served as its President since 2010. Mr. Russell has over 20 years of accounting, finance, operations, and SEC reporting
experience in biopharmaceutical and high-tech industries. From 2010 to the present, he has served as Chief Financial Officer for
various privately-held start-up companies. Mr. Russell was in charge of the Business Advisory Services for the Grant Thornton
Honolulu office from 2006 to 2010. From 2005 to 2006, Mr. Russell worked at a consulting company as the Operations Consulting
- Financial Management lead, advising Cisco Systems, Inc. Mr. Russell was the General Accounting Manager of the publicly traded
company Scios Inc. from 2003 to 2005, where he was in charge of SEC reporting and internal controls. Mr. Russell was the Controller
for several portfolio companies in the venture capital firm, Raza Foundries, Inc., from 2001 to 2002, and the General Accounting
Manager for inSilicon Corporation, a public company, from 2000 to 2001. Previous to that, Mr. Russell was an auditor at PricewaterhouseCoopers
LLP from 1995 to 2000. Mr. Russell is a licensed CPA in Hawaii and has a B.A. in Economics/Accounting from Claremont McKenna College.
Richard
M. Morris
has served as our Secretary since February 7, 2014. Mr. Morris has served as Secretary of Pharma since December
2017 and previously as Assistant Secretary of Pharma from its inception in May 2013 to December 2017. Mr. Morris also served as
Assistant Secretary of Holdings from July 2013 until its merger with us in December 2015. Mr. Morris is a Partner at Herrick,
Feinstein LLP, our legal counsel (“
Herrick
”). As a partner of Herrick, Mr. Morris represents a variety of clients,
primarily in corporate matters. Prior to becoming a lawyer, Mr. Morris was an auditor with the Commodities Exchange in New York
and later focused on operations and financial management at Kidder Peabody. He also was the U.S. Audit Manager for the financial
division for a diversified Australian company. Mr. Morris has a B.S. in Accounting from New York University (1982) and a J.D.
from Fordham University School of Law (1990), with bar admissions in New York and Connecticut.
David
M. Watumull
has served as our Chief Operating Officer since August 2017 and previously as our Vice President, Operations from
February 7, 2014 to August 2017. Mr. Watumull has also served as our Assistant Treasurer and Assistant Secretary since February
7, 2014. Mr. Watumull has served as the Chief Operating Officer of Pharma since December 2017 and previously as Vice President,
Operations of Pharma from its inception in May 2013 to December 2017. Mr. Watumull has also served as Assistant Treasurer and
Assistant Secretary of Pharma since July 2013 and previously as Secretary and Treasurer of Pharma from May 2013 to July 2013.
Mr. Watumull also served as Vice President, Operations, Assistant Treasurer, and Assistant Secretary of Holdings from July 2013
until it merged with us in December 2015, and previously as Director, Operations and Finance from 2009 to 2013, Operations Manager
from 2008 to 2009, and Program Manager from its inception in 2006 to 2009. Mr. Watumull oversees all operations with responsibility
for sales and marketing, product development and manufacturing, regulatory compliance, finance, and administration. Mr. Watumull
was previously Program Manager at Hawaii Biotech, Inc. from 2005 to 2006, Project Coordinator from 2004 to 2005, and Information
Technology Associate / Manager from 2002 to 2004. Mr. Watumull also worked at Aquasearch, Inc., from 2000 to 2001 in various capacities
including Medical Information Specialist and Information Technology Associate. Mr. Watumull graduated first in his high school
class and studied Electrical Engineering at the University of Hawaii.
Executive
officers are appointed by our Board of Directors. Each executive officer holds his or her office until he or she resigns, is removed
by our Board of Directors or his or her successor is elected and qualified. Directors are elected annually by our stockholders
at the annual meeting. Each director holds his or her office until his or her successor is elected and qualified or his or her
earlier resignation or removal.
Family
Relationships
David
G. Watumull is the father of David M. Watumull. There are no other family relationships among any of our officers or directors.
Involvement
in Certain Legal Proceedings
To
the best of our knowledge, none of our directors or executive officers has been convicted in a criminal proceeding, excluding
traffic violations or similar misdemeanors, or has been a party to any judicial or administrative proceeding during the past ten
years that resulted in a judgment, decree, or final order enjoining the person from future violations of, or prohibiting activities
subject to, federal or state securities laws, or a finding of any violation of federal or state securities laws, except for matters
that were dismissed without sanction or settlement. Except as set forth in our discussion below in “Certain Relationships
and Related Transactions, and Director Independence – Transactions with Related Persons,” none of our directors, director
nominees, or executive officers has been involved in any transactions with us or any of our directors, executive officers, affiliates,
or associates which are required to be disclosed pursuant to the rules and regulations of the Commission.
Code
of Ethics
Our
Code of Business Conduct and Ethics, effective as of February 7, 2014 (the “
Code of Ethics
”), contains the
ethical principles by which our Chief Executive Officer and Chief Financial Officer, among others, are expected to conduct themselves
when carrying out their duties and responsibilities. A copy of our Code of Ethics may be found on our website at www.cardaxpharma.com.
We will provide a copy of our Code of Ethics to any person, without charge, upon request, by writing to David G. Watumull, Cardax,
Inc., 2800 Woodlawn Drive, Suite 129, Honolulu, Hawaii 96822.
Board
Committees
We
are not required under the Securities and Exchange Act to maintain any committees of our Board of Directors. We have formed certain
committees of our board as a matter of preferred corporate practices.
We
have an audit committee, a compensation committee and a nominating and corporate governance committee, each of which has the composition
and responsibilities described below.
Audit
Committee.
Our audit committee oversees a broad range of issues surrounding our accounting and financial reporting processes
and audits of our consolidated financial statements, including the following:
|
●
|
monitors
the integrity of our financial statements, our compliance with legal and regulatory requirements, our independent registered
public accounting firm’s qualifications and independence, and the performance of our internal audit function and independent
registered public accounting firm;
|
|
|
|
|
●
|
assumes
direct responsibility for the appointment, compensation, retention and oversight of the work of any independent registered
public accounting firm engaged for the purpose of performing any audit, review or attest services and for dealing directly
with any such accounting firm;
|
|
|
|
|
●
|
provides
a medium for consideration of matters relating to any audit issues; and
|
|
|
|
|
●
|
prepares
the audit committee report that the rules require be included in our filings with the SEC.
|
The
members of our audit committee are George W. Bickerstaff, III (Chairperson) and Terence A. Kelly, Ph.D. Our audit committee has
a written charter available on our website at www.cardaxpharma.com.
Compensation
Committee.
Our compensation committee reviews and recommends policy relating to compensation and benefits of our officers,
directors and employees, including reviewing and approving corporate goals and objectives relevant to the compensation of our
Chief Executive Officer and other senior officers, evaluating the performance of these persons in light of those goals and objectives
and setting compensation of these persons based on such evaluations. The compensation committee reviews and evaluates, at least
annually, the performance of the compensation committee and its members, including compliance of the compensation committee with
its charter.
The
members of our compensation committee are Terence A. Kelly, Ph.D. (Chairperson) and George W. Bickerstaff, III. Our compensation
committee has a written charter available on our website at www.cardaxpharma.com.
Nominating
and Corporate Governance Committee.
The nominating and corporate governance committee oversees and assists our Board of Directors
in identifying, reviewing and recommending nominees for election as directors; evaluating our Board of Directors and our management;
developing, reviewing and recommending corporate governance guidelines and a corporate code of business conduct and ethics; and
generally advises our Board of Directors on corporate governance and related matters.
The
members of our nominating and corporate governance committee are Terence A. Kelly, Ph.D. (Chairperson) and George W. Bickerstaff,
III. Our nominating and corporate governance committee has a written charter available on our website at www.cardaxpharma.com.
Director
Independence
George
W. Bickerstaff, III, Terence A. Kelly, Ph.D., and Michele Galen are our independent directors. Because our common stock is not
currently listed on a national securities exchange, we have used the definition of “independence” of The NASDAQ Stock
Market to make this determination. NASDAQ Listing Rule 5605(a)(2) provides that an “independent director” is a person
other than an officer or employee of the Company or any other individual having a relationship that, in the opinion of the Company’s
Board, would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. The NASDAQ
listing rules provide that a director cannot be considered independent if:
|
●
|
the
director is, or at any time during the past three years was, an employee of the Company;
|
|
|
|
|
●
|
the
director or a family member of the director accepted any compensation from the Company in excess of $120,000 during any period
of 12 consecutive months within the three years preceding the independence determination (subject to certain exclusions, including,
among other things, compensation for board or board committee service);
|
|
|
|
|
●
|
a
family member of the director is, or at any time during the past three years was, an executive officer of the Company;
|
|
|
|
|
●
|
the
director or a family member of the director is a partner in, controlling stockholder of, or an executive officer of an entity
to which the Company made, or from which the Company received, payments in the current or any of the past three fiscal years
that exceed 5% of the recipient’s consolidated gross revenue for that year or $200,000, whichever is greater (subject
to certain exclusions);
|
|
|
|
|
●
|
the
director or a family member of the director is employed as an executive officer of an entity where, at any time during the
past three years, any of the executive officers of the Company served on the compensation committee of such other entity;
or
|
|
|
|
|
●
|
the
director or a family member of the director is a current partner of the Company’s outside auditor, or at any time during
the past three years was a partner or employee of the Company’s outside auditor, and who worked on the Company’s
audit.
|
Indemnification
We
maintain directors’ and officers’ liability insurance. Our amended and restated certificate of incorporation and amended
and restated bylaws include provisions limiting the liability of directors and officers and indemnifying them under certain circumstances.
We have entered into indemnification agreements with our directors to provide our directors and certain of their affiliated parties
with additional indemnification and related rights. See “Indemnification of Directors and Officers” for further information.
Insofar
as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers or persons
controlling the Company pursuant to Delaware law, we are informed that in the opinion of the Securities and Exchange Commission,
such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.
Conflicts
of Interest
Certain
potential conflicts of interest are inherent in the relationships between our officers and directors and us.
From
time to time, one or more of our affiliates may form or hold an ownership interest in and/or manage other businesses both related
and unrelated to the type of business that we own and operate. These persons expect to continue to form, hold an ownership interest
in and/or manage additional other businesses which may compete with our business with respect to operations, including financing
and marketing, management time and services and potential customers. These activities may give rise to conflicts between or among
the interests of us and other businesses with which our affiliates are associated. Our affiliates are in no way prohibited from
undertaking such activities, and neither us nor our stockholders will have any right to require participation in such other activities.
Further,
because we intend to transact business with some of our officers, directors and affiliates, as well as with firms in which some
of our officers, directors or affiliates have a material interest, potential conflicts may arise between the respective interests
of us and these related persons or entities. We believe that such transactions will be effected on terms at least as favorable
to us as those available from unrelated third parties.
With
respect to transactions involving real or apparent conflicts of interest, we have adopted policies and procedures which require
that: (i) the fact of the relationship or interest giving rise to the potential conflict be disclosed or known to the directors
who authorize or approve the transaction prior to such authorization or approval; and (ii) the transaction be fair and reasonable
to us at the time it is authorized or approved by our directors.
Executive
Compensation
The
following sets forth information with respect to the compensation awarded or paid to David G. Watumull, our Chief Executive Officer,
and David M. Watumull, our Chief Operating Officer, for all services rendered in all capacities to the Company and its predecessors
during the fiscal years ending December 31, 2016 and 2017. These executive officers are referred to as the “named executive
officers” throughout this prospectus. In addition, the following sets forth information with respect to the compensation
awarded or paid to our two highest compensated individuals not serving as executive officers, Gilbert M. Rishton, our Chief Science
Officer, and Timothy J. King, our Vice President of Research, for all services rendered in all capacities to the Company and its
predecessors during the fiscal years ending December 31, 2016 and 2017.
Compensation
of Executive Officers
The
following table sets forth information regarding each element of compensation that we paid or awarded to our named executive officers,
and our two highest compensated individuals not serving as executive officers, for the two fiscal years ended December 31, 2016
and 2017, which includes cash compensation, stock options awarded in lieu of cash compensation, and all other compensation:
Name
|
|
Year
|
|
Cash
Comp.
(1)
|
|
|
Stock
Options
in Lieu of
Cash Comp.
(2)
|
|
|
All
Other
Comp.
(3)
|
|
|
Total
|
|
David
G. Watumull
Chief Executive Officer
|
|
2016
2017
|
|
$
$
|
48,682
138,461
|
(4)
(4)
|
|
$
$
|
46,463
-
|
|
|
$
$
|
8,935
10,466
|
|
|
$
$
|
104,080
148,927
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
David
M. Watumull
Chief Operating Officer
(5)
|
|
2016
2017
|
|
$
$
|
55,718
107,500
|
(6)
(6)
|
|
$
$
|
33,771
-
|
|
|
$
$
|
3,736
7,350
|
|
|
$
$
|
93,225
114,850
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gilbert
M. Rishton
Chief Science Officer
|
|
2016
2017
|
|
$
$
|
27,003
76,827
|
(7)
(7)
|
|
$
$
|
40,694
-
|
|
|
$
$
|
167
525
|
|
|
$
$
|
67,864
77,352
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Timothy
J. King
Vice President, Research
|
|
2016
2017
|
|
$
$
|
45,146
99,712
|
(8)
(8)
|
|
$
$
|
33,771
-
|
|
|
$
$
|
-
-
|
|
|
$
$
|
78,917
99,712
|
|
|
(1)
|
The
amounts disclosed refer to cash compensation.
|
|
|
|
|
(2)
|
The
amounts disclosed refer to stock options awarded in lieu of cash compensation.
|
|
|
|
|
(3)
|
The
amounts disclosed refer to imputed income in connection with certain benefits and/or insurance premiums paid in lieu of additional
cash compensation.
|
|
|
|
|
(4)
|
On
March 28, 2016, Mr. David G. Watumull was furloughed and agreed to continue service as Chief Executive Officer for cash compensation
equal to the minimum wage. On September 6, 2016, the compensation arrangement of Mr. David G. Watumull was amended so that,
effective September 8, 2016, he would receive bi-weekly compensation equal to $4,327. On August 31, 2017, the compensation
arrangement of Mr. David G. Watumull was amended so that, effective September 1, 2017, he would receive bi-weekly compensation
equal to $7,212.
|
|
|
|
|
(5)
|
On
August 31, 2017, Mr. David M. Watumull was promoted to Chief Operating Officer.
|
|
|
|
|
(6)
|
On
March 28, 2016, Mr. David M. Watumull was furloughed and agreed to continue service as Vice President, Operations for cash
compensation equal to the minimum wage. On June 3, 2016, the compensation arrangement of David M. Watumull was amended so
that, effective May 30, 2016, he would receive bi-weekly compensation equal to $3,269. On August 31, 2017, the compensation
arrangement of Mr. David M. Watumull was amended so that, effective September 1, 2017, he would receive bi-weekly compensation
equal to $5,769.
|
|
|
|
|
(7)
|
On
March 28, 2016, Mr. Rishton was furloughed and would from time to time be re-engaged to the extent his services are required
at cash compensation equal to the hourly minimum wage. On September 6, 2016, the compensation arrangement of Mr. Rishton was
amended so that, effective September 8, 2016, he would receive bi-weekly compensation equal to $1,923. On August 31, 2017,
the compensation arrangement of Mr. Rishton was amended so that, effective September 1, 2017, he would receive bi-weekly compensation
equal to $4,904.
|
|
|
|
|
(8)
|
On
March 28, 2016, Mr. King was furloughed and would from time to time be re-engaged to the extent his services were required
at cash compensation equal to the hourly minimum wage. On June 3, 2016, the compensation arrangement of Mr. King was amended
so that, effective May 30, 2016, he would receive bi-weekly compensation equal to $1,635. On September 6, 2016, the compensation
arrangement of Mr. King was amended so that, effective September 8, 2016, he would receive bi-weekly compensation equal to
$3,269. On August 31, 2017, the compensation arrangement of Mr. King was amended so that, effective September 1, 2017, he
would receive bi-weekly compensation equal to $4,904.
|
Outstanding
Equity Awards to Executive Officers at Fiscal Year-End 2017
The
following table sets forth information regarding outstanding option awards to our named executive officers as of December 31,
2017:
|
|
Option
awards
(1)(2)
|
|
|
|
Name
|
|
Number
of
securities
underlying
unexercised
options
exercisable
|
|
|
Number
of
securities
underlying
unexercised
options
unexercisable
|
|
|
Equity
incentive
plan awards:
Number
of
securities
underlying
unexercised
unearned
options
|
|
|
Option
exercise
price
($)
|
|
|
Option
expiration date
|
David
G. Watumull
|
|
|
1,750,588
|
|
|
|
-
|
|
|
|
-
|
|
|
$
|
0.155
|
|
|
February
7, 2024
|
David
G. Watumull
|
|
|
4,941,845
|
|
|
|
-
|
|
|
|
-
|
|
|
$
|
0.625
|
|
|
February
7, 2024
|
David
G. Watumull
|
|
|
468,498
|
(3)
|
|
|
-
|
|
|
|
-
|
|
|
$
|
0.32
|
|
|
June
30, 2020
|
David
G. Watumull
|
|
|
390,686
|
(3)
|
|
|
-
|
|
|
|
-
|
|
|
$
|
0.20
|
|
|
June
30, 2020
|
David
G. Watumull
|
|
|
89,523
|
(3)
|
|
|
-
|
|
|
|
-
|
|
|
$
|
0.49
|
|
|
September
30, 2020
|
David
G. Watumull
|
|
|
137,675
|
(3)
|
|
|
-
|
|
|
|
-
|
|
|
$
|
0.27
|
|
|
December
31, 2020
|
David
G. Watumull
|
|
|
774,385
|
(3)
|
|
|
-
|
|
|
|
-
|
|
|
$
|
0.06
|
|
|
March
31, 2021
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
David
M. Watumull
|
|
|
45,058
|
|
|
|
-
|
|
|
|
-
|
|
|
$
|
0.155
|
|
|
February
7, 2024
|
David
M. Watumull
|
|
|
2,388,554
|
|
|
|
-
|
|
|
|
-
|
|
|
$
|
0.625
|
|
|
February
7, 2024
|
David
M. Watumull
|
|
|
160,806
|
(3)
|
|
|
-
|
|
|
|
-
|
|
|
$
|
0.32
|
|
|
June
30, 2020
|
David
M. Watumull
|
|
|
284,917
|
(3)
|
|
|
-
|
|
|
|
-
|
|
|
$
|
0.20
|
|
|
June
30, 2020
|
David
M. Watumull
|
|
|
67,639
|
(3)
|
|
|
-
|
|
|
|
-
|
|
|
$
|
0.49
|
|
|
September
30, 2020
|
David
M. Watumull
|
|
|
104,021
|
(3)
|
|
|
-
|
|
|
|
-
|
|
|
$
|
0.27
|
|
|
December
31, 2020
|
David
M. Watumull
|
|
|
562,846
|
(3)
|
|
|
-
|
|
|
|
-
|
|
|
$
|
0.06
|
|
|
March
31, 2021
|
|
(1)
|
The
type of securities underlying all outstanding option awards is our common stock.
|
|
|
|
|
(2)
|
None
of our named executive officers have received stock awards.
|
|
|
|
|
(3)
|
Stock
options awarded in lieu of cash compensation.
|
Compensation
of Directors
The
following table sets forth information regarding each element of compensation that we paid or awarded to our current independent
directors for the fiscal year ended December 31, 2017:
Name
|
|
Year
|
|
|
Cash
Comp.
|
|
|
Equity
Awards
|
|
|
Total
|
|
George
W. Bickerstaff, III
|
|
|
2017
|
|
|
$
|
-
|
|
|
$
|
58,333
|
(1)
|
|
$
|
58,333
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Terence
A. Kelly, Ph.D.
|
|
|
2017
|
|
|
$
|
-
|
|
|
$
|
58,333
|
(2)
|
|
$
|
58,333
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Michele
Galen
|
|
|
2017
|
|
|
$
|
-
|
|
|
$
|
58,333
|
(3)
|
|
$
|
58,333
|
|
(1)
|
The
amount disclosed represents compensation recognized in 2017 for equity awarded in connection with services provided by Mr.
Bickerstaff as an independent director. On August 31, 2017, the compensation arrangement of Mr. Bickerstaff was amended so
that effective September 1, 2017, he would receive quarterly equity compensation of $18,750 in arrears in the form of a grant
of shares of our common stock or non-qualified stock options to purchase shares of our common stock based on the higher of
the then current market price or $0.15 per share.
|
|
|
(2)
|
The
amount disclosed represents compensation recognized in 2017 for equity awarded in connection with services provided by Dr.
Kelly as an independent director. On August 31, 2017, the compensation arrangement of Dr. Kelly was amended so that effective
September 1, 2017, he would receive quarterly equity compensation of $18,750 in arrears in the form of a grant of shares of
our common stock or non-qualified stock options to purchase shares of our common stock based on the higher of the then current
market price or $0.15 per share.
|
|
|
(3)
|
The
amount disclosed represents compensation recognized in 2017 for equity awarded in connection with services provided by Ms.
Galen as an independent director. Ms. Galen was elected to the Board of Directors on January 4, 2017 with quarterly equity
compensation of $12,500 in arrears in the form of a grant of shares of our common stock or non-qualified stock options to
purchase shares of our common stock based on the higher of the then current market price or $0.15 per share. On August 31,
2017, the compensation arrangement of Ms. Galen was amended so that effective September 1, 2017, she would receive quarterly
equity compensation of $12,500 in arrears in the form of a grant of shares of our common stock or non-qualified stock options
to purchase shares of our common stock based on the higher of the then current market price or $0.15 per share.
|
Outstanding
Equity Awards to Directors at Fiscal Year-End 2017
The
following table sets forth information regarding outstanding equity awards to our independent directors as of December 31, 2017:
|
|
Stock
awards
(1)
|
|
|
Option
awards
(2)
|
|
|
|
|
Name
|
|
Number
of
securities
awarded
|
|
|
Number
of
securities
underlying
unexercised
options
exercisable
|
|
|
Number
of
securities
underlying
unexercised
options
unexercisable
|
|
|
Equity
incentive
plan awards:
Number
of
securities
underlying
unexercised
unearned
options
|
|
|
Option
exercise
price
($)
|
|
|
Option
expiration date
|
|
George
W. Bickerstaff, III
|
|
|
1,213,725
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
$
|
-
|
|
|
|
-
|
|
Terence
A. Kelly, Ph.D.
|
|
|
567,866
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
$
|
-
|
|
|
|
-
|
|
Terence
A. Kelly, Ph.D.
|
|
|
-
|
|
|
|
416,667
|
|
|
|
-
|
|
|
|
-
|
|
|
$
|
0.06
|
|
|
|
March
31, 2021
|
|
Terence
A. Kelly, Ph.D.
|
|
|
-
|
|
|
|
27,778
|
|
|
|
-
|
|
|
|
-
|
|
|
$
|
0.15
|
|
|
|
September
30, 2021
|
|
Terence
A. Kelly, Ph.D.
|
|
|
-
|
|
|
|
83,333
|
|
|
|
-
|
|
|
|
-
|
|
|
$
|
0.15
|
|
|
|
December
31, 2021
|
|
Terence
A. Kelly, Ph.D.
|
|
|
-
|
|
|
|
78,125
|
|
|
|
-
|
|
|
|
-
|
|
|
$
|
0.185
|
|
|
|
March
31, 2022
|
|
Terence
A. Kelly, Ph.D.
|
|
|
-
|
|
|
|
83,333
|
|
|
|
-
|
|
|
|
-
|
|
|
$
|
0.20
|
|
|
|
June
30, 2022
|
|
Michele
Galen
|
|
|
318,161
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
$
|
-
|
|
|
|
-
|
|
|
(1)
|
All
shares are fully vested.
|
|
|
|
|
(2)
|
The
type of securities underlying all outstanding option awards is our common stock.
|
Employment
and Consulting Agreements
Executive
Officer Compensation
On
February 7, 2014, we entered into employment agreements with each of Messrs. David G. Watumull, David M. Watumull, Gilbert M.
Rishton, and Timothy J. King, which provided for employment for an initial term of one year, subject to renewal and earlier termination
rights as provided in such agreements. These agreements provide for compensation terms and duration of employment as set forth
in each such agreement. Such agreements include restrictive covenants concerning competition with us and solicitation of our employees
and clients, if such individuals are terminated for cause as defined in such agreements.
|
●
|
To
conserve cash resources while seeking additional financing, we and our employees, including Messrs. David G. Watumull, David
M. Watumull, Gilbert M. Rishton, and Timothy J. King, agreed to reduce cash compensation effective January 15, 2015.
|
|
|
|
|
●
|
On
June 30, 2015, the compensation arrangements of Messrs. David G. Watumull, David M. Watumull, Gilbert M. Rishton, and Timothy
J. King were amended so that, effective after June 30, 2015, we had the right to pay any compensation due to such officer
during any calendar quarter that was not paid in cash in the form of shares of our common stock or incentive stock options
under the 2014 Plan. In addition, the amount of the unpaid cash compensation that accrued during the first and second quarters
of 2015 was paid with incentive stock options under the 2014 Plan.
|
|
|
|
|
●
|
On
March 28, 2016, we furloughed all of our employees and independent contractors indefinitely and arranged with our Chief Executive
Officer, David G. Watumull; our Chief Financial Officer, John B. Russell; and our Vice President, Operations, David M. Watumull,
to continue their services for cash compensation equal to the minimum wage. In addition, each of the directors agreed, effective
April 1, 2016, to suspend any additional equity compensation, until otherwise agreed by the Company.
|
|
|
|
|
●
|
On
June 3, 2016, the compensation arrangement of David M. Watumull was amended so that, effective May 30, 2016, he would receive
bi-weekly compensation equal to $3,269 and the compensation arrangement of Timothy J. King was amended so that, effective
May 30, 2016, he would receive bi-weekly compensation equal to $1,635.
|
|
●
|
On
September 6, 2016, the compensation arrangements of certain officers were amended so that effective September 8, 2016, (i)
David G. Watumull would receive bi-weekly compensation equal to $4,327, (ii) Gilbert M. Rishton would receive bi-weekly compensation
equal to $1,923, and (iii) Timothy J. King would receive bi-weekly compensation equal to $3,269.
|
|
|
|
|
●
|
On
August 31, 2017, the compensation arrangements of certain officers were amended so that effective September 1, 2017, (i) David
G. Watumull would receive bi-weekly compensation equal to $7,212, (ii) David M. Watumull would receive bi-weekly compensation
equal to $5,769, (iii) Gilbert M. Rishton would receive bi-weekly compensation equal to $4,904, and (iv) Timothy J. King would
receive bi-weekly compensation equal to $4,904.
|
On
July 30, 2013, we entered into a service agreement with JBR Business Solutions, LLC, under which John B. Russell agreed to serve
as our Chief Financial Officer, and under which Mr. Russell would be paid an aggregate of $7,000 a month. Mr. Russell is the Managing
Partner of JBR Business Solutions, LLC. To conserve cash resources while seeking additional financing, we and Mr. Russell, agreed
to reduce cash compensation effective January 15, 2015. On June 30, 2015, the compensation arrangement was amended so that, effective
after June 30, 2015, we had the right to pay up to 50% of any compensation due during any calendar quarter that was not paid in
cash in the form of shares of our common stock or non-qualified stock options under the 2014 Plan. On March 28, 2016, Mr. Russell
was furloughed and agreed to continue service as Chief Financial Officer for cash compensation equal to the minimum wage. On September
6, 2016, the compensation arrangement was amended so that effective September 30, 2016, he would receive monthly compensation
of $3,500. On August 31, 2017, the compensation arrangement was amended so that effective September 1, 2017, Mr. Russell would
receive monthly compensation of $5,250.
Director
Compensation
On
June 30, 2015, we entered into an agreement with George W. Bickerstaff, III and Terence A. Kelly, Ph.D. that provided for the
annual compensation of each independent director equal to $100,000, payable quarterly in arrears in the form of a grant of shares
of our common stock or non-qualified stock options to purchase shares of our common stock under the 2014 Plan.
Effective
April 1, 2016, the independent directors of the Company agreed to suspend any additional equity compensation, until otherwise
agreed by the Company
On
September 6, 2016, the compensation arrangements of the independent directors of the Company were amended so that effective September
30, 2016, they would each receive quarterly equity compensation of $12,500 in arrears in the form of a grant of shares of our
common stock or non-qualified stock options to purchase shares of our common stock under the 2014 Plan based on the higher of
the then current market price or $0.15 per share, with such compensation prorated for one of three months for the quarter ended
September 30, 2016.
On
January 4, 2017, our Board of Directors elected Michele Galen to serve as an independent director until our next annual meeting
of stockholders with quarterly equity compensation of $12,500 in arrears in the form of a grant of shares of our common stock
or non-qualified stock options to purchase shares of our common stock under the 2014 Plan based on the higher of the then current
market price or $0.15 per share.
On
August 31, 2017, the compensation arrangements of the independent directors of the Company were amended so that effective September
1, 2017, they would each receive quarterly equity compensation of $18,750 in arrears in the form of a grant of shares of our common
stock or non-qualified stock options to purchase shares of our common stock under the 2014 Plan based on the higher of the then
current market price or $0.15 per share.
2014
Equity Compensation Plan
Our
2014 Plan is administered by our compensation committee. The purpose of the 2014 Plan is to provide financial incentives for selected
directors, employees, advisors, and consultants of Cardax and/or its subsidiaries, thereby promoting the long-term growth and
financial success of the Company. The issuance of awards under the 2014 Plan is at the discretion of our compensation committee,
which has the authority to determine the persons to whom any awards shall be granted and the terms, conditions and restrictions
applicable to any award. Under the 2014 Plan, we may grant equity-based incentive awards, including options, restricted stock,
and other stock-based awards, to any directors, employees, advisors, and consultants that provide services to us or any of our
subsidiaries. An aggregate of 45,420,148 shares of our common stock have been reserved for issuance under the 2014 Plan, which
is subject to adjustment as described in such plan. As of May 1, 2018, there are 3,189,727 shares of common stock available
for future awards under the 2014 Plan.
SECURITY
OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
The
following table sets forth information regarding the ownership of our common stock as of May 1, 2018 for:
|
●
|
each
director;
|
|
|
|
|
●
|
each
person known by us to own beneficially 5% or more of our common stock;
|
|
|
|
|
●
|
each
officer named in the summary compensation table elsewhere in this prospectus; and
|
|
|
|
|
●
|
all
directors and executive officers as a group.
|
The
amounts and percentages of our common stock beneficially owned are reported on the basis of regulations of the SEC governing the
determination of beneficial ownership of securities. Under the rules of the SEC, a person is deemed to be a “beneficial
owner” of a security if that person has or shares “voting power,” which includes the power to vote or to direct
the voting of such security, or “investment power,” which includes the power to dispose of or to direct the disposition
of such security. A person is also deemed to be a beneficial owner of any securities of which that person has the right to acquire
beneficial ownership within 60 days. Under these rules more than one person may be deemed a beneficial owner of the same securities
and a person may be deemed to be a beneficial owner of securities as to which such person has no economic interest.
For
purposes of the table below, we have assumed that 150,642,406 shares of our common stock will be outstanding upon closing
of the Exchange Offer, based upon the following:
(i)
122,936,624 shares of our common stock outstanding as of May 1, 2018; and
(ii)
27,705,782 Exchange Shares issuable upon the tender of all Original Warrants under the Exchange Offer based on the Original Warrants
outstanding as of May 1, 2018.
Unless
otherwise indicated below, to the best of our knowledge each beneficial owner named in the table has sole voting and sole investment
power with respect to all shares beneficially owned, subject to community property laws where applicable.
|
|
Common
Stock Beneficially Owned Prior to the Exchange Offer
|
|
|
Common
Stock Beneficially Owned After the Exchange Offer
|
|
Name
|
|
Number
of Shares
|
|
|
%
(1)
|
|
|
Number
of Shares
|
|
|
%
|
|
Directors
and Executive Officers
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
George
W. Bickerstaff, III
(2)
|
|
|
2,283,169
|
(3)
|
|
|
1.9
|
%
|
|
|
2,283,169
|
|
|
|
1.5
|
%
|
Terence
A. Kelly, Ph.D.
(4)
|
|
|
1,303,398
|
(5)
|
|
|
1.1
|
%
|
|
|
1,303,398
|
|
|
|
0.9
|
%
|
Michele
Galen
(6)
|
|
|
387,605
|
(7)
|
|
|
0.3
|
%
|
|
|
387,605
|
|
|
|
0.3
|
%
|
David
G. Watumull
(8)
|
|
|
10,412,364
|
(9)
|
|
|
7.9
|
%
|
|
|
10,412,364
|
|
|
|
6.5
|
%
|
David
M. Watumull
(10)
|
|
|
3,613,841
|
(11)
|
|
|
2.9
|
%
|
|
|
3,613,841
|
|
|
|
2.3
|
%
|
John
B. Russell
(12)
|
|
|
331,997
|
(13)
|
|
|
0.3
|
%
|
|
|
331,997
|
|
|
|
0.2
|
%
|
All
directors and executive officers as a group (6 persons)
|
|
|
18,332,374
|
|
|
|
13.4
|
%
|
|
|
18,332,374
|
|
|
|
11.1
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Beneficial
Owner of 5% or more
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Eric
J. Pearson and Lianne L. Pearson
(14)
|
|
|
41,157,458
|
(15)
|
|
|
28.7
|
%
|
|
|
41,157,458
|
|
|
|
24.0
|
%
|
(1)
|
Based
on 122,936,624 shares of common stock issued and outstanding as of May 1, 2018.
|
|
|
(2)
|
The
address of Mr. George W. Bickerstaff, III is c/o Cardax, Inc., 2800 Woodlawn Drive, Honolulu, Hawaii 96822. Mr. Bickerstaff
is the current Chairman of our Board of Directors.
|
|
|
(3)
|
Represents
2,283,169 shares of common stock.
|
|
|
(4)
|
The
address of Dr. Terence A. Kelly is c/o Cardax, Inc., 2800 Woodlawn Drive, Honolulu, Hawaii 96822. Dr. Kelly is a member of
our Board of Directors.
|
|
|
(5)
|
Represents
(a) 614,162 shares of common stock, (b) 416,667 shares of common stock issuable upon exercise by Dr. Kelly of options that
are presently exercisable, at an exercise price of $0.06 per share, (c) 111,111 shares of common stock issuable upon exercise
by Dr. Kelly of options that are presently exercisable, at an exercise price of $0.15 per share, (d) 78,125 shares of common
stock issuable upon exercise by Dr. Kelly of options that are presently exercisable, at an exercise price of $0.185 per share,
and (e) 83,333 shares of common stock issuable upon exercise by Dr. Kelly of options that are presently exercisable, at an
exercise price of $0.20 per share.
|
|
|
(6)
|
The
address of Ms. Michele Galen is c/o Cardax, Inc., 2800 Woodlawn Drive, Honolulu, Hawaii 96822. Ms. Galen is a member of our
Board of Directors.
|
|
|
(7)
|
Represents
387,605 shares of common stock.
|
|
|
(8)
|
The
address of Mr. David G. Watumull is c/o Cardax, Inc., 2800 Woodlawn Drive, Honolulu, Hawaii 96822. Mr. David G. Watumull is
our President, CEO, and a member of our Board of Directors.
|
|
|
(9)
|
Represents
(a) 1,750,588 shares of common stock issuable upon exercise by Mr. David G. Watumull of options that are presently exercisable,
at an exercise price of $0.155 per share, (b) 4,941,845 shares of common stock issuable upon exercise by Mr. David G. Watumull
of options that are presently exercisable, at an exercise price of $0.625 per share, (c) 468,498 shares of common stock issuable
upon exercise by Mr. David G. Watumull of options that are presently exercisable, at an exercise price of $0.32 per share,
(d) 390,686 shares of common stock issuable upon exercise by Mr. David G. Watumull of options that are presently exercisable,
at an exercise price of $0.20 per share, (e) 89,523 shares of common stock issuable upon exercise by Mr. David G. Watumull
of options that are presently exercisable, at an exercise price of $0.49 per share, (f) 137,675 shares of common stock issuable
upon exercise by Mr. David G. Watumull of options that are presently exercisable, at an exercise price of $0.27 per share,
(g) 774,385 shares of common stock issuable upon exercise by Mr. David G. Watumull of options that are presently exercisable,
at an exercise price of $0.06 per share, (h) 408,172 shares of common stock issued in the Holdings Merger, which Mr. Watumull
may be deemed to beneficially own as the Trustee of the David G. Watumull Revocable Living Trust, (i) 50,992 shares of common
stock issuable upon exercise of a certain warrant issued in the Holdings Merger at an exercise price of $0.981 per share,
which Mr. Watumull may be deemed to beneficially own as the Trustee of the David G. Watumull Revocable Living Trust, (j) 350,000
shares of common stock issued in the 2016/2017 Unit Offering, which Mr. Watumull may be deemed to beneficially own as the
Trustee of the David G. Watumull Revocable Living Trust, (k) 350,000 shares of common stock issuable upon exercise of a certain
warrant issued in the 2016/2017 Unit Offering at an exercise price of $0.08 per share, which Mr. Watumull may be deemed to
beneficially own as the Trustee of the David G. Watumull Revocable Living Trust, (l) 350,000 shares of common stock issuable
upon exercise of a certain warrant issued in the 2016/2017 Unit Offering at an exercise price of $0.12 per share, which Mr.
Watumull may be deemed to beneficially own as the Trustee of the David G. Watumull Revocable Living Trust, and (m) 350,000
shares of common stock issuable upon exercise of a certain warrant issued in the 2016/2017 Unit Offering at an exercise price
of $0.16 per share, which Mr. Watumull may be deemed to beneficially own as the Trustee of the David G. Watumull Revocable
Living Trust.
|
|
|
(10)
|
The
address of Mr. David M. Watumull is c/o Cardax, Inc., 2800 Woodlawn Drive, Honolulu, Hawaii 96822. Mr. David M. Watumull is
our Chief Operating Officer.
|
(11)
|
Represents
(a) 45,058 shares of common stock issuable upon exercise by Mr. David M. Watumull of options that are presently exercisable,
at an exercise price of $0.155 per share, (b) 2,388,554 shares of common stock issuable upon exercise by Mr. David M. Watumull
of options that are presently exercisable, at an exercise price of $0.625 per share, (c) 160,806 shares of common stock issuable
upon exercise by Mr. David M. Watumull of options that are presently exercisable, at an exercise price of $0.32 per share,
(d) 284,917 shares of common stock issuable upon exercise by Mr. David M. Watumull of options that are presently exercisable,
at an exercise price of $0.20 per share, (e) 67,639 shares of common stock issuable upon exercise by Mr. David M. Watumull
of options that are presently exercisable, at an exercise price of $0.49 per share, (f) 104,021 shares of common stock issuable
upon exercise by Mr. David M. Watumull of options that are presently exercisable, at an exercise price of $0.27 per share,
and (g) 562,846 shares of common stock issuable upon exercise by Mr. David M. Watumull of options that are presently exercisable,
at an exercise price of $0.06 per share.
|
|
|
(12)
|
The
address of Mr. John B. Russell is c/o Cardax, Inc., 2800 Woodlawn Drive, Honolulu, Hawaii 96822. Mr. Russell is our Chief
Financial Officer.
|
|
|
(13)
|
Represents
(a) 59,835 shares of common stock issuable upon exercise of options that are presently exercisable, at an exercise price of
$0.32 per share, which Mr. Russell may be deemed to beneficially own as the Managing Partner of JBR Business Solutions, LLC,
(b) 62,424 shares of common stock issuable upon exercise of options that are presently exercisable, at an exercise price of
$0.20 per share, which Mr. Russell may be deemed to beneficially own as the Managing Partner of JBR Business Solutions, LLC,
(c) 18,956 shares of common stock issuable upon exercise of options that are presently exercisable, at an exercise price of
$0.49 per share, which Mr. Russell may be deemed to beneficially own as the Managing Partner of JBR Business Solutions, LLC,
(d) 24,988 shares of common stock issuable upon exercise of options that are presently exercisable, at an exercise price of
$0.27 per share, which Mr. Russell may be deemed to beneficially own as the Managing Partner of JBR Business Solutions, LLC,
and (e) 165,794 shares of common stock issuable upon exercise of options that are presently exercisable, at an exercise price
of $0.06 per share, which Mr. Russell may be deemed to beneficially own as the Managing Partner of JBR Business Solutions,
LLC.
|
(14)
|
The
address of Dr. Eric J. Pearson and Mrs. Lianne L. Pearson is 814 Mokulua Drive, Kailua, Hawaii 96734.
|
|
|
(15)
|
Represents
(a) 208,333 shares of common stock issued in the 2017 Unit Offering, (b) 7,796,961 shares of common stock issued in the 2017
Unit Offering, which the Pearson’s may be deemed to beneficially own as the beneficiaries of the Eric J Pearson DVM
401(k) Profit Sharing Plan FBO Eric J Pearson and Lianne Pearson, (c) 968,993 shares of common stock issued in the 2017 Unit
Offering, which the Pearson’s may be deemed to beneficially own as the beneficiaries of the Sunwest Trust FBO Lianne
L. Pearson Roth IRA, (d) 1,234,262 shares of common stock issued in the 2017 Unit Offering, which the Pearson’s may
be deemed to beneficially own as the beneficiaries of the Sunwest Trust FBO Eric J. Pearson Roth IRA, (e) 400,000 shares of
common stock issued in the 2017 Unit Offering, which the Pearson’s may be deemed to beneficially own as the beneficiaries
of the Sunwest Trust FBO Eric J. Pearson Roth IRA, (f) 9,903,584 shares of common stock issued in the 2017 Unit Offering,
which the Pearson’s may be deemed to beneficially own as the beneficiaries of the Eric J Pearson DVM 401(k) Profit Sharing
Plan FBO Eric J Pearson and Lianne Pearson, (g) 66,596 shares of common stock issued in the 2017(2) Unit Offering, which the
Pearson’s may be deemed to beneficially own as the beneficiaries of the Sunwest Trust as Custodian for Lianne Pearson
Roth IRA, (h) 208,333 shares of common stock issuable upon exercise of a certain warrant issued in the 2017 Unit Offering
at an exercise price of $0.12 per share, (i) 7,796,961 shares of common stock issuable upon exercise of a certain warrant
issued in the 2017 Unit Offering at an exercise price of $0.12 per share, which the Pearson’s may be deemed to beneficially
own as the beneficiaries of the Eric J Pearson DVM 401(k) Profit Sharing Plan FBO Eric J Pearson and Lianne Pearson, (j) 968,993
shares of common stock issuable upon exercise of a certain warrant issued in the 2017 Unit Offering at an exercise price of
$0.12 per share, which the Pearson’s may be deemed to beneficially own as the beneficiaries of the Sunwest Trust FBO
Lianne L. Pearson Roth IRA, (k) 1,234,262 shares of common stock issuable upon exercise of a certain warrant issued in the
2017 Unit Offering at an exercise price of $0.12 per share, which the Pearson’s may be deemed to beneficially own as
the beneficiaries of the Sunwest Trust FBO Eric J. Pearson Roth IRA, (l) 400,000 shares of common stock issuable upon exercise
of a certain warrant issued in the 2017 Unit Offering at an exercise price of $0.12 per share, which the Pearson’s may
be deemed to beneficially own as the beneficiaries of the Sunwest Trust FBO Eric J. Pearson Roth IRA, (m) 9,903,584 shares
of common stock issuable upon exercise of a certain warrant issued in the 2017 Unit Offering at an exercise price of $0.12
per share, which the Pearson’s may be deemed to beneficially own as the beneficiaries of the Eric J Pearson DVM 401(k)
Profit Sharing Plan FBO Eric J Pearson and Lianne Pearson, and (n) 66,596 shares of common stock issuable upon exercise of
a certain warrant issued in the 2017(2) Unit Offering at an exercise price of $0.30 per share, which the Pearson’s may
be deemed to beneficially own as the beneficiaries of the Sunwest Trust as Custodian for Lianne Pearson Roth IRA.
|
Certain
Relationships and Related PARTY Transactions
On
October 16, 2017, the Company engaged M.M. Dillon & Co., to serve as the Financial Advisor for the Company in connection
with this Exchange Offer, and related transactions. George W. Bickerstaff, III, a director of the Company, is currently a Managing
Director of M.M. Dillon & Co., and as such, abstained from voting on the engagement of M.M. Dillon & Co.
On
May 2, 2018, the terms of M.M. Dillon & Co.’s engagement were modified, and such modifications were approved
by our Board (with Mr. Bickerstaff abstaining) on April 30, 2018.
As
the Financial Advisor in connection with this Exchange Offer, M.M. Dillon & Co. shall be paid a cash fee of
3.5%
of the gross proceeds from the Exchange Offer and a 5-year common stock purchase warrant with a fair market value equal to 3.5%
of the gross proceeds from the Exchange Offer.
Other
than compensation arrangements with directors and executive officers, which are described under “Executive Compensation—
Employment and Consulting Agreements”, and except as described above, we have no other related-party transactions that are
subject to disclosure.
GENERAL
TERMS OF EXCHANGE OFFER
Purpose
of the Exchange Offer
We
are making the Exchange Offer primarily to raise capital from holders of Original Warrants. We believe that by allowing holders
of Original Warrants to exchange the Original Warrants for Exchange Shares, the Company can raise additional capital for
general corporate purposes in an efficient and cost-effective manner.
You
should read the discussion under the heading “Description of Securities” for more information about the Exchange Shares.
Terms
of the Exchange Offer
Upon
the terms and subject to the conditions described in this prospectus and in the Letter of Transmittal, we are offering to issue
Exchange Shares to the holders of outstanding Original Warrants who validly tender their Original Warrants on or prior to the
Expiration Date. All outstanding Original Warrants that are not tendered prior to the Expiration Date or, for any valid reason,
not accepted by us, will continue to be outstanding according to their terms unmodified.
As
of May 1, 2018, there are outstanding 27,705,782 Original Warrants subject to the Exchange Offer. This prospectus and the
Letter of Transmittal are being sent to all registered holders of the outstanding Original Warrants. There will be no fixed record
date for determining registered holders of the outstanding Original Warrants entitled to participate in the Exchange Offer.
The
Exchange Agent will act as agent for the tendering holders of the Original Warrants for the purposes of receiving the Original
Warrants and the completed, signed, and dated Letter of Transmittal and other required documents. The Exchange Payment should
be sent directly to us. We will issue the Exchange Shares on a continuous basis during the Exchange Period.
We
intend to conduct the Exchange Offer in accordance with the applicable requirements of the Securities Act and the Exchange Act,
and the rules and regulations promulgated by the SEC thereunder.
Expiration
Time
The
Exchange Offer will expire on the Expiration Date, which is at 5:00 p.m., New York City time, on the date that is 20 business
days after the effective date of this Registration Statement unless extended by us at our sole discretion.
Extensions,
Termination, or Amendment
Subject
to applicable law, we expressly reserve the right, at any time or at various times, and regardless of whether any events preventing
satisfaction of the conditions to the Exchange Offer, to extend the period of time during which the Exchange Offer is open by
giving oral (to be confirmed in writing) or written notice of such extension to the Exchange Agent and by making public disclosure
by press release or other appropriate means of such extension to the extent required by law.
During
any extension of the Exchange Offer, all Original Warrants previously tendered and not accepted by us will remain subject to the
Exchange Offer and may, subject to the terms and conditions of the Exchange Offer, be accepted by us, and all Original Warrants
previously tendered and accepted by us pursuant to the Exchange Offer will remain effective. In addition, we may waive conditions
without extending the Exchange Offer in accordance with applicable law.
If
any of the conditions described below under “Conditions to the Exchange Offer” have not been satisfied with respect
to the Exchange Offer, we reserve the right, at our sole discretion:
|
●
|
to
extend the Exchange Offer,
|
|
|
|
|
●
|
to
delay accepting any Original Warrants tendered pursuant to the Exchange Offer,
|
|
|
|
|
●
|
to
terminate the Exchange Offer, or
|
|
|
|
|
●
|
to
otherwise amend the Exchange Offer in any respect in compliance with applicable securities laws and stock exchange rules.
|
Announcements
Any
extension, termination, or amendment of the Exchange Offer will be followed as promptly as practicable by announcement thereof,
such announcement in the case of an extension to be issued no later than 9:00 a.m., New York City time, on the next business day
following the previously scheduled Expiration Date. Without limiting the manner in which we may choose to make such announcement,
we will not, unless otherwise required by law, have any obligation to publish, advertise, or otherwise communicate any such announcement
other than by making a release to an appropriate news agency or another means of announcement that we deem appropriate.
Acceptance
of Tendered Original Warrants Pursuant to the Exchange Offer
If
the conditions to the Exchange Offer are satisfied, or if we waive all of the conditions that have not been satisfied, we will
accept, during the Exchange Period, and after we receive completed and duly executed Letters of Transmittal with
respect to any and all of the Original Warrants tendered at such time and the Exchange Payment, the tendered Original Warrants
by notifying the Exchange Agent of our acceptance. The notice may be oral if we promptly confirm it in writing.
We
expressly reserve the right, in our sole discretion, to delay acceptance of the Original Warrants tendered pursuant to the Exchange
Offer, or to terminate the Exchange Offer and not accept the Original Warrants tendered pursuant to the Exchange Offer, (1) if
any of the conditions to the Exchange Offer shall not have been satisfied or validly waived by us, or (2) in order to comply in
whole or in part with any applicable law.
In
all cases, the Exchange Shares will be issued only after timely receipt by the Exchange Agent of the Original Warrants, the properly
completed and duly executed Letter of Transmittal (or a facsimile thereof), and any other documents required by the Letter of
Transmittal, and timely receipt by the Company of the Exchange Payment.
For
purposes of the Exchange Offer, we will have accepted the Original Warrants tendered pursuant to the Exchange Offer, if, as and
when we give oral or written notice to the Exchange Agent of our acceptance of such Original Warrants pursuant to the Exchange
Offer.
If,
for any reason whatsoever, acceptance of any Original Warrants tendered or the issuance of the Exchange Shares is delayed or we
extend the Exchange Offer or are unable to accept the tender of the Original Warrants pursuant to the Exchange Offer, then, without
prejudice to our rights set forth herein, we may instruct the Exchange Agent to retain the Original Warrants tendered.
We
will have the right, which may be waived, to reject the defective tender of Original Warrants pursuant to the Exchange Offer as
invalid and ineffective. If we waive our rights to reject a defective tender, subject to the other terms and conditions set forth
in the Exchange Offer and the Letter of Transmittal, you will be entitled to the Exchange Shares.
Procedures
for Participating in the Exchange Offer
General
In
order to participate in the Exchange Offer, you must tender your Original Warrants as described below. It is your responsibility
to tender your Original Warrants. We have the right to waive any defects. However, we are not required to waive defects and are
not required to notify you of defects in your tender.
If
you have any questions or need help in tendering your Original Warrants pursuant to the Exchange Offer, please contact the Solicitation
Agent whose address and telephone number are listed in this prospectus.
See “Solicitation
Agent.”
The
method of tendering the Original Warrants and delivering the Letters of Transmittal and other required documents is at your election
and risk. If delivery is by mail, we recommend that registered mail, properly insured, with return receipt requested, be used.
In all cases, sufficient time should be allowed to assure timely delivery. No Original Warrants, Letters of Transmittal, or other
required documents should be sent to the Company.
Proper
Participation in the Exchange
All
Original Warrants are currently in certificated form. For a holder of Original Warrants to tender their Original Warrants pursuant
to the Exchange Offer, (1) the Original Warrants and a properly completed and duly executed Letter of Transmittal (or a facsimile
thereof), together with any signature guarantees and any other documents required by the Instructions to the Letter of Transmittal,
must be received by the Exchange Agent in accordance with the instructions specified in the Letter of Transmittal and at the address
or facsimile number set forth in this prospectus and (2) the Exchange Payment must be received by the Company in accordance with
the instructions specified in the Letter of Transmittal and at the address or pursuant to the wire instructions set forth in this
prospectus prior to the Expiration Date.
In
all cases, the issuance of the Exchange Shares pursuant to the Exchange Offer will be made during the Exchange Period only
after timely receipt by the Company of the Exchange Payment and timely receipt by the Exchange Agent of:
|
●
|
the
Original Warrants;
|
|
|
|
|
●
|
the
Letter of Transmittal (or a facsimile thereof) properly completed and duly executed; and
|
|
|
|
|
●
|
any
required signature guarantees and other documents required by the Letter of Transmittal.
|
Procedures
for Tendering Original Warrants Held Through a Custodian
If
you are a beneficial owner of Original Warrants, but the holder of such Original Warrants is a custodial entity such as a bank,
broker, dealer, trust company, or other nominee, and you seek to tender your Original Warrants pursuant to the Exchange Offer,
you must provide appropriate instructions to such holder of the Original Warrants. Beneficial owners may be instructed to complete
and deliver an instruction letter to such holder of Original Warrants for this purpose. We urge you to contact such person that
holds Original Warrants for you if you wish to tender your Original Warrants pursuant to the Exchange Offer.
Signature
Guarantees
Signatures
on all Letters of Transmittal must be guaranteed by a recognized participant in the Securities Transfer Agents Medallion Program,
if and only if
Original Warrants are registered in the name of a person other than the signer of the Letter of Transmittal,
or the Exchange Shares are to be issued in the name of a person other than the holder of the Original Warrant, or the Exchange
Shares are being issued through Deposit/Withdrawal At Custodian or “DWAC”, or as otherwise required by the Exchange
Agent.
Determination
of Validity of Tender
All
questions as to the validity, form, eligibility (including time of receipt) and acceptance of any tendered Original Warrants pursuant
to this Exchange Offer and any of the procedures described above, and the form and validity of all documents will be determined
by us in our sole discretion, which determination will be final and binding, subject to the rights of our Original Warrant holders
to challenge such determination in a court of competent jurisdiction. We reserve the absolute right to reject any or all tenders
of Original Warrants determined by us not to be in proper form, or if the acceptance of or tender of Original Warrants may, in
the opinion of our counsel, be unlawful. We also reserve the right to waive any conditions to the Exchange Offer that we are legally
permitted to waive.
Your
tender of Original Warrants pursuant to the Exchange Offer will not be deemed to have been made until all defects or irregularities
in your tender have been cured or waived. Neither we, the Exchange Agent, nor any other person or entity is under any duty
to give notification of any defects or irregularities in any tender or withdrawal of any tender pursuant to the
Exchange Offer, or will incur any liability for failure to give any such notification.
Return
of Original Warrants
If
we do not accept any Original Warrants in the Exchange Offer for any reason described in the terms and conditions of the Exchange
Offer or if a greater number of Original Warrants are tendered than the holder of the Original Warrants desires to tender and
exchange in the Exchange Offer, we will return such Original Warrants without expense to the holder. These actions will occur
as promptly as practicable after the expiration or termination of the Exchange Offer.
Your
Representations to Us
By
signing or agreeing to be bound by the Letter of Transmittal and other required documents, you will represent to us that, among
other things:
|
●
|
any
Exchange Shares or that you receive will be acquired in the ordinary course of your business or for your own personal investment;
|
|
|
|
|
●
|
you
have no arrangement or understanding with any person to participate in the distribution of the Exchange Shares;
|
|
|
|
|
●
|
you
are not our “affiliate,” as defined in Rule 405 under the Securities Act;
|
|
|
|
|
●
|
if
you are not a broker-dealer, you are not engaged in and do not intend to engage in the distribution of the Exchange Shares;
and
|
|
|
|
|
●
|
if
you are a broker-dealer, that you will receive Exchange Shares for your own account in exchange for the tender of the
Original Warrants that were acquired as a result of market-making activities or other trading activities and that you
will deliver a prospectus in connection with any resale of such Exchange Shares.
|
Resales
Each
broker-dealer that receives Exchange Shares for its own account in exchange for the tender of Original Warrants, where such Original
Warrants were acquired by such broker-dealer as a result of any trading activities must acknowledge that it will deliver a prospectus
in connection with any resale of such Exchange Shares. See “Solicitation Agents.”
Conditions
to the Exchange Offer
Notwithstanding
any other provisions of the Exchange Offer, we will not be required to accept the tendered Original Warrants pursuant to the Exchange
Offer or to issue the Exchange Shares pursuant to the Exchange Offer, and may terminate, amend or extend the Exchange Offer or
delay issuing the Exchange Shares, if any of the following shall occur or exist or have not been satisfied, or have not been waived
by us, prior to the Expiration Date:
●
no action or event shall have occurred, no action shall have been taken, and no statute, rule, regulation, judgment, order, stay,
decree, or injunction shall have been promulgated, enacted, entered or enforced applicable to the Exchange Offer or the exchange
of Original Warrants for Exchange Shares under the Exchange Offer by or before any court or governmental regulatory or administrative
agency, authority, or tribunal of competent jurisdiction, including, without limitation, taxing authorities, that challenges the
making of the Offer or the exchange of Original Warrants for Exchange Shares under the Exchange Offer or would reasonably be expected
to, directly or indirectly, prohibit, prevent, restrict or delay consummation of, or would reasonably be expected to otherwise
adversely affect in any material manner, the Exchange Offer or the exchange of Original Warrants for Exchange Shares under the
Exchange Offer;
●
there shall not have occurred:
|
o
|
any
general suspension of or limitation on trading in securities on OTCQB, whether or not mandatory,
|
|
|
|
|
o
|
a
declaration of a banking moratorium or any suspension of payments in respect of banks by federal or state authorities in the
United States, whether or not mandatory,
|
|
|
|
|
o
|
a
commencement of a war, armed hostilities, a terrorist act, or other national or international calamity directly or indirectly
relating to the United States, or
|
|
|
|
|
o
|
in
the case of any of the foregoing existing at the time of the commencement of the Offer, a material acceleration or worsening
thereof; and
|
●
effectiveness with the SEC of our registration statement on Form S-4.
These
conditions are for our benefit and may be asserted by us or may be waived by us, including any action or inaction by us giving
rise to any condition, in whole or in part, at any time and from time to time at or prior to the Expiration Date, in our reasonable
discretion. We may additionally terminate the Exchange Offer if any condition is not satisfied on or prior to the Expiration Date.
If any of these events occur, subject to the termination rights described above, we may (i) return any tendered Original Warrants
to you, (ii) extend the Exchange Offer and retain all tendered Original Warrants until the expiration of the extended Exchange
Offer, or (iii) amend the Exchange Offer in any respect by giving oral or written notice of such amendment to the Exchange Agent
and making public disclosure of such amendment to the extent required by law. Notwithstanding the foregoing, in no event may we
terminate, amend or extend the Exchange Offer or delay issuing the Exchange Shares if the occurrence, existence, or nonsatisfaction
of any of the foregoing resulted from our action or failure to act.
We
have not made a decision as to what circumstances would lead us to waive any condition, and any such waiver would depend on circumstances
prevailing at the time of such waiver. Although we have no present plans or arrangements to do so, we reserve the right to amend,
at any time, the terms of the Exchange Offer. We will give holders of Original Warrants notice of such amendments as may be required
by applicable law.
Transfer
of Original Warrants
The
Original Warrants provide that they may be transferred under their terms in compliance with state and federal securities laws.
The
holder may sell the Original Warrant only pursuant to either: (i) the registration requirements of the Securities Act, including
any applicable prospectus delivery requirements, in compliance with the plan of distribution set forth in the applicable registration
statement; or (ii) an exemption therefrom, including Rule 144 under the Securities Act.
In
general, under Rule 144, a holder may transfer securities, subject to certain holding requirements and subject to the availability
of current public information about the Company. The holders of the Original Warrants currently satisfy the holding period requirements,
and the Company currently satisfies the public information requirements. As such, Company has arranged for an opinion of counsel
to be delivered to the stock record agent to holders seeking to transfer the Original Warrants, subject to compliance with all
applicable federal and state securities laws and other applicable law.
Upon
receipt by the Company of satisfactory evidence of the ownership of and the loss, theft, destruction, or mutilation of any Original
Warrant, and (i) in the case of loss, theft, or destruction, upon receipt by the Company of indemnity satisfactory to it, or (ii)
in the case of mutilation, upon receipt of such Original Warrant and upon surrender and cancellation of such Original Warrant,
the Company may execute and deliver in lieu thereof a new warrant representing the right to purchase an equal number of shares
of common stock.
The
description of the Original Warrants is qualified in its entirety by reference to the forms of such warrants filed as exhibits
to the registration statement of which this prospectus forms a part.
Fees
and Expenses
We
will bear the expenses of soliciting the tender of the Original
Warrants pursuant to the Exchange Offer. The principal solicitation is being made by email and mail; however, we may make additional
solicitation by facsimile, telephone, or in person by our officers and regular employees and those of our affiliates.
We
have retained a financial advisor and a solicitation agent in connection with the Exchange Offer, who will be paid fees in connection
with this Exchange Offer. We will also pay the Exchange Agent reasonable and customary fees for their services and reimburse them
for their related reasonable out-of-pocket expenses. We may also pay brokerage houses and other custodians, nominees, and
fiduciaries the reasonable out-of-pocket expenses incurred by them in forwarding copies of this prospectus, Letter of Transmittal,
and related documents to the beneficial owners of the Original Warrants and in handling or forwarding Original Warrants tendered
pursuant to the Exchange Offer.
We
will pay cash expenses to be incurred in connection with the Exchange Offer. They include:
|
●
|
SEC
registration fees for the Exchange Shares,
|
|
|
|
|
●
|
Financial
Advisor and Solicitation Agent fees,
|
|
|
|
|
●
|
fees
and expenses of the Exchange Agent,
|
|
|
|
|
●
|
accounting,
advisory, and legal fees,
|
|
|
|
|
●
|
printing
costs, and
|
|
|
|
|
●
|
related
fees and expenses.
|
If
your Original Warrants are held or the Exchange Shares will be held through a broker or other nominee on your behalf, your
broker or other nominee may charge you a commission in connection with the Exchange Offer.
Transfer
Taxes
If
you tender your Original Warrants pursuant to the Exchange Offer, you will not be required to pay any transfer taxes. We will
pay all transfer taxes, if any, applicable to the tender of Original Warrants in the Exchange Offer. The tendering holder will,
however, be required to pay any transfer taxes, whether imposed on the registered holder or any other person, if:
|
●
|
certificates
representing the Exchange Shares issued in exchange for the Original Warrants are to be delivered to, or are to be issued
in the name of, any person other than the registered holder of the Original Warrants tendered,
|
|
|
|
|
●
|
tendered
Original Warrants are registered in the name of any person other than the person signing the Letter of Transmittal, or
|
|
|
|
|
●
|
a
transfer tax is imposed for any reason other than the issuance of Exchange Shares in exchange for the tender of Original Warrants
in the Exchange Offer.
|
If
satisfactory evidence of payment of any transfer taxes payable by an exercising holder is not submitted with the Letter of Transmittal,
the amount of the transfer taxes will be billed directly to that exercising holder. The Exchange Agent will retain possession
of the Exchange Shares with a value equal to the amount of the transfer taxes due until it receives payment of the taxes.
Consequences
of Failure to Tender
If
you currently hold Original Warrants and do not tender them in connection with the Exchange Offer, then, following the
expiration of the Exchange Offer, your Original Warrants will continue to be outstanding according to their terms unmodified.
The Original Warrants will continue to be exercisable per their terms.
Other
Participation
in the Exchange Offer is voluntary, and you should carefully consider whether to accept. You are urged to consult your financial,
legal, and tax advisors in making your decision on what action to take.
In
the future, we may at our discretion seek to acquire untendered Original Warrants in open market or privately negotiated transactions,
through subsequent exchange offers or otherwise. We have no present plan to acquire any Original Warrants that do not participate
in the Exchange Offer.
Solicitation
Agent
We
have appointed CIM Securities as the Solicitation Agent for the Exchange Offer. You should direct questions, requests for
assistance, and requests for additional copies of the prospectus and the Letter of Transmittal that may accompany this prospectus
to the Solicitation Agent as follows:
CIM
Securities, LLC
Attn:
Andrew Daniels, Managing Director
509
Madison Avenue, 9th Floor
New
York, NY 10022
646-603-6717
Andrew.Daniels@brooklinecm.com
Exchange
Agent
We
have appointed VStock Transfer, LLC as the Exchange Agent for the Exchange Offer. The Original Warrants, Letter of Transmittal,
and all other documents required to participate in the Exchange Offer should be directed to the Exchange Agent as follows:
VStock
Transfer, LLC
18
Lafayette Place
Woodmere,
NY 11598
855-9VSTOCK
info@vstocktransfer.com
The
Exchange Payment should be sent directly to the Company pursuant to the instructions on the Letter of Transmittal.
Delivery
to an address other than set forth above will not constitute a valid delivery
DESCRIPTION
OF SECURITIES
Authorized
Capital Stock
Our
authorized share capital consists of 400,000,000 shares of common stock, par value $0.001 per share, and 50,000,000 shares of
preferred stock, par value $0.001 per share.
Common
Stock
As
of May 1, 2018, 122,936,624 shares of our common stock were outstanding. The outstanding shares of common stock are validly
issued, fully paid and non-assessable.
Holders
of common stock are entitled to one vote for each share on all matters submitted to a stockholder vote. Holders of common stock
do not have cumulative voting rights. Therefore, holders of a majority of the shares of common stock voting for the election of
directors can elect all of the directors. Holders of common stock representing a majority of the voting power of the Company’s
capital stock issued, outstanding and entitled to vote, represented in person or by proxy, are necessary to constitute a quorum
at any meeting of stockholders. A vote by the holders of a majority of the Company’s outstanding shares is required to effectuate
certain fundamental corporate changes such as liquidation, merger, or an amendment to the Company’s certificate of incorporation.
Holders
of common stock are entitled to share in all dividends that our Board of Directors, in its discretion, declares from legally available
funds. In the event of a liquidation, dissolution or winding up, each outstanding share entitles its holder to participate pro
rata in all assets that remain after payment of liabilities and after providing for each class of stock, if any, having preference
over the common stock. The common stock has no pre-emptive, subscription or conversion rights and there are no redemption provisions
applicable to the common stock.
Preferred
Stock
As
of the date of this prospectus, there were no shares of our preferred stock issued and outstanding.
Our
authorized preferred stock is “blank check” preferred. Accordingly, subject to limitations prescribed by law, our
Board is expressly authorized, at its discretion, to adopt resolutions to issue shares of preferred stock of any class or series,
to fix the number of shares of any class or series of preferred stock and to change the number of shares constituting any series
and to provide for or change the voting powers, designations, preferences and relative, participating, optional or other special
rights, qualifications, limitations or restrictions thereof, including dividend rights (including whether the dividends are cumulative),
dividend rates, terms of redemption (including sinking fund provisions), redemption prices, conversion rights and liquidation
preferences of the shares constituting any series of the preferred stock, in each case without any further action or vote by our
stockholders.
Options
We
adopted our 2014 Plan, pursuant to which we may grant options or other equity incentive awards to employees or other persons on
terms and conditions determined by our Board of Directors or our compensation committee. The options or other equity awards that
may be granted under this plan may qualify as incentive stock options under the Internal Revenue Code of 1986, as amended. The
number of shares of our common stock reserved for issuance upon the exercise or exchange of such options or other equity incentive
awards accounted for 13% of our capitalization as of May 1, 2018, determined on a fully diluted basis.
As
of the date of this prospectus, we have outstanding options to purchase an aggregate of 38,596,761 shares of our common stock
under our 2014 Plan adopted and approved by the Board and our stockholders as follows:
|
●
|
Options
to purchase an aggregate of 19,148,909 shares of our common stock at an exercise price equal to $0.625 per share, exercisable
through February 7, 2024. Fifty percent of these options became immediately exercisable as of February 7, 2014, and the remaining
50% vested ratably on a monthly basis through February 7, 2015.
|
|
|
|
|
●
|
Options
to purchase an aggregate of 684,984 shares of our common stock at an exercise price equal to $0.155 per share, exercisable
through May 15, 2020. These options became immediately exercisable on February 7, 2014.
|
|
|
|
|
●
|
Options
to purchase an aggregate of 4,274,606 shares of our common stock at an exercise price equal to $0.155 per share, exercisable
through February 7, 2024. These options became immediately exercisable on February 7, 2014.
|
|
|
|
|
●
|
Options
to purchase an aggregate of 1,979,246 shares of our common stock at an exercise price equal to $0.32 per share, exercisable
through June 30, 2020. These options became immediately exercisable on June 30, 2015.
|
|
|
|
|
●
|
Options
to purchase an aggregate of 2,672,830 shares of our common stock at an exercise price equal to $0.20 per share, exercisable
through June 30, 2020. These options became immediately exercisable on June 30, 2015.
|
|
|
|
|
●
|
Options
to purchase an aggregate of 713,653 shares of our common stock at an exercise price equal to $0.49 per share, exercisable
through September 30, 2020. These options became immediately exercisable on September 30, 2015.
|
|
|
|
|
●
|
Options
to purchase an aggregate of 1,091,161 shares of our common stock at an exercise price equal to $0.27 per share, exercisable
through December 31, 2020. These options became immediately exercisable on December 31, 2015.
|
|
|
|
|
●
|
Options
to purchase an aggregate of 5,175,469 shares of our common stock at an exercise price equal to $0.06 per share, exercisable
through March 31, 2021. These options became immediately exercisable on March 31, 2016.
|
|
|
|
|
●
|
An
option to purchase an aggregate of 100,000 shares of our common stock at an exercise price equal to $0.07 per share, exercisable
through July 11, 2021. One quarter (1/4) of the shares vested on the last day of each calendar quarter following July 11,
2016.
|
|
|
|
|
●
|
An
option to purchase an aggregate of 27,778 shares of our common stock at an exercise price equal to $0.15 per share, exercisable
through September 30, 2021. This option became immediately exercisable on September 30, 2016.
|
|
|
|
|
●
|
An
option to purchase an aggregate of 83,333 shares of our common stock at an exercise price equal to $0.15 per share, exercisable
through December 31, 2021. This option became immediately exercisable on December 31, 2016.
|
|
|
|
|
●
|
An
option to purchase an aggregate of 78,125 shares of our common stock at an exercise price equal to $0.185 per share, exercisable
through March 31, 2022. This option became immediately exercisable on March 31, 2017.
|
|
|
|
|
●
|
An
option to purchase an aggregate of 83,333 shares of our common stock at an exercise price equal to $0.20 per share, exercisable
through June 30, 2022. This option became immediately exercisable on June 30, 2017.
|
|
|
|
|
●
|
An
option to purchase an aggregate of 400,000 shares of our common stock at an exercise price equal to $0.50 per share, exercisable
through September 25, 2027. One-fourth (1/4) of the shares vest on September 25, 2018 and one forty-eighth (1/48) of the shares
vest on the last day of each full month thereafter.
|
|
●
|
An
option to purchase an aggregate of 50,000 shares of our common stock at an exercise price equal to $0.47 per share, exercisable
through September 25, 2027. This option became immediately exercisable on January 31, 2018.
|
|
|
|
|
●
|
An
option to purchase an aggregate of 1,000,000 shares of our common stock at an exercise price equal to $0.44 per share, exercisable
through November 1, 2027. One-fourth (1/4) of the shares vest on November 1, 2018 and one forty-eighth (1/48) of the shares
vest on the last day of each full month thereafter.
|
|
|
|
|
●
|
An
option to purchase an aggregate of 100,000 shares of our common stock at an exercise price equal to $0.37 per share, exercisable
through November 27, 2027. One-fourth (1/4) of the shares vest on November 27, 2018 and one forty-eighth (1/48) of the shares
vest on the last day of each full month thereafter.
|
|
|
|
|
●
|
An
option to purchase an aggregate of 100,000 shares of our common stock at an exercise price equal to $0.34 per share, exercisable
through December 13, 2027. One-fourth (1/4) of the shares vest on December 13, 2018 and one forty-eighth (1/48) of the shares
vest on the last day of each full month thereafter.
|
|
|
|
|
●
|
An
option to purchase an aggregate of 500,000 shares of our common stock at an exercise price equal to $0.16 per share, exercisable
through January 1, 2028. One-fourth (1/4) of the shares vest on January 1, 2019 and one forty-eighth (1/48) of the shares
vest on the last day of each full month thereafter.
|
|
|
|
|
●
|
Options
to purchase an aggregate of 333,334 shares of our common stock at an exercise price equal to $0.16 per share, exercisable
through January 1, 2023. One-twelfth (1/12) of the shares vest on the last day of each month thereafter.
|
Warrants
As
of the date of this prospectus, we have outstanding warrants to purchase an aggregate of 127,434,122 shares of our common stock
as follows:
|
●
|
Warrants
to purchase 27,705,782 shares of our common stock at an exercise price of $0.625 per share, subject to certain specified adjustments
for changes or reclassifications to our common stock. Each warrant may be exercised at any time, in whole or in part, on any
business day that is on or prior to February 7, 2019. Warrants for the purchase of up to 3,660,445 shares of our common stock
may be exercised on a cashless exercise basis, in accordance with the terms set forth in such warrants. A “cashless
exercise” means that in lieu of paying the aggregate purchase price for the shares being purchased upon exercise of
the warrants in cash, the holder will forfeit a number of shares underlying the warrants with a “fair market value”
equal to such aggregate exercise price.
|
|
|
|
|
●
|
A
warrant to purchase 300,000 shares of our common stock at an exercise price of $0.50 per share until February 7, 2019.
|
|
|
|
|
●
|
A
warrant to purchase 30,000 shares of our common stock at an exercise price of $0.40 per share until November 10, 2019.
|
|
|
|
|
●
|
A
warrant to purchase 50,000 shares of our common stock at an exercise price of $0.30 per share until March 31, 2020.
|
|
|
|
|
●
|
Warrants
to purchase 12,041,450 shares of our common stock at an exercise price of $0.10 per share until March 31, 2020.
|
|
|
|
|
●
|
Warrants
to purchase 4,515,554 shares of our common stock at an exercise price of $0.1667 per share until March 31, 2020.
|
|
|
|
|
●
|
A
warrant to purchase 149,000 shares of our common stock at an exercise price of $0.30 per share until December 31, 2020.
|
|
●
|
A
warrant to purchase 111,750 shares of our common stock at an exercise price of $0.1667 per share until December 31, 2020.
|
|
|
|
|
●
|
Warrants
to purchase 15,750,000 shares of our common stock at an exercise price of $0.08 per share until various dates in 2021 and
2022.
|
|
|
|
|
●
|
Warrants
to purchase 16,250,000 shares of our common stock at an exercise price of $0.12 per share until various dates in 2021 and
2022.
|
|
|
|
|
●
|
Warrants
to purchase 16,250,000 shares of our common stock at an exercise price of $0.16 per share until various dates in 2021 and
2022.
|
|
|
|
|
|
Warrants
to purchase 31,453,788 shares of our common stock at an exercise price of $0.12 per share until various dates in 2022.
|
|
|
|
|
|
Warrants
to purchase 416,595 shares of our common stock at an exercise price of $0.30 per share until various dates in 2022.
|
|
|
|
|
●
|
Warrants
to purchase 101,984 shares of our common stock at an exercise price of $0.981 per share until various dates in 2018.
|
|
|
|
|
●
|
Warrants
to purchase 295,747 shares of our common stock at an exercise price of $0.981 per share until various dates in 2019.
|
|
|
|
|
●
|
Warrants
to purchase 159,058 shares of our common stock at an exercise price of $0.981 per share until various dates in 2020.
|
|
|
|
|
●
|
Warrants
to purchase 177,164 shares of our common stock at an exercise price of $0.25 per share until December 31, 2019.
|
|
|
|
|
●
|
A
warrant to purchase 558,750 shares of our common stock at an exercise price of $0.08 per share until May 3, 2022.
|
|
|
|
|
●
|
A
warrant to purchase 558,750 shares of our common stock at an exercise price of $0.12 per share until May 3, 2022.
|
|
|
|
|
●
|
A
warrant to purchase 558,750 shares of our common stock at an exercise price of $0.16 per share until May 3, 2022.
|
The
above description of warrants is qualified in its entirety by reference to the forms of such warrants filed as exhibits to the
registration statement of which this prospectus forms a part.
Other
Convertible Securities
Other
than as described above, we do not have outstanding any options, warrants or other securities that are convertible into, or exchangeable
for, shares of our common stock.
Registration
Rights
Between
2015 and 2017, we sold approximately $7 million of subscriptions in securities under separate subscription agreements (each, a
“
Subscription Agreement
”), by and between the Company and investors, pursuant to which we issued and sold to
the investors units, consisting of shares of our common stock and warrants to purchase shares of our common stock (“
Units
”).
Under the terms of the Subscription Agreements, the Company agreed to register such Units. We expect to fulfill our obligations
under these registration rights promptly after the closing of this offering.
On
July 13, 2016, we entered into an Equity Purchase Agreement with Southridge. Pursuant to the Equity Purchase Agreement, Southridge
shall commit to purchase up to $5 million of our common stock over the course of twenty-four (24) months commencing on February
9, 2017, the effective date of our registration statement pursuant to the registration rights agreement. The price that we may
specify in any exercise of a Put Right will be determined by calculating a 12% discount to the lowest closing bid price—subject
to a pre-designated floor—during a ten trading day period following delivery of a notice of the exercise of our Put Right
to Southridge.
Anti-Takeover
Provisions
Amended
and Restated Certificate of Incorporation and Bylaws
Our
Amended and Restated Bylaws provides that our stockholders do not have cumulative voting rights, and thus stockholders holding
a majority of the voting power of our shares of common stock outstanding will be able to elect all of our directors. The authorized
number of directors may be changed only by resolution of our board of directors, and vacancies and newly created directorships
on our board of directors may, except as otherwise required by law or determined by our board, only be filled by a majority vote
of the directors then serving on our board of directors, even though less than a quorum (except, that (i) stockholders removing
any director may at the same meeting fill the vacancy and (ii) if the directors fail to fill any such vacancy, the stockholders
may at any special meeting called for that purpose fill such vacancy.). A special meeting of stockholders may be called only by
our board of directors, the Chairman of the Board of Directors, or by the Chief Executive Officer. Our amended and restated bylaws
also provide that stockholders seeking to present proposals before a meeting of stockholders to nominate candidates for election
as directors at a meeting of stockholders must provide timely advance notice in writing, and specify requirements as to the form
and content of a stockholder’s notice.
The
foregoing provisions make it more difficult for our existing stockholders to replace our board of directors as well as for another
party to obtain control of our company by replacing our board of directors. Since our board of directors has the power to retain
and discharge our officers, these provisions could also make it more difficult for existing stockholders or another party to effect
a change in management. In addition, the authorization of undesignated preferred stock makes it possible for our board of directors
to issue preferred stock with voting or other rights or preferences that could impede the success of any attempt to change the
control of our company. These provisions are intended to enhance the likelihood of continued stability in the composition of our
board of directors and its policies and to discourage certain types of transactions that may involve an actual or threatened acquisition
of our company. These provisions are also designed to reduce our vulnerability to an unsolicited acquisition proposal and to discourage
certain tactics that may be used in proxy fights. However, such provisions could have the effect of discouraging others from making
tender offers for our shares and may have the effect of deterring hostile takeovers or delaying changes in control of our company
or our management. As a consequence, these provisions also may inhibit fluctuations in the market price of our stock that could
result from actual or rumored takeover attempts.
In
addition, our authorized but unissued common shares could be used by our Board of Directors for defensive purposes against a hostile
takeover attempt, including (by way of example) the private placement of shares or the granting of options to purchase shares
to persons or entities sympathetic to, or contractually bound to support, management. We have no such present arrangement or understanding
with any person. Further, our common stock may be reserved for issuance upon exercise of stock purchase rights designed to deter
hostile takeovers, commonly known as a “poison pill.”
Section
203 of the Delaware General Corporation Law
We
are subject to Section 203 of the Delaware General Corporation Law, or Section 203, which prohibits a Delaware corporation from
engaging in any business combination with any interested stockholder for a period of three years after the date that such stockholder
became an interested stockholder, with the following exceptions:
|
●
|
before
such date, our board of directors approved either the business combination or the transaction that resulted in the stockholder
becoming an interested stockholder;
|
|
|
|
|
●
|
upon
closing of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder
owned at least eighty-five percent (85%) of the voting stock of the corporation outstanding at the time the transaction began,
excluding for purposes of determining the voting stock outstanding (but not the outstanding voting stock owned by the interested
stockholder) those shares owned by: (i) persons who are directors and also officers; and (ii) employee stock plans in which
employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered
in a tender or exchange offer; or
|
|
|
|
|
●
|
on
or after such date, the business combination is approved by our board of directors and authorized at an annual or special
meeting of the stockholders, and not by written consent, by the affirmative vote of at least 66 2∕3% of the outstanding
voting stock that is not owned by the interested stockholder.
|
In
general, Section 203 defines business combination to include the following:
|
●
|
any
merger or consolidation involving the corporation and the interested stockholder;
|
|
|
|
|
●
|
any
sale, transfer, pledge or other disposition of ten percent (10%) or more of the assets of the corporation involving the interested
stockholder;
|
|
|
|
|
●
|
subject
to certain exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation
to the interested stockholder;
|
|
|
|
|
●
|
any
transaction involving the corporation that has the effect of increasing the proportionate share of the stock or any class
or series of the corporation beneficially owned by the interested stockholder; or
|
|
|
|
|
●
|
the
receipt by the interested stockholder of the benefit of any loss, advances, guarantees, pledges or other financial benefits
by or through the corporation.
|
In
general, Section 203 defines an “interested stockholder” as an entity or person who, together with the person’s
affiliates and associates, beneficially owns, or within three years prior to the time of determination of interested stockholder
status did own, fifteen percent (15%) or more of the outstanding voting stock of the corporation.
Limitation
on Liability and Indemnification Matters
See
the section of this prospectus entitled “Management — Indemnification”.
Listing
Our
common stock is traded on the OTCQB under the trading symbol “CDXI”.
Exchange
Agent
Our
independent exchange agent is VStock Transfer, LLC. VStock Transfer’s address is 18 Lafayette Place, Woodmere, NY
11598.
CERTAIN
UNITED STATED FEDERAL INCOME TAX CONSIDERATIONS
Material
U.S. Federal Income Tax Consequences
General
The
following description summarizes the material U.S. federal income tax consequences of the exchange of Original Warrants and Exchange
Payment for Exchange Shares (the “
Exchange
”) and the ownership and disposition of the Exchange Shares. This
description assumes that holders hold the Original Warrants, and will hold the Exchange Shares received upon exchange of the Original
Warrants, as capital assets (generally, property held for investment). This description does not address all of the tax consequences
that might be relevant to a holder’s particular circumstances or to holders that may be subject to special tax rules, such
as banks or other financial institutions, insurance companies, real estate investment trusts, regulated investment companies,
tax exempt organizations, dealers in securities, traders in securities that elect to use a mark-to-market method of accounting
for their securities holdings, persons who hold Exchange Shares or Original Warrants as part of a “straddle,” hedging
transaction, conversion transaction, or other similar integrated transaction for U.S. federal income tax purposes, or U.S. holders
(as defined below) that have a functional currency other than the U.S. dollar.
If
a partnership (or any other entity treated as a partnership for U.S. federal income tax purposes) holds Exchange Shares or Original
Warrants, the tax treatment of the partnership and a partner in such partnership generally will depend on the status of the partner
and the nature of the activities of the partnership. A holder that is a partnership, and the partners in such partnerships, should
consult its tax advisors regarding the tax consequences of the Exchange, and the ownership and disposition of Exchange Shares
received in the exchange.
This
description does not address the tax consequences arising under the laws of any foreign, state, or local tax jurisdiction. Moreover,
except to the extent specifically set forth below, this description does not address the U.S. federal estate and gift tax, or
alternative minimum tax, or other non-income tax consequences of the ownership and disposition of Exchange Shares received upon
exchange of the Original Warrants.
This
description is based on the United States Internal Revenue Code of 1986, as amended (the “
Code
”), existing
and proposed Treasury Regulations promulgated thereunder, judicial decisions, published positions of the U.S. Internal Revenue
Service (the “
IRS
”), and other applicable authorities, each as in effect on the date hereof. These authorities
are subject to change, possibly with retroactive effect, or differing interpretations by the IRS or a court, which could affect
the tax consequences described herein. We have not obtained, and have no plans to request, a ruling from the IRS with respect
to any of the U.S. federal income tax consequences described below, and as a result, there can be no assurance that the IRS or
the courts will agree with any of the conclusions stated in this description.
This
description is for general information only and is not tax advice. It is not intended to constitute a complete description of
all tax consequences for holders relating to the Exchange or relating to the ownership and disposition of the Exchange Shares.
You are urged to consult with your tax advisor regarding the U.S. federal income tax consequences of the Exchange and of the ownership
and disposition of Exchange Shares, applicable in your particular situation, as well as any consequences under the federal estate
or gift tax, the federal alternative minimum tax, or under the tax laws of any state, local, foreign, or other taxing jurisdiction.
Tax
Consequences to U.S. Holders
Subject
to the limitations stated above, the following description addresses certain material U.S. federal income tax consequences of
the Exchange and of the ownership and disposition of the Exchange Shares, that are expected to apply if you are a U.S. holder
of the Original Warrants or Exchange Shares. For this purpose, you are a “U.S. holder” if you are:
|
●
|
an
individual who is a citizen or resident of the United States;
|
|
|
|
|
●
|
a
corporation (or other entity taxable as a corporation for U.S. federal income tax purposes) created or organized in or under
the laws of the United States or any State thereof, including the District of Columbia;
|
|
●
|
an
estate the income of which is subject to U.S. federal income taxation regardless of its source; or
|
|
|
|
|
●
|
a
trust (i) if a court within the United States is able to exercise primary supervision over the administration of the trust
and one or more United States persons (as defined in Section 7701(a)(30) of the Code) have the authority to control all substantial
decisions of the trust, or (ii) that has a valid election in effect under applicable U.S. Treasury Regulations to be treated
as a U.S. person.
|
The
Exchange Offer
The
United States federal income tax consequences of the Exchange are not free from doubt. However, the Company believes that it is
appropriate to treat the Exchange, for United States federal income tax purposes, as a “recapitalization” within the
meaning of Section 368(a)(1)(E) of the Code. If the Exchange does qualify as a recapitalization, it is expected that (i) you will
not recognize any gain or loss on the Exchange, (ii) your aggregate tax basis in the Exchange Shares received in the Exchange
will equal the sum of (x) your aggregate tax basis in your Original Warrants surrendered in the Exchange and (y) the Exchange
Payment made in connection with the Exchange, and (iii) your holding period for the Exchange Shares received in the Exchange will
include your holding period for the surrendered Original Warrants. Special tax basis and holding period rules apply to holders
that acquired different blocks of Original Warrants at different prices or at different times. You should consult your tax advisor
as to the applicability of these special rules to your particular circumstances.
The
foregoing tax discussion is based on current tax law, regulations and interpretive rulings as they exist at this time. The IRS
has not made a determination, nor has the Company received any opinion of counsel, on the U.S. federal income tax consequences
of the Exchange Offer or of a holder’s participation in the Exchange Offer, and there is no published guidance directly
on point. Because of the lack of authority dealing with transactions similar to the Exchange Offer, the U.S. federal income tax
consequences of the Exchange Offer are unclear, and alternative characterizations are possible that could require you to immediately
recognize income, gain or loss, or may impact your holding period.
For
example, the IRS could re-characterize the Exchange, for U.S. federal income tax purposes, as an exchange of each Original Warrant
for a new warrant providing the holder with a right to purchase an Exchange Share at an exercise price of $0.15 (a “
New
Warrant
”), qualifying as a recapitalization within the meaning of Section 368(a)(1)(E) of the Code, followed by an immediate
exercise of a New Warrant for an Exchange Share. In such case, upon exercise of a New Warrant for an Exchange Share, a holder
generally will not recognize gain or loss and will instead be treated as acquiring an Exchange Share as a result of such exercise.
The holder will have an adjusted tax basis in the Exchange Share so acquired equal to the sum of such holder’s adjusted
tax basis in the New Warrant immediately prior to such exercise, plus the exercise price deemed paid by such holder for the Exchange
Share in connection with a deemed exercise of such New Warrant. Under this alternative characterization of the Exchange, the holding
period for the Exchange Shares will generally commence on the date after the date of the Exchange.
In
light of the uncertainty and discussion above, we urge you to consult your tax advisor regarding the potential tax consequences
of the Exchange Offer to you in your particular circumstances, including the consequences of possible alternative characterizations.
Ownership
and Disposition of Exchange Shares
Dividends
.
Distributions of cash or property, if any, that we pay on the Exchange Shares will constitute dividends for U.S. federal income
tax purposes to the extent paid from our current or accumulated earnings and profits (as determined under U.S. federal income
tax principles) and will be includible in your gross income as ordinary dividend income when actually or constructively received
by you. Distributions in excess of our current and accumulated earnings and profits will be treated first as a tax-free return
of capital to the extent of your tax basis in the Exchange Shares, and thereafter will be treated as capital gain from the sale
or exchange of the Exchange Shares. If you are a non-corporate U.S. holder, dividends you receive with respect to the Exchange
Shares are eligible for U.S. federal income taxation at the rates generally applicable to long-term capital gains for individuals,
provided that you satisfy applicable holding period and other requirements.
In
general, corporate holders of Exchange Shares will be entitled to a deduction (sometimes referred to as a “dividends received
deduction”) equal to 70% of distributions which are treated as dividends on Exchange Shares. However, these holders will
not be entitled to this deduction with respect to amounts treated as a return of capital or capital gain. In addition, the benefit
of this deduction may be reduced by the corporate alternative minimum tax. Furthermore, the dividends received deduction is subject
to various limitations which, among other things, require a certain holding period and restrict the availability of the deduction
if the underlying stock on which the dividend is paid is “debt financed.” Corporate holders should consult their tax
advisors as to their eligibility for this deduction.
Sale
or Exchange
. Upon a sale or other taxable disposition of the Exchange Shares, you generally will recognize capital gain or
loss equal to the difference between (i) the amount of cash and the fair market value of any property you receive on the disposition
and (ii) your adjusted tax basis for the Exchange Shares. The capital gain or loss will be long-term capital gain or loss if you
held the Exchange Shares for more than one year. The deductibility of capital losses is subject to limitations.
In
certain circumstances, a redemption of Exchange Shares may be treated as a distribution (and not a sale as discussed immediately
above). A redemption of Exchange Shares will be treated as a sale if all of the holder’s interest in the Company is redeemed
or certain other tests are met which generally involve a sufficient reduction in the holder’s interest (including deemed
interest under certain constructive ownership rules) in the Company. If the transaction is treated as a sale, then the tax treatment
of the holder will follow that which is described above with respect to the sale other taxable disposition of Exchange Shares.
Alternatively, the entire amount of the cash and property received in connection with a redemption may be treated as a distribution
(and not as a sale). Redemption treatment will be applied without an offset of the holder’s adjusted tax basis in the redeemed
shares of Exchange Shares. Rather, the redemption proceeds will be treated in the same manner as distributions (described above
under “—Dividends”). If the redemption is treated as a distribution (as opposed to a sale), then the holder’s
adjusted tax basis in the redeemed shares of our common stock, to the extent not reduced through distributions treated as a return
of capital, will be transferred to the holder’s remaining shares of our common stock.
Tax
on Net Investment Income
A
3.8% Medicare contribution tax will generally apply to all or some portion of the net investment income of a U.S. holder who is
an individual with adjusted gross income that exceeds a threshold amount. In the case of individuals, a 3.8% tax is imposed for
each taxable year on the lesser of (a) net investment income for the year or (b) the modified adjusted gross income for such year
in excess of a threshold amount ($250,000 if married filing jointly or if considered a “surviving spouse” for federal
income tax purposes, $125,000 if married filing separately, and $200,000 in other cases). For these purposes, dividends received
with respect to the Exchange Shares, and gains or losses realized from the taxable disposition of the Exchange Shares, will generally
be taken into account in computing your net investment income.
Information
Reporting and Backup Withholding
In
general, any dividends you receive with respect to the Exchange Shares, and amounts you receive with respect to a sale or other
disposition of the Exchange Shares, are reported to the IRS and to you, unless you are an exempt payee and the payment is not
subject to backup withholding. Such dividends and other amounts may be subject to backup withholding (at a rate of 28%), and subject
to related information reporting with respect to otherwise exempt payees, unless you provide to us (i) your correct taxpayer identification
number and certification (on Form W-9) that you are not subject to backup withholding, or (ii) proof that you are an exempt payee.
Any amounts withheld from a payment under the backup withholding rules will be allowed as a credit against your U.S. federal income
tax liability and may entitle you to a refund, provided you timely furnish the required information or returns to the IRS.
Tax
Consequences to Non-U.S. Holders
Subject
to the limitations stated above, the following description addresses certain material U.S. federal income tax consequences of
the Exchange and of the ownership and disposition of the Exchange Shares, that are expected to apply if you are a non-U.S. holder
of the Original Warrants or Exchange Shares. For this purpose, you are a “non-U.S. holder” if you are an individual,
corporation, estate, or trust that is not a U.S. holder as defined above. Special rules may apply to certain non-U.S. holders
such as “controlled foreign corporations,” “passive foreign investment companies,” individuals present
in the United States for 183 days or more in the taxable year of disposition (but who are not U.S. residents) or, in certain circumstances,
individuals who are former U.S. citizens or residents.
The
Exchange Offer
The
Exchange should generally have the same tax consequences for non-U.S. holders as described above for U.S. holders (other than
for foreign tax credit purposes).
Ownership
and Disposition of Exchange Shares
Distributions.
Generally, but subject to the discussions below under “Additional Withholding Tax on Payments Made to Foreign Accounts,”
distributions of cash or property, if any, (other than our common stock, if any, distributed pro rata to our shareholders) paid
to a non-U.S. holder will be subject to withholding of United States federal income tax at a 30% rate or such lower rate as may
be specified by an applicable United States income tax treaty. In order to obtain the benefit of any applicable United States
income tax treaty, a non-U.S. holder will have to file certain forms (e.g., Form W-8BEN or Form W-8BEN-E). Such forms generally
would contain your name and address and a certification that such non-U.S. holder is eligible for the benefits of such treaty.
Sale
or Exchange.
Generally, but subject to the discussions below under “Additional Withholding Tax on Payments Made to Foreign
Accounts,” a non-U.S. holder will not be subject to United States federal income or withholding tax on any gain realized
on the sale or exchange of our common stock unless (1) such gain is effectively connected with your conduct of a trade or business
in the United States and, where an income tax treaty applies, is attributable to a permanent establishment, (2) if an individual
non-U.S. holder is present in the United States for 183 days or more in the taxable year of such sale or exchange and certain
other conditions are met, or (3) if the rules of the Foreign Investment in Real Property Tax Act, or FIRPTA (described below)
treat the gain as effectively connected with a U.S. trade or business.
The
FIRPTA rules may apply to a sale, exchange or other disposition of Exchange Shares if we are, or were within five years before
the transaction, a “U.S. real property holding corporation,” or a USRPHC. In general, we would be a USRPHC if interests
in U.S. real estate comprised a majority of our assets. We do not believe that we are a USRPHC or that we will become one in the
future. If we are or become a USRPHC, so long as our common stock is regularly traded on an established securities market, only
a non-U.S. holder who, actually or constructively, holds or held (at any time during the shorter of the five-year period preceding
the date of disposition or the holder’s holding period) more than 5% of our common stock will be subject to U.S. federal
income tax on the disposition of our common stock.
Income
Effectively Connected with a U.S. Trade or Business.
Except as may be otherwise provided in an applicable United States income
tax treaty, if a non-U.S. holder conducts a trade or business within the United States, such non-U.S. holder generally will be
taxed at ordinary United States federal income tax rates (on a net income basis) on dividends and gains that are effectively connected
with the conduct of such trade or business and such dividends will not be subject to the withholding described above. A non-U.S.
holder that is a foreign corporation may also be subject to a 30% “branch profits tax” unless such non-U.S. holder
qualifies for a lower rate under an applicable United States income tax treaty. To claim an exemption from withholding on dividends
because the income is effectively connected with a United States trade or business, a non-U.S. holder must provide a properly
executed Form W-8ECI (or such successor form as the IRS designates) prior to the payment of dividends.
Information
Reporting and Backup Withholding
A
non-U.S. holder may be required to comply with certain certification procedures to establish that the holder is not a U.S. person
in order to avoid backup withholding tax with respect to our payment of dividends on, or the proceeds of a sale or other disposition
of, an Exchange Share. Any amounts withheld under the backup withholding rules will be allowed as a refund or a credit against
that non-U.S. holder’s U.S. federal income tax liability provided the required information is timely furnished to the IRS.
In certain circumstances, the name and address of the beneficial owner and the amount of dividends paid on an Exchange Share,
as well as the amount, if any, of tax withheld, may be reported to the IRS. Copies of these information returns may also be made
available under the provisions of a specific treaty or agreement to the tax authorities of the country in which the non-U.S. holder
resides or is established.
Additional
Withholding Tax on Payments Made to Foreign Accounts
Withholding
taxes may be imposed under Sections 1471 to 1474 of the Code (such Sections commonly referred to as the Foreign Account Tax Compliance
Act, or “FATCA”) on certain types of payments made to non-U.S. financial institutions and certain other non-U.S. entities.
Specifically, a 30% withholding tax may be imposed on payments of dividends on, or gross proceeds from the sale or other disposition
of, Exchange Shares paid to a “foreign financial institution” or a “non-financial foreign entity” (each
as defined in the Code), unless (1) the foreign financial institution undertakes certain diligence and reporting obligations,
(2) the non-financial foreign entity either certifies it does not have any “substantial United States owners” (as
defined in the Code) or furnishes identifying information regarding each substantial United States owner, or (3) the foreign financial
institution or non-financial foreign entity otherwise qualifies for an exemption from these rules. If the payee is a foreign financial
institution and is subject to the diligence and reporting requirements in (1) above, it must enter into an agreement with the
U.S. Department of the Treasury requiring, among other things, that it undertake to identify accounts held by certain “specified
United States persons” or “United States-owned foreign entities” (each as defined in the Code), annually report
certain information about such accounts, and withhold 30% on certain payments to non-compliant foreign financial institutions
and certain other account holders. Foreign financial institutions located in jurisdictions that have an intergovernmental agreement
with the United States governing FATCA may be subject to different rules.
Under
the applicable U.S. Treasury regulations and administrative guidance, withholding under FATCA generally applies to payments of
dividends, and will apply to payments of gross proceeds from the sale or other disposition of Exchange Shares on or after January
1, 2019.
Holders
should consult their tax advisors regarding the potential application of withholding under FATCA to their Exchange Shares.
SOLICITATION
AGENTS
We
have engaged M.M. Dillion & Co. to serve as financial advisor and CIM Securities, to serve as solicitation agent for this
Exchange Offer. As compensation for their services, we have agreed to pay M.M. Dillon & Co. a cash fee of 3.5% of the gross
proceeds from the Exchange Offer and a 5-year common stock purchase warrant with a fair market value equal to 3.5% of the gross
proceeds from the Exchange Offer and CIM Securities a cash fee of 4.3% of the gross proceeds from the Exchange Offer and a 5-year
common stock purchase warrant with a fair market value equal to 3.5% of the gross proceeds from the Exchange Offer. The fair market
value of the common stock purchase warrants shall be based on a Black-Scholes valuation as of the day immediately prior to the
filing date of the initial registration statement in connection with the Exchange Offer.
M.M.
Dillion & Co. and CIM Securities will also be reimbursed for reasonable out-of-pocket expenses incurred in connection
with the Exchange Offer (including reasonable fees and disbursements of counsel).
The
agreement between us and M.M. Dillon & Co. and CIM Securities provides that we will indemnify M.M. Dillon & Co.
and CIM Securities against certain liabilities, including liabilities under the Securities Act.
M.M.
Dillion & Co. and CIM Securities may allow or re-allow any of the compensation payable to them to any broker-dealers
that participate in the exchange offering. Any such allowance or re-allowance will be on terms and conditions agreed by CIM
Securities and the applicable broker-dealer.
George
W. Bickerstaff, III, a director of the Company, is currently a Managing Director of M.M. Dillon & Co. See “Certain Relationships
and Related Party Transactions
”.
This
prospectus, as it may be amended or supplemented from time to time, may be used by a broker-dealer in connection with resales
of Exchange Shares received in exchange for Original Warrants where such Original Warrants were acquired as a result of market-making
activities or other trading activities. We have agreed that, for a period of 90 days after the consummation of the Exchange Offer,
we will make this prospectus, as amended or supplemented, available to any broker-dealer for use in connection with any such resale,
and will deliver as many additional copies of this prospectus and each amendment or supplement to this prospectus and any documents
incorporated by reference in this prospectus as any broker-dealer may request in the Letter of Transmittal. In addition, all dealers
effecting transactions in connection with this Exchange Offer may be required to deliver a prospectus.
We
will not receive any proceeds from any sale of Exchange Shares by broker-dealers other than the Exchange Payment. Exchange Shares
received by broker-dealers for their own account pursuant to the Exchange Offer may be sold from time to time in one or more transactions
in the over-the-counter market, in negotiated transactions, through the writing of options on the Exchange Shares or a combination
of such methods of resale, at market prices prevailing at the time of resale, at prices related to such prevailing market prices
or at negotiated prices. Any such resale may be made directly to purchasers or through brokers or dealers who may receive compensation
in the form of commissions or concessions from any such broker- dealer and/or the purchasers of any such Exchange Shares. Any
broker-dealer that resells Exchange Shares that were received by it for its own account pursuant to the Exchange Offer and any
broker or dealer that participates in a distribution of such Exchange Shares may be deemed to be an “underwriter”
within the meaning of the Securities Act, and any profit of any such resale of Exchange Shares and any commission or concessions
received by any such persons may be deemed to be underwriting compensation under the Securities Act.
Legal
Matters
The
validity of the shares of our common stock covered by this prospectus will be passed upon by Herrick, Feinstein LLP, New York,
New York.
Experts
The
financial statements included in this prospectus have been so included in reliance on the report of KBL, LLP, an independent registered
public accounting firm, given on the authority of said firm as experts in auditing and accounting.
Where
You Can Find Additional Information
We
have filed with the SEC under the Securities Act a registration statement on Form S-4 relating to the shares of common stock that
will be issued in connection with the Exchange Offer. The registration statement, including the attached exhibits and schedules,
contains additional relevant information about us and our capital stock. This prospectus does not contain all of the information
set forth in the registration statement and the exhibits and schedules thereto. For further information about us and our common
stock, you should refer to the registration statement, including the exhibits and schedules thereto. Statements contained in this
prospectus as to the contents of any contract or other document referred to are not necessarily complete and in each instance,
if such contract or document is filed as an exhibit, reference is made to the copy of such contract or other document filed as
an exhibit to the registration statement, each statement being qualified in all respects by such reference. You may inspect a
copy of the registration statement and the exhibits and schedules thereto without charge at the Public Reference Room of the SEC
at 100 F Street, N.E., Washington, D.C. 20549. You may obtain copies of all or any part of the registration statement from such
office at prescribed rates. You may also obtain information on the operation of the Public Reference Room by calling the SEC at
1-800-SEC-0330. In addition, the SEC maintains an Internet website, which is located at http://www.sec.gov, that contains reports,
proxy and information statements and other information regarding issuers that file electronically with the SEC. You may access
the registration statement, of which this prospectus is a part, at the SEC’s Internet website.
INDEX
TO FINANCIAL STATEMENTS
Cardax,
Inc., and Subsidiary
December
31, 2017 and 2016
Contents
REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To
the Board of Directors and Stockholders
of Cardax, Inc. and Subsidiaries
Opinion
on the Financial Statements
We
have audited the accompanying consolidated balance sheets of Cardax, Inc. and Subsidiaries (the “Company”) as of December
31, 2017 and 2016, the related consolidated statements of operations, changes in stockholders’ deficit, and cash flows for
the years then ended, and the related notes (collectively referred to as the “consolidated financial statements”).
In our opinion, the consolidated financial statements present fairly, in all material respects, the consolidated financial position
of the Company as of December 31, 2017 and 2016, and the results of its consolidated operations and its cash flows for the years
then ended in conformity with accounting principles generally accepted in the United States of America.
Basis
for Opinion
These
consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an
opinion on the Company’s consolidated financial statements based on our audits. We are a public accounting firm registered
with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with
respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities
and Exchange Commission and the PCAOB.
We
conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit
to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether
due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal controls
over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial
reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial
reporting. Accordingly, we express no such opinion.
Our
audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether
due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis,
evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting
principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated
financial statements. We believe that our audits provide a reasonable basis for our opinion.
Going
Concern Consideration
The
accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern.
As discussed in Note 1 to the consolidated financial statements, the Company has sustained significant operating losses and needs
to obtain additional financing to continue the services they provide. These conditions raise substantial doubt about the Company’s
ability to continue as a going concern. Management’s plans in regard to these matters are also described in Note 1. The
consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.
/s/
KBL, LLP
We
have served as the Company’s auditor since 2013.
KBL,
LLP
New
York, NY
March
26, 2018
Cardax,
Inc., and Subsidiary
CONSOLIDATED
BALANCE SHEETS
As
of December 31,
|
|
2017
|
|
|
2016
|
|
ASSETS
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CURRENT
ASSETS
|
|
|
|
|
|
|
|
|
Cash
|
|
$
|
2,236,837
|
|
|
$
|
158,433
|
|
Accounts
receivable
|
|
|
37,243
|
|
|
|
-
|
|
Inventories
|
|
|
340,425
|
|
|
|
10,827
|
|
Deposits
and other assets
|
|
|
90,831
|
|
|
|
122,876
|
|
Prepaid
expenses
|
|
|
22,838
|
|
|
|
19,919
|
|
|
|
|
|
|
|
|
|
|
Total
current assets
|
|
|
2,728,174
|
|
|
|
312,055
|
|
|
|
|
|
|
|
|
|
|
PROPERTY
AND EQUIPMENT, net
|
|
|
1,901
|
|
|
|
7,755
|
|
|
|
|
|
|
|
|
|
|
INTANGIBLE
ASSETS, net
|
|
|
426,610
|
|
|
|
430,770
|
|
|
|
|
|
|
|
|
|
|
TOTAL
ASSETS
|
|
$
|
3,156,685
|
|
|
$
|
750,580
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
LIABILITIES
AND STOCKHOLDERS’ DEFICIT
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CURRENT
LIABILITIES
|
|
|
|
|
|
|
|
|
Accrued
payroll and payroll related expenses
|
|
$
|
3,490,225
|
|
|
$
|
3,510,464
|
|
Accounts
payable and accrued expenses
|
|
|
603,391
|
|
|
|
657,094
|
|
Fees
payable to directors
|
|
|
418,546
|
|
|
|
418,546
|
|
Employee
settlement
|
|
|
50,000
|
|
|
|
50,000
|
|
|
|
|
|
|
|
|
|
|
Total
current liabilities
|
|
|
4,562,162
|
|
|
|
4,636,104
|
|
|
|
|
|
|
|
|
|
|
COMMITMENTS
AND CONTINGENCIES
|
|
|
-
|
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
Total
liabilities
|
|
|
4,562,162
|
|
|
|
4,636,104
|
|
|
|
|
|
|
|
|
|
|
STOCKHOLDERS’
DEFICIT
|
|
|
|
|
|
|
|
|
Preferred
Stock - $0.001 par value; 50,000,000 shares authorized, 0 shares issued and outstanding as of December 31, 2017 and 2016,
respectively
|
|
|
-
|
|
|
|
-
|
|
Common
stock - $0.001 par value; 400,000,000 shares authorized, 122,674,516 and 85,068,709 shares issued and outstanding December
31, 2017 and 2016, respectively
|
|
|
122,675
|
|
|
|
85,069
|
|
Additional
paid-in-capital
|
|
|
56,401,069
|
|
|
|
51,963,269
|
|
Deferred
compensation
|
|
|
(10,125
|
)
|
|
|
-
|
|
Accumulated
deficit
|
|
|
(57,919,096
|
)
|
|
|
(55,933,862
|
)
|
|
|
|
|
|
|
|
|
|
Total
stockholders’ deficit
|
|
|
(1,405,477
|
)
|
|
|
(3,885,524
|
)
|
|
|
|
|
|
|
|
|
|
TOTAL
LIABILITIES AND STOCKHOLDERS’ DEFICIT
|
|
$
|
3,156,685
|
|
|
$
|
750,580
|
|
Cardax,
Inc., and Subsidiary
CONSOLIDATED
STATEMENTS OF OPERATIONS
For
the years ended December 31,
|
|
2017
|
|
|
2016
|
|
|
|
|
|
|
|
|
REVENUES,
net
|
|
$
|
610,323
|
|
|
$
|
35,258
|
|
|
|
|
|
|
|
|
|
|
COST
OF GOODS SOLD
|
|
|
274,707
|
|
|
|
14,580
|
|
|
|
|
|
|
|
|
|
|
GROSS
PROFIT
|
|
|
335,616
|
|
|
|
20,678
|
|
|
|
|
|
|
|
|
|
|
OPERATING
EXPENSES:
|
|
|
|
|
|
|
|
|
General
and administrative expenses
|
|
|
1,070,085
|
|
|
|
831,673
|
|
Sales
and marketing
|
|
|
535,242
|
|
|
|
117,181
|
|
Research
and development
|
|
|
460,991
|
|
|
|
347,885
|
|
Stock
based compensation
|
|
|
242,146
|
|
|
|
525,062
|
|
Depreciation
and amortization
|
|
|
29,422
|
|
|
|
29,101
|
|
|
|
|
|
|
|
|
|
|
Total
operating expenses
|
|
|
2,337,886
|
|
|
|
1,850,902
|
|
|
|
|
|
|
|
|
|
|
Loss
from operations
|
|
|
(2,002,270
|
)
|
|
|
(1,830,224
|
)
|
|
|
|
|
|
|
|
|
|
OTHER
INCOME (EXPENSES):
|
|
|
|
|
|
|
|
|
Other
income
|
|
|
17,253
|
|
|
|
47,082
|
|
Interest
income
|
|
|
3,320
|
|
|
|
2,362
|
|
Interest
expense
|
|
|
(3,537
|
)
|
|
|
(2,925
|
)
|
|
|
|
|
|
|
|
|
|
Total
other income (expense)
|
|
|
17,036
|
|
|
|
46,519
|
|
|
|
|
|
|
|
|
|
|
Loss
before the provision for income taxes
|
|
|
(1,985,234
|
)
|
|
|
(1,783,705
|
)
|
|
|
|
|
|
|
|
|
|
PROVISION
FOR INCOME TAXES
|
|
|
-
|
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
NET
LOSS
|
|
$
|
(1,985,234
|
)
|
|
$
|
(1,783,705
|
)
|
|
|
|
|
|
|
|
|
|
NET LOSS PER
SHARE
|
|
|
|
|
|
|
|
|
Basic
|
|
$
|
(0.02
|
)
|
|
$
|
(0.02
|
)
|
Diluted
|
|
$
|
(0.02
|
)
|
|
$
|
(0.02
|
)
|
|
|
|
|
|
|
|
|
|
SHARES
USED IN CALCULATION OF NET LOSS PER SHARE
|
|
|
|
|
|
|
|
|
Basic
|
|
|
99,951,385
|
|
|
|
76,227,524
|
|
Diluted
|
|
|
99,951,385
|
|
|
|
76,227,524
|
|
Cardax,
Inc., and Subsidiary
CONSOLIDATED
STATEMENT OF CHANGES IN STOCKHOLDERS’ DEFICIT
Years
ended December 31, 2016 and 2017
|
|
Common
Stock
|
|
|
Additional
|
|
|
Deferred
|
|
|
Accumulated
|
|
|
|
|
|
|
Shares
|
|
|
Amount
|
|
|
Paid-In-Capital
|
|
|
Compensation
|
|
|
Deficit
|
|
|
Total
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance
at January 1, 2016
|
|
|
69,087,955
|
|
|
$
|
69,088
|
|
|
$
|
50,333,188
|
|
|
$
|
-
|
|
|
$
|
(54,150,157
|
)
|
|
$
|
(3,747,881
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common
stock grants to independent directors
|
|
|
468,254
|
|
|
|
468
|
|
|
|
41,198
|
|
|
|
-
|
|
|
|
-
|
|
|
|
41,666
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common
stock grant to institutional investor
|
|
|
1,500,000
|
|
|
|
1,500
|
|
|
|
105,000
|
|
|
|
-
|
|
|
|
-
|
|
|
|
106,500
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Restricted
stock issuances
|
|
|
14,012,500
|
|
|
|
14,013
|
|
|
|
1,106,987
|
|
|
|
-
|
|
|
|
-
|
|
|
|
1,121,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock
based compensation - options
|
|
|
-
|
|
|
|
-
|
|
|
|
376,896
|
|
|
|
-
|
|
|
|
-
|
|
|
|
376,896
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net
loss
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(1,783,705
|
)
|
|
|
(1,783,705
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at December
31, 2016
|
|
|
85,068,709
|
|
|
|
85,069
|
|
|
|
51,963,269
|
|
|
|
-
|
|
|
|
(55,933,862
|
)
|
|
|
(3,885,524
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common
stock grants to independent directors
|
|
|
793,025
|
|
|
|
793
|
|
|
|
149,207
|
|
|
|
-
|
|
|
|
-
|
|
|
|
150,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common
stock issuance to institutional investor
|
|
|
567,644
|
|
|
|
568
|
|
|
|
59,432
|
|
|
|
-
|
|
|
|
-
|
|
|
|
60,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Restricted
stock issuances
|
|
|
34,107,883
|
|
|
|
34,108
|
|
|
|
4,044,327
|
|
|
|
-
|
|
|
|
-
|
|
|
|
4,078,435
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Restricted
stock issuance to a broker for fees
|
|
|
558,750
|
|
|
|
559
|
|
|
|
44,141
|
|
|
|
-
|
|
|
|
-
|
|
|
|
44,700
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock option
exercise
|
|
|
645,288
|
|
|
|
645
|
|
|
|
(645
|
)
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrant exercise
|
|
|
733,217
|
|
|
|
733
|
|
|
|
39,267
|
|
|
|
-
|
|
|
|
-
|
|
|
|
40,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Deferred
compensation
|
|
|
200,000
|
|
|
|
200
|
|
|
|
40,300
|
|
|
|
(10,125
|
)
|
|
|
-
|
|
|
|
30,375
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock
based compensation - options
|
|
|
-
|
|
|
|
-
|
|
|
|
61,771
|
|
|
|
-
|
|
|
|
-
|
|
|
|
61,771
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net
loss
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(1,985,234
|
)
|
|
|
(1,985,234
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance
at December 31, 2017
|
|
|
122,674,516
|
|
|
$
|
122,675
|
|
|
$
|
56,401,069
|
|
|
$
|
(10,125
|
)
|
|
$
|
(57,919,096
|
)
|
|
$
|
(1,405,477
|
)
|
Cardax,
Inc., and Subsidiary
CONSOLIDATED
STATEMENTS OF CASH FLOWS
For
the years ended December 31,
|
|
2017
|
|
|
2016
|
|
CASH
FLOWS FROM OPERATING ACTIVITIES:
|
|
|
|
|
|
|
|
|
Net
loss
|
|
$
|
(1,985,234
|
)
|
|
$
|
(1,783,705
|
)
|
Adjustments
to reconcile net loss to net cash used in operating activities:
|
|
|
|
|
|
|
|
|
Depreciation
and amortization
|
|
|
29,422
|
|
|
|
29,101
|
|
Stock
based compensation
|
|
|
242,146
|
|
|
|
230,833
|
|
Changes
in assets and liabilities:
|
|
|
|
|
|
|
|
|
Accounts
receivable
|
|
|
(37,243
|
)
|
|
|
-
|
|
Inventories
|
|
|
(329,598
|
)
|
|
|
(10,827
|
)
|
Deposits
and other assets
|
|
|
32,045
|
|
|
|
(35,161
|
)
|
Prepaid
expenses
|
|
|
(2,919
|
)
|
|
|
(17,386
|
)
|
Accrued
payroll and payroll related expenses
|
|
|
(20,239
|
)
|
|
|
269,638
|
|
Accounts
payable and accrued expenses
|
|
|
(9,003
|
)
|
|
|
60,736
|
|
|
|
|
|
|
|
|
|
|
Net
cash used in operating activities
|
|
|
(2,080,623
|
)
|
|
|
(1,256,771
|
)
|
|
|
|
|
|
|
|
|
|
CASH
FLOWS FROM INVESTING ACTIVITIES:
|
|
|
|
|
|
|
|
|
Increase
in intangible assets
|
|
|
(19,408
|
)
|
|
|
(29,206
|
)
|
|
|
|
|
|
|
|
|
|
Net
cash used in investing activities
|
|
|
(19,408
|
)
|
|
|
(29,206
|
)
|
|
|
|
|
|
|
|
|
|
CASH
FLOWS FROM FINANCING ACTIVITIES:
|
|
|
|
|
|
|
|
|
Proceeds
from the issuance of common stock
|
|
|
4,138,435
|
|
|
|
1,121,000
|
|
Proceeds
from the exercise of warrants
|
|
|
40,000
|
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
Net
cash provided by financing activities
|
|
|
4,178,435
|
|
|
|
1,121,000
|
|
|
|
|
|
|
|
|
|
|
NET
INCREASE (DECREASE) IN CASH
|
|
|
2,078,404
|
|
|
|
(164,977
|
)
|
|
|
|
|
|
|
|
|
|
CASH
AT THE BEGINNING OF THE PERIOD
|
|
|
158,433
|
|
|
|
323,410
|
|
|
|
|
|
|
|
|
|
|
CASH
AT THE END OF THE PERIOD
|
|
$
|
2,236,837
|
|
|
$
|
158,433
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
NON-CASH
INVESTING AND FINANCING ACTIVITIES:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Conversion
of accrued payroll and payroll related expenses into stock options
|
|
$
|
-
|
|
|
$
|
227,784
|
|
Conversion
of accounts payable into stock options
|
|
$
|
-
|
|
|
$
|
66,445
|
|
Conversion
of accounts payable into restricted stock
|
|
$
|
44,700
|
|
|
$
|
-
|
|
|
|
|
|
|
|
|
|
|
SUPPLEMENTAL
DISCLOSURES:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash
paid for interest
|
|
$
|
3,537
|
|
|
$
|
2,925
|
|
Cash
paid for income taxes
|
|
$
|
-
|
|
|
$
|
-
|
|
Cardax,
Inc., and Subsidiary
NOTES
TO THE CONSOLIDATED
FINANCIAL
STATEMENTS (continued)
NOTE
1 – COMPANY BACKGROUND
Cardax
Pharmaceuticals, Inc. (“Holdings”) was incorporated in the State of Delaware on March 23, 2006.
Holdings
was formed for the purpose of developing a platform of proprietary, exceptionally safe, small molecule compounds for large unmet
medical needs where oxidative stress and inflammation play important causative roles. Holdings’ platform has application
in arthritis, metabolic syndrome, liver disease, and cardiovascular disease, as well as macular degeneration and prostate disease.
Holdings’ current primary focus is on the development of astaxanthin technologies. Astaxanthin is a naturally occurring
marine compound that has robust anti-oxidant and anti-inflammatory activity.
In
May of 2013, Holdings formed a 100% owned subsidiary company called Cardax Pharma, Inc. (“Pharma”). Pharma was formed
to maintain Holdings’ operations going forward, leaving Holdings as an investment holding company.
On
November 29, 2013, Holdings entered into a definitive merger agreement (“Merger Agreement”) with Koffee Korner Inc.,
a Delaware corporation (“Koffee Korner”) (OTCQB:KOFF), and its wholly owned subsidiary (“Koffee Sub”),
pursuant to which, among other matters and subject to the conditions set forth in such Merger Agreement, Koffee Sub would merge
with and into Pharma. In connection with such merger agreement and related agreements, upon the consummation of such merger, Pharma
would become a wholly owned subsidiary of Koffee Korner and Koffee Korner would issue shares of its common stock to Holdings.
At the effective time of such merger, Holdings would own a majority of the shares of the then issued and outstanding shares of
common stock of Koffee Korner.
On
February 7, 2014, Holdings completed its merger with Koffee Korner, which was renamed to Cardax, Inc. (the “Company”)
(OTCQB:CDXI). Concurrent with the merger: (i) the Company received aggregate gross cash proceeds of $3,923,100 in exchange for
the issuance and sale of an aggregate 6,276,960 of shares of the Company’s common stock, together with five year warrants
to purchase an aggregate of 6,276,960 shares of the Company’s common stock at $0.625 per share, (ii) the notes issued on
January 3, 2014, in the outstanding principal amount of $2,076,000 and all accrued interest thereon, automatically converted into
3,353,437 shares of the Company’s common stock upon the reverse merger at $0.625 per share, together with five year warrants
to purchase 3,321,600 shares of common stock at $0.625 per share, (iii) the notes issued in 2013, in the outstanding principal
amount of $8,489,036 and all accrued interest thereon, automatically converted into 14,446,777 shares of the Company’s common
stock upon the reverse merger at $0.625 per share, together with five year warrants to purchase 14,446,777 shares of common stock
at $0.625 per share, (iv) stock options to purchase 15,290,486 shares of Holdings common stock at $0.07 per share were cancelled
and substituted with stock options to purchase 6,889,555 shares of the Company’s common stock at $0.155 per share, (v) additional
stock options to purchase 20,867,266 shares of the Company’s common stock at $0.625 per share were issued, and (vi) the
notes issued in 2008 and 2009, in the outstanding principal amounts of $55,000 and $500,000, respectively, and all accrued interest
thereon, were repaid in full. The assets and liabilities of Koffee Korner were distributed in accordance with the terms of a spin-off
agreement on the closing date.
Cardax,
Inc., and Subsidiary
NOTES
TO THE CONSOLIDATED
FINANCIAL
STATEMENTS (continued)
NOTE
1 – COMPANY BACKGROUND (continued)
The
share exchange transaction was treated as a reverse acquisition, with Holdings and Pharma as the acquirers and Koffee Korner and
Koffee Sub as the acquired parties. Unless the context suggests otherwise, when the Company refers to business and financial information
for periods prior to the consummation of the reverse acquisition, the Company is referring to the business and financial information
of Holdings and Pharma. Under accounting principles generally accepted in the United States of America (“U.S. GAAP”)
guidance Accounting Standards Codification (“ASC”) No. 805-40,
Business Combinations – Reverse Acquisitions
,
the Acquisition has been treated as a reverse acquisition with no adjustment to the historical book and tax basis of the Company’s
assets and liabilities.
On
August 28, 2014, the Company entered into an Agreement and Plan of Merger (the “Holdings Merger Agreement”) with its
principal stockholder, Holdings, pursuant to which Holdings would merge with and into the Company (the “Holdings Merger”).
On September 18, 2015, the Company filed a Form S-4 with the SEC in contemplation of the Holdings Merger. There would not be any
cash consideration exchanged in the Holdings Merger. Upon the closing of the Holdings Merger, the stockholders of Holdings would
receive an aggregate number of shares and warrants to purchase shares of the Company’s common stock equal to the aggregate
number of shares of the Company’s common stock that were held by Holdings on the date of the closing of the Holdings Merger.
The Company’s restricted shares of common stock held by Holdings would be cancelled upon the closing of the Holdings Merger.
Accordingly, there would not be not any change to the Company’s fully diluted capitalization due to the Holdings Merger.
On
November 24, 2015, the Holdings Merger Agreement was amended and restated (the “Amended Holdings Merger Agreement”).
Under the terms of Amended Holdings Merger Agreement, the shares of common stock, par value $0.001 per share of Holdings and the
shares of all other issued and outstanding capital stock of Holdings that by their terms were convertible or could otherwise be
exchanged for shares of Holdings common stock, would be converted into and exchanged for the Company’s shares of common
stock in a ratio of approximately 2.2:1. In addition, the Company would grant Holdings’ option and warrant holders warrants
to purchase the Company’s warrants at the same stock conversion ratio. On November 24, 2015, the Company filed an amendment
to the Form S-4 with the SEC and on December 29, 2015, the Form S-4 was declared effective by the SEC.
On
December 30, 2015, the Company completed its merger with Holdings, pursuant to the Amended Holdings Merger Agreement. At closing,
Holdings merged with and into the Company, with the Company surviving the Holdings Merger. Pursuant to the Amended Holdings Merger
Agreement, there was not any cash consideration exchanged in the Holdings Merger. Upon the closing of the Holdings Merger, the
stockholders of Holdings received an aggregate number of shares and warrants to purchase shares of Company common stock equal
to the aggregate number of shares of Company common stock that were held by Holdings on the date of the closing of the Holdings
Merger. The Company’s restricted shares of common stock held by Holdings were cancelled upon the closing of the Holdings
Merger. Accordingly, there was not any change to the Company’s fully diluted capitalization due to the Holdings Merger.
The
Company is engaged in the development, marketing, and distribution of consumer health products. The Company’s first commercial
product, ZanthoSyn®, is a physician recommended anti-inflammatory supplement for health and longevity that features astaxanthin
with optimal absorption and purity. The Company sells ZanthoSyn® primarily through e-commerce and wholesale channels. As a
second-generation product, the Company is developing CDX-085, its patented astaxanthin derivative for highly concentrated astaxanthin
product applications. The Company also plans to pursue pharmaceutical applications of astaxanthin and related compounds. The safety
and efficacy of the Company’s products have not been directly evaluated in clinical trials or confirmed by the FDA.
Cardax,
Inc., and Subsidiary
NOTES
TO THE CONSOLIDATED
FINANCIAL
STATEMENTS (continued)
NOTE
1 – COMPANY BACKGROUND (continued)
Going
concern matters
The
accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization
of assets and the satisfaction of liabilities in the normal course of business. As shown in the accompanying condensed consolidated
financial statements, the Company incurred a net loss of $1,985,234 and $1,783,705 for the years ended December 31, 2017 and 2016,
respectively. The Company has incurred losses since inception resulting in an accumulated deficit of $57,919,096 as of December
31, 2017, and has had negative cash flows from operating activities since inception. The Company expects that its marketing program
for ZanthoSyn® will continue to focus on outreach to physicians, healthcare professionals, retail personnel, and consumers,
and anticipates further losses in the development of its business. As a result of these and other factors, management has determined
there is substantial doubt about the Company’s ability to continue as a going concern.
In
addition to the $4,138,435 raised in the year ended December 31, 2017, the Company plans to raise additional capital to carry
out its business plan. The Company’s ability to raise additional capital through future equity and debt securities issuances
is unknown. Obtaining additional financing, the successful development of the Company’s contemplated plan of operations,
and its transition, ultimately, to profitable operations are necessary for the Company to continue operations. The ability to
successfully resolve these factors raises substantial doubt about the Company’s ability to continue as a going concern.
The consolidated financial statements of the Company do not include any adjustments that may result from the outcome of these
uncertainties.
On
March 28, 2016, the Company furloughed all of its employees and independent contractors indefinitely and arranged with its Chief
Executive Officer, David G. Watumull; its Chief Financial Officer, John B. Russell; and its Vice President, Operations, David
M. Watumull, to continue their services for cash compensation equal to the minimum wage. In September 2017, the Company ended
this furlough and restored their employees to 75% of their base pay.
NOTE
2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis
of presentation
The
consolidated financial statements have been consistently prepared in accordance with accounting principles generally accepted
in the United States (“U.S. GAAP”) and include the accounts of Cardax, Inc., and its wholly owned subsidiary, Cardax
Pharma, Inc., and its predecessor, Cardax Pharmaceuticals, Inc., which was merged with and into Cardax, Inc. All significant intercompany
balances and transactions have been eliminated in consolidation.
Use
of estimates
The
preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions
that affect the amounts reported in our consolidated financial statements and the accompanying notes. Estimates in these consolidated
financial statements include asset valuations, estimates of future cash flows from and the economic useful lives of long-lived
assets, valuations of stock compensation, certain accrued liabilities, income taxes and tax valuation allowances, and fair value
estimates. Despite management’s intention to establish accurate estimates and reasonable assumptions, actual results could
differ materially from these estimates and assumptions.
Cash
The
Company considers all highly liquid investments with maturities of three months or less at the time of purchase to be cash equivalents.
The Company held no cash equivalents as of December 31, 2017 and 2016.
The
Company maintains cash deposit accounts at one financial institution. Accounts at this institution are insured by the Federal
Deposit Insurance Corporation up to $250,000. The Company’s cash balance at times may exceed these limits. As of December
31, 2017 and 2016, the Company had $1,988,139 and $0, respectively, in excess of federally insured limits on deposit.
Cardax,
Inc., and Subsidiary
NOTES
TO THE CONSOLIDATED
FINANCIAL
STATEMENTS (continued)
NOTE
2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)
Accounts
receivable
Accounts
receivable of $37,243 and $0 as of December 31, 2017 and 2016, respectively, consists of amounts due from sales of consumer health
products.
It
is the Company’s policy to provide for an allowance for doubtful collections based upon a review of outstanding receivables,
historical collection information, and existing economic conditions. Normal receivables are due 60 days after the issuance of
the invoice. Receivables past due more than 90 days are considered delinquent. Delinquent receivables are written off based on
individual credit evaluation and specific circumstances of the customer. There was no allowance necessary as of December 31, 2017
and 2016.
Inventories
Inventories
are stated at the lower of cost or market. Cost is determined using the average cost method. Market is defined as sales price
less cost to dispose and a normal profit margin. Inventory costs include third party costs for finished goods. The Company utilizes
contract manufacturers and receives inventory in finished form.
The
Company provides a reserve against inventory for known or expected inventory obsolescence. The reserve is determined by specific
review of inventory items for product age and quality that may affect salability. There were no reserves necessary for inventory
as of December 31, 2017 and 2016.
Property
and equipment, net
Property
and equipment are recorded at cost, less depreciation. Equipment under capital lease obligations and leasehold improvements are
amortized on the straight-line method over the shorter period of the lease term or the estimated useful life of the equipment.
Such amortization is included in depreciation and amortization in the consolidated financial statements. Depreciation is calculated
using the straight-line method over the estimated useful lives of the respective assets are as follows.
Furniture
and office equipment
|
|
7
years
|
Research
and development equipment
|
|
3
to 7 years
|
Information
technology equipment
|
|
5
years
|
Software
|
|
3
years
|
Major
additions and improvements are capitalized, and routine expenditures for repairs and maintenance are charged to expense as incurred.
When assets are retired or otherwise disposed of, the cost and related accumulated depreciation are removed from the accounts,
and any resulting gain or loss is charged to income for the period.
Impairment
of long-lived assets
The
Company evaluates long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount
of an asset or group of assets, as appropriate, may not be recoverable.
When
the sum of the undiscounted future net cash flows expected to result from the use and the eventual disposition is less than the
carrying amounts, an impairment loss would be measured based on the discounted cash flows compared to the carrying amounts. There
was no impairment charge recorded for the years ended December 31, 2017 and 2016.
Revenue
recognition
The
Company recognizes revenue from the sale of its products through e-commerce and wholesale channels when the transfer of title
and risk of loss occurs. For shipments with terms of FOB Shipping Point, revenue is recognized upon shipment. For shipments with
terms of FOB Destination, revenue is recognized upon delivery.
Sales
returns and allowances are recorded as a reduction to sales in the period in which sales are recorded. The Company records shipping
charges and sales tax gross in revenues and cost of goods sold. Sales discounts and other adjustments are recorded at the time
of sale.
Cardax,
Inc., and Subsidiary
NOTES
TO THE CONSOLIDATED
FINANCIAL
STATEMENTS (continued)
NOTE
2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)
Cost
of goods sold
Cost
of goods sold is comprised of costs to manufacture or acquire products sold to customers, direct and indirect distribution costs,
and other costs incurred in the sale of goods.
Shipping
and handling costs
Shipping
and handling costs are included in cost of goods sold. Shipping and handling costs were $10,366 and $3,884 for the years ended
December 31, 2017 and 2016, respectively.
Sales
and use tax
Revenues,
as presented on the accompanying income statement, include taxes collected from customers and remitted to governmental authorities.
Such taxes were $5,132 and $1,205 for the years ended December 31, 2017 and 2016, respectively.
Research
and development
Research
and development costs are expensed as incurred and consists primarily of salaries and wages of scientists and related personnel
engaged in research and development activities, scientific consultations, manufacturing of product candidates, third-party research,
laboratory supplies, rents associated with operating leased laboratory equipment, and scientific advisory boards. The focus of
these costs is on the development of Astaxanthin technologies. For the years ended December 31, 2017 and 2016, research and development
costs were $460,991 and $347,885, respectively.
Advertising
Advertising
costs are expensed as incurred and are included as an element of sales and marketing costs in the accompanying consolidated statements
of operations. For the years ended December 31, 2017 and 2016, advertising costs were $84,317 and $27,939, respectively.
Income
taxes
The
Company accounts for income taxes under an asset and liability approach. Deferred income taxes reflect the impact of temporary
differences between assets and liabilities recognized for financial reporting purposes and the amounts recognized for income tax
reporting purposes, net operating loss carry-forwards, and other tax credits measured by applying currently enacted tax laws.
A valuation allowance is provided when necessary to reduce deferred tax assets to an amount that is more likely than not to be
realized.
The
Company determines whether a tax position is more likely than not to be sustained upon examination, including resolution of any
related appeals or litigation processes, based on the technical merits of the position. The Company uses a two-step approach to
recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining
if the weight of available evidence indicates that it is more likely than not that the position will be sustained upon tax authority
examination, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit
as the largest amount that is more than 50% likely of being realized upon ultimate settlement.
The
Company files income tax returns in the United States (“U.S.”) Federal and the States of Hawaii and California jurisdictions.
Tax regulations within each jurisdiction are subject to the interpretation of the related tax laws and regulations and require
significant judgment to apply.
The
Company did not recognize any tax liabilities for income taxes associated with unrecognized tax benefits as of December 31, 2017
and 2016. The Company’s policy is to include interest and penalties related to unrecognized tax benefits, if any, within
the provision for income taxes in the consolidated statements of operations.
Cardax,
Inc., and Subsidiary
NOTES
TO THE CONSOLIDATED
FINANCIAL
STATEMENTS (continued)
NOTE
2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)
Fair
value measurements
U.S.
GAAP establishes a framework for measuring fair value. That framework provides a fair value hierarchy that prioritizes the inputs
to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active
markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements).
The
three levels of the fair value hierarchy are described below:
|
Level
1:
|
Inputs
to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets that the Company
has the ability to access.
|
|
|
|
|
Level
2:
|
Inputs
to the valuation methodology include:
|
|
●
|
Quoted
prices for similar assets or liabilities in active markets;
|
|
|
|
|
●
|
Quoted
prices for identical or similar assets or liabilities in inactive markets;
|
|
|
|
|
●
|
Inputs
other than quoted prices that are observable for the asset or liability; and
|
|
|
|
|
●
|
Inputs
that are derived principally from or corroborated by observable market data by correlation or other means.
|
If
the asset or liability has a specified (contractual) term, the Level 2 input must be observable for substantially the full term
of the asset or liability.
|
Level
3:
|
Inputs
to the valuation methodology are unobservable and significant to the fair value measurement.
|
The
asset’s or liability’s fair value measurement level within the fair value hierarchy is based on the lowest level of
any input that is significant to the fair value measurement. Valuation techniques used need to maximize the use of observable
inputs and minimize the use of unobservable inputs.
As
of December 31, 2017 and 2016, there were no recurring fair value measurements of assets and liabilities subsequent to initial
recognition.
Stock
based compensation
The
Company accounts for stock based compensation costs under the provisions of ASC No. 718,
Compensation—Stock Compensation
and ASC No. 505,
Equity
, which require the measurement and recognition of compensation expense related to the fair
value of stock based compensation awards that are ultimately expected to vest. Stock based compensation expense recognized includes
the compensation cost for all stock based payments granted to employees, officers, directors, and consultants based on the grant
date fair value estimated. These standards also apply to awards modified, repurchased, or canceled during the periods reported.
Basic
and diluted net loss per share
Basic
earnings per common share is calculated by dividing net loss for the year by the weighted average number of common shares outstanding
during the year. Diluted earnings per common share is calculated by dividing net loss for the year by the sum of the weighted
average number of common shares outstanding during the year plus the number of potentially dilutive common shares (“dilutive
securities”) that were outstanding during the year. Dilutive securities include options granted pursuant to the Company’s
stock option plans, and warrants issued to non-employees. Potentially dilutive securities are excluded from the computation of
earnings per share in periods in which a net loss is reported, as their effect would be antidilutive.
Cardax,
Inc., and Subsidiary
NOTES
TO THE CONSOLIDATED
FINANCIAL
STATEMENTS (continued)
NOTE
2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)
Recent
accounting pronouncements
In
May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”)
No. 2014-09,
Revenue from Contracts with Customers
, related to revenue recognition. The underlying principle of this ASU
is that a business or other organization will recognize revenue to depict the transfer of promised goods or services to customers
in an amount that reflects what it expects in exchange for the goods or services. This ASU also requires more detailed disclosures
and provides additional guidance for transactions that were not addressed completely in prior accounting guidance. ASU No. 2014-09
provides alternative methods of initial adoption. The Company is currently assessing the impact of this ASU on the Company’s
consolidated financial statements. In August 2015, the FASB issued ASU No. 2015-14,
Revenue from Contracts with Customers (Topic
606): Deferral of the Effective Date
, which defers the effective date of ASU No. 2014-09 by one year to fiscal years beginning
after December 15, 2017, including interim periods within those years and permitted early adoption of the standard, but not before
the original effective date. The Company has assessed the impact of these ASUs and does not believe that they will have a material
effect on the Company’s consolidated financial statements.
The
FASB issued four additional ASUs in 2016 that affect the guidance in ASU No. 2014-09,
Revenue from Contracts with Customers
,
and are effective upon adoption of ASU No. 2014-09. The Company has assessed the impact of these ASUs and does not believe that
they will have a material effect on the Company’s consolidated financial statements, including the following ASUs:
|
●
|
In
March 2016, the FASB issued ASU No. 2016-08,
Revenue from Contracts with Customers (Topic 606): Principal versus Agent
Considerations (Reporting Revenue Gross versus Net)
. This ASU clarifies the implementation guidance on principal versus
agent considerations. The guidance includes indicators to assist an entity in determining whether it controls a specified
good or service before it is transferred to the customers.
|
|
|
|
|
●
|
In
April 2016, the FASB issued ASU No. 2016-10,
Identifying Performance Obligations and Licensing
. This ASU clarifies
the following two aspects of ASU No. 2014-09: identifying performance obligations and licensing implementation guidance. The
amendment requires revenue recognition to depict the transfer of goods or services to customers in an amount that reflects
the consideration that a company expects to be entitled to in exchange for the goods or services. To achieve this principle,
a company must apply five steps including identifying the contract with a customer, identifying the performance obligations
in the contract, determining the transaction price, allocating the transaction price to the performance obligations, and recognizing
revenue when (or as) the company satisfies the performance obligations. Additional quantitative and qualitative disclosures
to enhance the understanding about the nature, amount, timing, and uncertainty of revenue and cash flows are also required.
|
|
|
|
|
●
|
In
May 2016, the FASB issued ASU No. 2016-12,
Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements
and Practical Expedients
. This ASU makes narrow-scope amendments to ASU No. 2014-09,
Revenue from Contracts with Customers
,
and provides practical expedients to simplify the transition to the new standard and to clarify certain aspects of the standard.
|
|
|
|
|
●
|
In
December 2016, the FASB issued ASU 2016-20,
Technical Corrections and Improvements to Topic 606, Revenue from Contracts
with Customers (Topic 606)
. This ASU addresses technical corrections and improvements to clarify the codification and
to correct unintended application of guidance. Those items generally are not expected to have a significant effect on current
accounting practice or create a significant administrative cost for most entities. The amendments in this Update are of a
similar nature to the items typically addressed in the Technical Corrections and Improvements project.
|
In
February 2016, the FASB issued ASU No. 2016-02,
Leases
. This ASU requires management to recognize lease assets and lease
liabilities for all leases. ASU No. 2016-02 retains a distinction between finance leases and operating leases. The classification
criteria for distinguishing between finance leases and operating leases are substantially similar to the classification criteria
for distinguishing between capital leases and operating leases in the previous leases guidance.
Cardax,
Inc., and Subsidiary
NOTES
TO THE CONSOLIDATED
FINANCIAL
STATEMENTS (continued)
NOTE
2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)
Recent
accounting pronouncements (continued)
The
result of retaining a distinction between finance leases and operating leases is that under the lessee accounting model, the effect
of leases in the statement of comprehensive income and the statement of cash flows is largely unchanged from previous U.S. GAAP.
The guidance in ASU No. 2016-02 is effective for fiscal years beginning after December 15, 2018, including interim periods within
those fiscal years. The Company is currently assessing the impact of this ASU on the Company’s consolidated financial statements.
In
March 2016, the FASB issued ASU No. 2016-09,
Compensation - Stock Compensation
. This ASU was issued as part of the FASB’s
simplification initiative focused on improving areas of U.S. GAAP for which cost and complexity may be reduced while maintaining
or improving the usefulness of information disclosed within the financial statements. The amendments focused on simplification
specifically with regard to share-based payment transactions, including income tax consequences, classification of awards as equity
or liabilities, and classification on the statement of cash flows. The guidance in ASU No. 2016-09 is effective for fiscal years
beginning after December 15, 2016, including interim periods within those fiscal years. Early adoption is permitted. The amendments
in this ASU should be applied prospectively to an award modified on or after the adoption date. The Company has assessed the impact
of this ASU and does not believe that this update has a significant impact on its consolidated financial statements.
In
November 2016, the FASB issued ASU 2016-18,
Statement of Cash Flows (Topic 23)
. The amendments of ASU No. 2016-18 require
that a statement of cash flow explain the change during a period in the total of cash, cash equivalents, and amounts generally
described as restricted cash or restricted cash equivalents. The guidance of ASU No. 2016-18 is effective for years beginning
after December 15, 2017, including interim periods within those years. The Company has assessed the impact of this ASU and does
not believe that this update has a significant impact on its consolidated financial statements.
In
May 2017, the FASB issued ASU No. 2017-09,
Compensation-Stock Compensation: Scope of Modification Accounting
. The amendments
of ASU No. 2017-09 provide guidance about which changes to the terms or conditions of a share-based payment award require an entity
to apply modification accounting. The guidance of ASU No. 2017-09 is effective for years beginning after December 15, 2017, including
interim periods within those years. The Company has assessed the impact of this ASU and does not believe that this update has
a significant impact on its consolidated financial statements.
The
Company does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have
a material effect on the consolidated financial statements.
Reclassifications
The
Company has made certain reclassifications to conform its prior periods’ data to the current presentation. These reclassifications
had no effect on the reported results of operations or cash flows.
NOTE
3 – INVENTORIES
Inventories
consist of the following as of December 31:
|
|
2017
|
|
|
2016
|
|
Finished
goods
|
|
$
|
240,917
|
|
|
$
|
10,827
|
|
Raw
materials
|
|
|
98,937
|
|
|
|
-
|
|
Packing
supplies and materials
|
|
|
571
|
|
|
|
-
|
|
Total
inventories
|
|
$
|
340,425
|
|
|
$
|
10,827
|
|
Cardax,
Inc., and Subsidiary
NOTES
TO THE CONSOLIDATED
FINANCIAL
STATEMENTS (continued)
NOTE
4 – PROPERTY AND EQUIPMENT, net
Property
and equipment, net, consists of the following as of December 31:
|
|
2017
|
|
|
2016
|
|
Information
technology equipment
|
|
$
|
31,892
|
|
|
$
|
31,892
|
|
Less
accumulated depreciation
|
|
|
(29,991
|
)
|
|
|
(24,137
|
)
|
Total
property and equipment, net
|
|
$
|
1,901
|
|
|
$
|
7,755
|
|
Depreciation
expense was $5,854 and $6,168, for the years ended December 31, 2017 and 2016, respectively.
NOTE
5 – INTANGIBLE ASSETS, net
Intangible
assets, net, consists of the following as of December 31:
|
|
2017
|
|
|
2016
|
|
Patents
|
|
$
|
493,027
|
|
|
$
|
432,985
|
|
Less
accumulated amortization
|
|
|
(263,843
|
)
|
|
|
(240,275
|
)
|
|
|
|
229,184
|
|
|
|
192,710
|
|
Patents
pending
|
|
|
197,426
|
|
|
|
238,060
|
|
Total
intangible assets, net
|
|
$
|
426,610
|
|
|
$
|
430,770
|
|
Patents
are amortized straight-line over a period of fifteen years. Amortization expense was $23,568 and $22,933 for the years ended December
31, 2017 and 2016, respectively.
The
Company has capitalized costs for several patents that are still pending. In those instances, the Company has not recorded any
amortization. The Company will commence amortization when these patents are approved.
The
Company owns 22 issued patents, including 14 in the United States and 8 others in China, India, Japan, and Hong Kong. These patents
will expire during the years of 2023 to 2028, subject to any patent term extensions of the individual patent. The Company has
4 foreign patent applications pending in Europe, Canada, and Brazil.
NOTE
6 – STOCKHOLDERS’ DEFICIT
Self-directed
stock issuance
During
the year ended December 31, 2016, the Company sold securities in a self-directed offering in the aggregate amount of $1,121,000
at $0.08 per unit. Each unit consisted of 1 share of restricted common stock (14,012,500 shares), a five-year warrant to purchase
1 share of restricted common stock (14,012,500 warrant shares) at $0.08 per share, a five-year warrant to purchase 1 share of
restricted common stock (14,012,500 warrant shares) at $0.12 per share, and a five-year warrant to purchase 1 share of restricted
common stock (14,012,500 warrant shares) at $0.16 per share.
Cardax,
Inc., and Subsidiary
NOTES
TO THE CONSOLIDATED
FINANCIAL
STATEMENTS (continued)
NOTE
6 – STOCKHOLDERS’ DEFICIT (continued)
During
the year ended December 31, 2017, the Company sold securities in a self-directed offering in the aggregate amount of $179,000,
$3,774,456, and $124,979 at $0.08, $0.12, and $0.30, respectively, per unit. Each $0.08 unit consisted of 1 share of restricted
common stock (2,237,500 shares), a five-year warrant to purchase 1 share of restricted common stock (2,237,500 warrant shares)
at $0.08 per share, a five-year warrant to purchase 1 share of restricted common stock (2,237,500 warrant shares) at $0.12 per
share, and a five-year warrant to purchase 1 share of restricted common stock (2,237,500 warrant shares) at $0.16 per share. Each
$0.12 unit consisted of 1 share of restricted common stock (31,453,788 shares) and a five-year warrant to purchase 1 share of
restricted common stock (31,453,788 warrant shares) at $0.12 per share. Each $0.30 unit consisted of 1 share of restricted common
stock (416,595 shares) and a five-year warrant to purchase 1 share of restricted common stock (416,595 warrant shares) at $0.30
per share.
Equity
purchase agreement
In
July 2016, the Company entered into an equity purchase agreement (the “EPA”) and a registration rights agreement with
an investor. Pursuant to the terms of the EPA, the Company has the right, but not the obligation, to sell shares of its common
stock to the investor on the terms specified in the EPA. On the date of the EPA, the Company issued 1,500,000 shares to the investor.
The total fair value of this stock on the date of grant was $106,500. These shares were fully vested upon issuance.
During
the years ended December 31, 2017 and 2016, the Company sold 567,644 and 0 shares of common stock for $60,000 and $0, respectively,
pursuant to the EPA.
Payable
settlement
In
May 2017, the Company settled a payable in the amount of $44,700 with a previously engaged broker dealer through the issuance
of securities at $0.08 per unit. Each unit consisted of 1 share of restricted common stock (558,750 shares), a five-year warrant
to purchase 1 share of restricted common stock (558,750 warrant shares) at $0.08 per share, a five-year warrant to purchase 1
share of restricted common stock (558,750 warrant shares) at $0.12 per share, and a five-year warrant to purchase 1 share of restricted
common stock (558,750 warrant shares) at $0.16 per share.
Shares
outstanding
As
of December 31, 2017 and 2016, the Company had a total of 122,674,516 and 85,068,709 shares of common stock outstanding.
NOTE
7 – STOCK GRANTS
Director
stock grants
During
2017 and 2016, the Company granted its independent directors an aggregate of 793,025 and 468,254, respectively, shares of restricted
common stock in the Company. The expense recognized for these grants based on the grant date fair value was $150,000 and $41,666
for the years ended December 31, 2017 and 2016, respectively. These shares were fully vested upon issuance.
Consultant
stock grants
On
April 10, 2017, the Company granted a consultant 100,000 shares of restricted common stock valued at $0.23 per share. These shares
are subject to a risk of forfeiture and vest quarterly in arrears commencing on April 1, 2017. The Company recognized $17,250
in stock based compensation related to this grant during the year ended December 31, 2017.
On
August 8, 2017, the Company granted a consultant 100,000 shares of restricted common stock valued at $0.175 per share. These shares
are subject to a risk of forfeiture and vest 25% upon grant and quarterly in arrears thereafter commencing on September 1, 2017.
The Company recognized $13,125 in stock based compensation related to this grant during the year ended December 31, 2017.
Cardax,
Inc., and Subsidiary
NOTES
TO THE CONSOLIDATED
FINANCIAL
STATEMENTS (continued)
NOTE
8 – STOCK OPTION PLANS
On
February 7, 2014, the Company adopted the 2014 Equity Compensation Plan. Under this plan, the Company may issue options to purchase
shares of common stock to employees, directors, advisors, and consultants. The aggregate number of shares that may be issued under
this plan is 30,420,148. On April 16, 2015, the majority stockholder of the Company approved an increase in the Company’s
2014 Equity Compensation Plan by 15 million shares.
Under
the terms of the 2014 Equity Compensation Plan and the 2006 Stock Incentive Plan (collectively, the “Plans”), incentive
stock options may be granted to employees at a price per share not less than 100% of the fair market value at date of grant. If
the incentive stock option is granted to a 10% stockholder, then the purchase or exercise price per share shall not be less than
110% of the fair market value per share of common stock on the grant date. Non-statutory stock options and restricted stock may
be granted to employees, directors, advisors, and consultants at a price per share, not less than 100% of the fair market value
at date of grant. Options granted are exercisable, unless specified differently in the grant documents, over a default term of
ten years from the date of grant and generally vest over a period of four years.
A
summary of stock option activity is as follows:
|
|
Options
|
|
|
Weighted
average exercise price
|
|
|
Weighted
average remaining contractual term in years
|
|
|
Aggregate
intrinsic value
|
|
Outstanding
January 1, 2016
|
|
|
34,167,354
|
|
|
$
|
0.47
|
|
|
|
6.57
|
|
|
$
|
974,066
|
|
Exercisable
January 1, 2016
|
|
|
34,167,354
|
|
|
$
|
0.47
|
|
|
|
6.57
|
|
|
$
|
974,066
|
|
Canceled
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Granted
|
|
|
6,156,580
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercised
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Forfeited
|
|
|
(3,501,965
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
Outstanding
December 31, 2016
|
|
|
36,821,969
|
|
|
$
|
0.41
|
|
|
|
5.94
|
|
|
$
|
301,273
|
|
Exercisable
December 31, 2016
|
|
|
36,771,969
|
|
|
$
|
0.41
|
|
|
|
5.94
|
|
|
$
|
299,273
|
|
Canceled
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Granted
|
|
|
2,161,458
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercised
|
|
|
(770,000
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
Forfeited
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Outstanding
December 31, 2017
|
|
|
38,213,427
|
|
|
$
|
0.41
|
|
|
|
5.23
|
|
|
$
|
562,456
|
|
Exercisable
December 31, 2017
|
|
|
36,213,427
|
|
|
$
|
0.41
|
|
|
|
4.98
|
|
|
$
|
562,456
|
|
The
aggregate intrinsic value in the table above is before applicable income taxes and represents the excess amount over the exercise
price option recipients would have received if all options had been exercised on December 31, 2017, based on a valuation of the
Company’s stock for that day.
Cardax,
Inc., and Subsidiary
NOTES
TO THE CONSOLIDATED
FINANCIAL
STATEMENTS (continued)
NOTE
8 – STOCK OPTION PLANS (continued)
A
summary of the Company’s non-vested options for the years ended December 31, 2017 and year ended December 31, 2016 are presented
below:
Non-vested at
January 1, 2016
|
|
|
-
|
|
Granted
|
|
|
6,156,580
|
|
Vested
|
|
|
(6,106,580
|
)
|
Forfeited
|
|
|
-
|
|
Non-vested at
December 31, 2016
|
|
|
50,000
|
|
Granted
|
|
|
2,161,458
|
|
Vested
|
|
|
(211,458
|
)
|
Forfeited
|
|
|
-
|
|
Non-vested
at December 31, 2017
|
|
|
2,000,000
|
|
The
Company estimates the fair value of stock options granted on each grant date using the Black-Scholes option valuation model and
recognizes an expense ratably over the requisite service period. The range of fair value assumptions related to options issued
outstanding were as follows for the years ended December 31:
|
|
2017
|
|
|
2016
|
|
Dividend
yield
|
|
|
0.0
|
%
|
|
|
0.0
|
%
|
Risk-free
rate
|
|
|
1.89%
- 2.26
|
%
|
|
|
0.80%
- 1.03
|
%
|
Expected
volatility
|
|
|
221%
- 232
|
%
|
|
|
141%
- 225
|
%
|
Expected
term
|
|
|
5
- 7 years
|
|
|
|
5
years
|
|
The
expected volatility was calculated based on the historical volatilities of publicly traded peer companies, determined by the Company,
and the historical volatility of the Company. The risk-free interest rate used was based on the U.S. Treasury constant maturity
rate in effect at the time of grant for the expected term of the stock options to be valued. The expected dividend yield was zero,
as the Company does not anticipate paying a dividend within the relevant timeframe. Due to a lack of historical information needed
to estimate the Company’s expected term, it was estimated using the simplified method allowed.
The
Company records forfeitures as they occur and reverses compensation cost previously recognized, in the period the award is forfeited,
for an award that is forfeited before completion of the requisite service period.
Stock
option exercise
During
the year ended December 31, 2017, the Company issued 645,288 shares of common stock in connection with the cashless exercise of
stock options for 100,000, 45,000, and 625,000 shares of common stock at $0.155, $0.06, and $0.06, respectively, per share with
124,712 shares of common stock withheld with an aggregate fair market value equal to the aggregate exercise price.
Cardax,
Inc., and Subsidiary
NOTES
TO THE CONSOLIDATED
FINANCIAL
STATEMENTS (continued)
NOTE
8 – STOCK OPTION PLANS (continued)
The
Company recognized stock based compensation expense related to options during the:
|
|
Years
ended December 31
|
|
|
|
2017
|
|
|
2016
|
|
|
|
Number
|
|
|
Amount
|
|
|
Number
|
|
|
Amount
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
In
lieu of accrued salaries
|
|
|
-
|
|
|
$
|
-
|
|
|
|
3,796,385
|
|
|
$
|
227,784
|
|
In
lieu of accrued fees for outside services
|
|
|
-
|
|
|
|
-
|
|
|
|
1,107,417
|
|
|
|
66,445
|
|
Compensation
for outside services
|
|
|
50,000
|
|
|
|
3,500
|
|
|
|
50,000
|
|
|
|
3,500
|
|
Employee
compensation (unvested)
|
|
|
2,000,000
|
|
|
|
33,271
|
|
|
|
-
|
|
|
|
-
|
|
Director
compensation
|
|
|
161,458
|
|
|
|
25,000
|
|
|
|
1,152,778
|
|
|
|
79,167
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
|
2,211,458
|
|
|
$
|
61,771
|
|
|
|
6,106,580
|
|
|
$
|
376,896
|
|
NOTE
9 – WARRANTS
The
following is a summary of the Company’s warrant activity:
|
|
Warrants
|
|
|
Weighted
average exercise price
|
|
|
Weighted
average remaining contractual term in years
|
|
|
Aggregate
intrinsic value
|
|
Outstanding
January 1, 2016
|
|
|
47,003,962
|
|
|
$
|
0.46
|
|
|
|
3.49
|
|
|
$
|
2,579,541
|
|
Exercisable
January 1, 2016
|
|
|
47,003,962
|
|
|
$
|
0.46
|
|
|
|
3.49
|
|
|
$
|
2,579,541
|
|
Canceled
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Granted
|
|
|
42,037,500
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercised
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Forfeited
|
|
|
(676,426
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
Outstanding
December 31, 2016
|
|
|
88,365,036
|
|
|
$
|
0.30
|
|
|
|
3.50
|
|
|
$
|
543,770
|
|
Exercisable
December 31, 2016
|
|
|
88,365,036
|
|
|
$
|
0.30
|
|
|
|
3.50
|
|
|
$
|
543,770
|
|
Canceled
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Granted
|
|
|
40,259,133
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercised
|
|
|
(798,000
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
Forfeited
|
|
|
(392,047
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
Outstanding
December 31, 2017
|
|
|
127,434,122
|
|
|
$
|
0.24
|
|
|
|
3.15
|
|
|
$
|
3,957,689
|
|
Exercisable
December 31, 2017
|
|
|
127,434,122
|
|
|
$
|
0.24
|
|
|
|
3.15
|
|
|
$
|
3,957,689
|
|
Cardax,
Inc., and Subsidiary
NOTES
TO THE CONSOLIDATED
FINANCIAL
STATEMENTS (continued)
NOTE
9 – WARRANTS (continued)
The
Company estimates the fair value of warrants granted on each grant date using the Black-Scholes option valuation model. The expected
volatility was calculated based on the historical volatilities of publicly traded peer companies, determined by the Company. The
risk-free interest rate used was based on the U.S. Treasury constant maturity rate in effect at the time of grant for the expected
term of the warrants to be valued. The expected dividend yield was zero, as the Company does not anticipate paying a dividend
within the relevant timeframe. The expected warrant term is the life of the warrant.
The
Company did not recognize any stock based compensation expense related to warrants during the years ended December 31, 2017 and
2016, respectively.
Warrant
exercise
During
the year ended December 31, 2017, the Company issued 233,217 shares of common stock in connection with the cashless exercise of
a warrant for 298,000 shares of common stock at $0.10 per share with 64,783 shares of common stock withheld with an aggregate
fair market value equal to the aggregate exercise price.
During
the year ended December 31, 2017, the Company issued 500,000 shares of common stock in connection with the exercise of a warrant
for 500,000 shares of common stock at $0.08 per share in exchange for $40,000.
Warrant
expiration
During
the years ended December 31, 2017 and 2016, warrants to purchase an aggregate of 392,047 and 676,426, respectively, shares of
restricted common stock expired.
NOTE
10 – RELATED PARTY TRANSACTIONS
Executive
chairman agreement
As
part of an executive chairman agreement, a director provided services to the Company. This agreement was amended on April 1, 2015.
Under the terms of this amendment, the director received $37,500 in equity instruments issued quarterly in arrears as compensation.
Effective April 1, 2016, the director agreed to suspend any additional equity compensation, until otherwise agreed by the Company.
Effective August 12, 2016, the Company accepted the request for a leave of absence and resignation by the director as Executive
Chairman and member of the Board of Directors.
The
Company incurred $0 and $37,500 in stock based compensation to this director during the years ended December 31, 2017 and 2016,
respectively.
The
amount payable to this director was $293,546 as of December 31, 2017 and 2016.
NOTE
11 – INCOME TAXES
The
Company accounts for income taxes using the asset and liability method. Under this method, deferred income tax assets and liabilities
are determined based upon the difference between the financial statement carrying amounts and the tax basis of assets and liabilities
and are measured using the enacted tax rate expected to apply to taxable income in the years in which the differences are expected
to be reversed.
In
2017, the Company adopted FASB issued ASU No. 2015-17,
Income Taxes (Topic 740)
. This ASU was issued as part of the FASB’s
simplification initiative focused on improving areas of U.S. GAAP for which cost and complexity may be reduced while maintaining
or improving the usefulness of information disclosed within the financial statements. ASU No. 2015-17 simplifies the presentation
of deferred income taxes by requiring that deferred tax liabilities and assets be presented net and classified as noncurrent in
a classified statement of financial position. As a result of this adoption, the Company now presents deferred tax assets as a
single line item, net, in long-term assets or labilities.
Cardax,
Inc., and Subsidiary
NOTES
TO THE CONSOLIDATED
FINANCIAL
STATEMENTS (continued)
NOTE
11 – INCOME TAXES (continued)
There
was not a provision for income taxes for the years ended December 31, 2017 and 2016.
The
Company accounts for income taxes using the asset and liability method. Under this method, deferred income tax assets and liabilities
are determined based upon the difference between the financial statement carrying amounts and the tax basis of assets and liabilities
and are measured using the enacted tax rate expected to apply to taxable income in the years in which the differences are expected
to be reversed.
The
following table presents a reconciliation of the statutory Federal rate and the Company’s effective tax rate for the years
ended December 31:
|
|
2017
|
|
|
2016
|
|
Tax
provision (benefit) at Federal statutory rate
|
|
|
(34.00
|
)%
|
|
|
(34.00
|
)%
|
Accrued
compensation
|
|
|
(0.32
|
)%
|
|
|
0.89
|
%
|
Stock
based compensation
|
|
|
4.15
|
%
|
|
|
10.01
|
%
|
Depreciation
and amortization
|
|
|
0.59
|
%
|
|
|
0.36
|
%
|
Other
|
|
|
0.26
|
%
|
|
|
0.09
|
%
|
Change
in valuation allowance
|
|
|
29.32
|
%
|
|
|
22.65
|
%
|
Effective
tax rate
|
|
|
0.00
|
%
|
|
|
0.00
|
%
|
The
effective tax rate for the three and years ended December 31, 2017 and 2016, differs from the statutory rate of 34% as a result
of state taxes (net of Federal benefit), permanent differences, and a reserve against deferred tax assets.
Deferred
income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial
reporting purposes and the amounts used for income tax purposes. The following table presents significant components of the Company’s
deferred tax assets and liabilities for the years ended December 31:
|
|
2017
|
|
|
2016
|
|
DEFERRED
TAX ASSETS, net:
|
|
|
|
|
|
|
|
|
Net
operating loss carryforwards
|
|
$
|
8,705,467
|
|
|
$
|
12,013,384
|
|
Accrued
compensation
|
|
|
1,074,903
|
|
|
|
1,535,184
|
|
Stock
based compensation
|
|
|
66,348
|
|
|
|
200,700
|
|
Credit
carryforwards
|
|
|
71,910
|
|
|
|
100,318
|
|
Depreciation
and amortization carryforwards
|
|
|
(71,054
|
)
|
|
|
(87,903
|
)
|
Total
|
|
|
9,847,574
|
|
|
|
13,761,683
|
|
Less
valuation allowance
|
|
|
(9,847,574
|
)
|
|
|
(13,761,683
|
)
|
NET
DEFERRED TAX ASSETS assets
|
|
$
|
-
|
|
|
$
|
-
|
|
Cardax,
Inc., and Subsidiary
NOTES
TO THE CONSOLIDATED
FINANCIAL
STATEMENTS (continued)
NOTE
11 – INCOME TAXES (continued)
As
of December 31, 2017, the Company had a Federal net operating loss carryforward of $33,345,946. The net operating loss carryforward
expires at various dates beginning in 2026 if not utilized. In addition, the Company had a net operating loss carryforward for
Hawaii income tax purposes of $26,606,541 as of December 31, 2017, which expires at various dates beginning in 2026 if not utilized.
These amounts differ from the Company’s accumulated deficit due to permanent and temporary tax differences.
The
Company’s valuation allowance was primarily related to the operating losses. The valuation allowance is determined in accordance
with the provisions of ASC No. 740,
Income Taxes
, which requires an assessment of both negative and positive evidence when
measuring the need for a valuation allowance. Based on the available objective evidence and the Company’s history of losses,
management provides no assurance that the net deferred tax assets will be realized. As of December 31, 2017 and 2016, the Company
has applied a valuation allowance against its deferred tax assets net of the expected income from the reversal of the deferred
tax liabilities.
Recent
tax legislation
On
December 22, 2017, the Tax Cuts and Jobs Act (“TCJA”) was enacted into law, which significantly changes existing U.S.
tax law and includes numerous provisions that affect our business, such as reducing the U.S. federal statutory tax rate. The TCJA
reduces the U.S. federal statutory tax rate from 35% to 21% effective January 1, 2018.
As
a result of TCJA, we recorded a change in our deferred tax asset of approximately, $3.8 million, which was offset by an adjustment
to the allowance.
Uncertain
tax positions
The
Company is subject to taxation in the United States and two state jurisdictions. The preparation of tax returns requires management
to interpret the applicable tax laws and regulations in effect in such jurisdictions, which could affect the amount of tax paid
by the Company. Management, in consultation with its tax advisors, files its tax returns based on interpretations that are believed
to be reasonable under the circumstances. The income tax returns, however, are subject to routine reviews by the various taxing
authorities. As part of these reviews, a taxing authority may disagree with respect to the tax positions taken by management (“uncertain
tax positions”) and therefore may require the Company to pay additional taxes.
Management
evaluates the requirement for additional tax accruals, including interest and penalties, which the Company could incur as a result
of the ultimate resolution of its uncertain tax positions. Management reviews and updates the accrual for uncertain tax positions
as more definitive information becomes available from taxing authorities, completion of tax audits, expiration of statute of limitations,
or upon occurrence of other events.
As
of December 31, 2017 and 2016, there was no liability for income tax associated with unrecognized tax benefits. The Company recognizes
accrued interest related to unrecognized tax benefits as well as any related penalties in interest income or expense in its consolidated
statements of operations, which is consistent with the recognition of these items in prior reporting periods.
The
federal and state income tax returns of the Company are subject to examination by the IRS and state taxing authorities, generally
for three years after they were filed.
State
tax credits
The
Company received a refundable tax credit of $17,253 and $47,082 from the State of Hawaii during the years ended December 31, 2017
and 2016, respectively. This amount is recorded as other income in the consolidated statement of operations.
Cardax,
Inc., and Subsidiary
NOTES
TO THE CONSOLIDATED
FINANCIAL
STATEMENTS (continued)
NOTE
12 – BASIC AND DILUTED NET LOSS PER SHARE
The
following table sets forth the computation of the Company’s basic and diluted net loss per share for the years ended December
31:
|
|
2017
|
|
|
|
Net
Loss
(Numerator)
|
|
|
Shares
(Denominator)
|
|
|
Per
share
amount
|
|
Basic
loss per share
|
|
$
|
(1,985,234
|
)
|
|
|
99,951,385
|
|
|
$
|
(0.02
|
)
|
Effect
of dilutive securities—Common stock options and warrants
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
Diluted
loss per share
|
|
$
|
(1,985,234
|
)
|
|
|
99,951,385
|
|
|
$
|
(0.02
|
)
|
|
|
2016
|
|
|
|
Net
Loss
(Numerator)
|
|
|
Shares
(Denominator)
|
|
|
Per
share
amount
|
|
Basic
loss per share
|
|
$
|
(1,783,705
|
)
|
|
|
76,227,524
|
|
|
$
|
(0.02
|
)
|
Effect
of dilutive securities—Common stock options and warrants
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
Diluted
loss per share
|
|
$
|
(1,783,705
|
)
|
|
|
76,227,524
|
|
|
$
|
(0.02
|
)
|
The
following outstanding shares of common stock equivalents were excluded from the computation of diluted net loss per share for
the periods presented because including them would have been antidilutive for the years ended December 31:
|
|
2017
|
|
|
2016
|
|
Common
stock options
|
|
|
38,213,427
|
|
|
|
36,821,969
|
|
Common
stock warrants
|
|
|
127,434,122
|
|
|
|
88,365,036
|
|
Total
common stock equivalents
|
|
|
165,647,549
|
|
|
|
125,187,005
|
|
Cardax,
Inc., and Subsidiary
NOTES
TO THE CONSOLIDATED
FINANCIAL
STATEMENTS (continued)
NOTE
13 – LEASES
Manoa
Innovation Center
The
Company entered into an automatically renewable month-to-month lease for office space on August 13, 2010. Under the terms of this
lease, the Company must provide a written notice 45 days prior to vacating the premises. Total rent expense under this agreement
as amended was $29,690 and $32,049, for the years ended December 31, 2017 and 2016, respectively.
NOTE
14 – COMMITMENTS
Patent
payable
As
part of the formation of the Company, a patent license was transferred to the Company. The original license began in 2006. Under
the terms of the license the Company agreed to pay $10,000 per year through 2015 and royalties of 2% on any revenues resulting
from the license. There were no revenues generated by this license during the years ended December 31, 2017 and 2016. The remaining
obligation of $20,000 as of December 31, 2017 and 2016, is recorded as a part of accounts payable on the consolidated balance
sheets. The license expired in February 2016.
Employee
settlement
As
of December 31, 2017 and 2016, the Company owed a former employee a severance settlement payable in the amount of $50,000 for
accrued vacation benefits. As part of the severance settlement, a stock option previously granted to the former employee was fully
vested and extended.
BASF
agreement and license
In
November 2006, the Company entered into a joint development and supply agreement with BASF SE (“BASF”). Under the
agreement, the Company granted BASF an exclusive world-wide license to the Company’s rights related to the development and
commercialization of Astaxanthin consumer health products; the Company retains all rights related to Astaxanthin pharmaceutical
products. The Company is to receive specified royalties based on future net sales of such Astaxanthin consumer health products.
No royalties were realized from this agreement during the years ended December 31, 2017 and 2016.
Capsugel
agreement
On
August 18, 2014, the Company entered into a collaboration agreement with Capsugel US, LLC (“Capsugel”) for the joint
commercial development of Astaxanthin products (“Capsugel Astaxanthin Products”) for the consumer health market that
contain nature-identical synthetic Astaxanthin and use Capsugel’s proprietary formulation technology. The agreement provides
for the parties to jointly administer activities under a product development plan that will include identifying at least one mutually
acceptable third party marketer who will further develop, market and distribute Capsugel Astaxanthin Products. Capsugel will share
revenues with the Company based on net sales of products that are developed under the collaboration. No revenues were realized
from this agreement during the years ended December 31, 2017 and 2016. In January 2016, the Company suspended development of a
Capsugel Astaxanthin Product, ASTX-1F, based on certain technical issues which, together with other business and regulatory issues,
materially impeded the formulation of ASTX-1F as a commercially viable product for the consumer health market.
Cardax,
Inc., and Subsidiary
NOTES
TO THE CONSOLIDATED
FINANCIAL
STATEMENTS (continued)
NOTE
15 – SUBSEQUENT EVENTS
The
Company evaluated all material events through the date the financials were ready for issuance and noted the following non-recognized
events for disclosure.
In
January 2018: (i) an unvested option to purchase 50,000 shares of common stock was fully vested and the expiration modified from
90 days post termination of services to September 2027; (ii) an option to purchase 500,000 shares of common stock was granted
to a service provider and shall be exercisable at $0.16 per share, vest over 4 years, and expire in 10 years; (iii) an option
to purchase 166,667 shares of common stock was granted to a service provider and shall be exercisable at $0.16 per share, vest
over 1 year, and expire in 5 years; and (iv) an option to purchase 166,667 shares of common stock was granted to an employee and
shall be exercisable at $0.16 per share, vest over 1 year, and expire in 5 years.
***
Through
and including , 2018, all dealers effecting
transactions in the registered securities offered hereby, whether or not participating in this offering, may be required to deliver
a prospectus. This delivery requirement is in addition to the obligation of dealers to deliver a prospectus when acting as an
underwriter and with respect to an unsold allotment or subscription.
Offer
to Exchange
Each
$0.625 Warrant to purchase shares of Common Stock
and
$0.15
in cash
for
Shares
of Common Stock
PROSPECTUS
,
2018
We
Are Not Asking You for a Proxy and You are Requested To Not Send Us a Proxy
PART
II
INFORMATION
NOT REQUIRED IN PROSPECTUS
Item
20. Indemnification of Directors and Officers
Our
amended and restated certificate of incorporation and bylaws limit our directors’ and officers’ liability to the fullest
extent permitted under Delaware corporate law. Specifically, our directors and officers are not liable to us or our stockholders
for monetary damages for any breach of fiduciary duty by a director or officer, except for liability:
|
●
|
for
any breach of the director’s or officer’s duty of loyalty to us or our stockholders;
|
|
|
|
|
●
|
for
acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law;
|
|
|
|
|
●
|
under
Section 174 of the Delaware General Corporation Law; or
|
|
|
|
|
●
|
for
any transaction from which a director or officer derives an improper personal benefit.
|
If
the Delaware General Corporation Law is amended to authorize corporate action further eliminating or limiting the personal liability
of directors or officers, then the liability of our directors or officers shall be eliminated or limited to the fullest extent
permitted by the Delaware General Corporation Law, as so amended.
The
provision regarding indemnification of our directors and officers in our amended and restated certificate of incorporation generally
does not limit liability under state or federal securities laws.
Delaware
law and our amended and restated certificate of incorporation and bylaws provide that we will, in certain situations, indemnify
any person made or threatened to be made a party to a proceeding by reason of that person’s former or present official capacity
with our company against judgments, penalties, fines, settlements and reasonable expenses including reasonable attorney’s
fees. Any person is also entitled, subject to certain limitations, to payment or reimbursement of reasonable expenses in advance
of the final disposition of the proceeding.
The
limitation of liability and indemnification provisions in our amended and restated certificate of incorporation may discourage
stockholders from bringing a lawsuit against directors for breach of their fiduciary duty. These provisions may also have the
effect of reducing the likelihood of derivative litigation against directors and officers, even though such an action, if successful,
might otherwise benefit us and our stockholders. In addition, your investment may be adversely affected to the extent that, in
a class action or direct suit, we pay the costs of settlement and damage awards against directors and officers pursuant to these
indemnification provisions.
Insofar
as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers or persons
controlling the Company pursuant to Delaware law, we are informed that in the opinion of the Securities and Exchange Commission,
such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.
Item
21. Exhibits and Financial Statement Schedules.
(a)
Exhibits
Exhibit
No.
|
|
Description
|
|
|
|
2.1
|
|
Agreement
and Plan of Merger, dated as of November 27, 2013, by and among Koffee Korner Inc., Cardax Acquisition, Inc., Cardax Pharmaceuticals,
Inc. and Cardax Pharma, Inc.
(1)
|
|
|
|
2.2
|
|
First
Amendment to the Agreement and Plan of Merger, dated as of January 10, 2014, by and among Koffee Korner Inc., Cardax Acquisition,
Inc., Cardax Pharmaceuticals, Inc. and Cardax Pharma, Inc.
(2)
|
|
|
|
2.3
|
|
Second
Amendment to the Agreement and Plan of Merger, dated as of February 7, 2014, by and among Koffee Korner Inc., Cardax Acquisition,
Inc., Cardax Pharmaceuticals, Inc. and Cardax Pharma, Inc.
(3)
|
|
|
|
2.4
|
|
Amended
and Restated Agreement and Plan of Merger, dated as of November 24, 2015 by and among Cardax Pharmaceuticals, Inc. and Cardax,
Inc.
(4)
|
|
|
|
3.1
|
|
Certificate
of Incorporation, as amended, of Cardax, Inc.
(2)
|
|
|
|
3.2
|
|
Amended
and Restated Bylaws of Cardax, Inc.
(2)
|
4.1
|
|
Form
of specimen certificate representing Common Stock of Cardax, Inc.
(3)
|
|
|
|
4.2
|
|
Form
of Class A Warrant
(3)
|
|
|
|
4.3
|
|
Form
of Noteholder Warrant
(3)
|
|
|
|
4.4
|
|
Form
of Placement Agent Warrant
(3)
|
|
|
|
4.5
|
|
Form
of Financial Consultant Warrant
(3)
|
|
|
|
4.6
|
|
Form
of Warrant issued to JLS Ventures, LLC
(3)
|
|
|
|
5.1
|
|
Opinion
of Herrick, Feinstein LLP**
|
|
|
|
10.1
|
|
Cardax,
Inc. 2014 Equity Compensation Plan
(2)
|
|
|
|
10.2
|
|
Form
of Stock Option Agreement under the 2014 Equity Compensation Plan
(3)
|
|
|
|
10.3
|
|
Form
of Notice of Stock Option Grant under the 2014 Equity Compensation Plan
(3)
|
|
|
|
10.4
|
|
Form
of Notice of Stock Option Grant In Substitution of Stock Option Grant under the Cardax Pharmaceuticals, Inc. 2006 Equity Compensation
Plan
(3)
|
|
|
|
10.5
|
|
Stock
Purchase Agreement, dated as of January 10, 2014, by and among Koffee Korner Inc., Cardax Pharmaceuticals, Inc. and Cardax
Pharma, Inc.
(2)
|
10.6
|
|
Spin-off
Agreement, dated as of February 7, 2014, between Koffee Korner Inc. and Nazneen D’Silva
(3)
|
|
|
|
10.7
|
|
Senior
Executive Employment Agreement, dated February 7, 2014, of David G. Watumull and the supplement thereto dated June 30, 2015
(3)
|
|
|
|
10.8
|
|
Senior
Executive Employment Agreement, dated February 7, 2014, of David M. Watumull
(3)
|
|
|
|
10.9
|
|
Senior
Executive Employment Agreement, dated February 7, 2014, of Gilbert M. Rishton
(3)
|
|
|
|
10.10
|
|
Senior
Executive Employment Agreement, dated February 7, 2014, of Timothy J. King
(3)
|
|
|
|
10.11
|
|
Agreement
for Services as the Executive Chairman dated February 7, 2014, by and between Cardax, Inc. and Nicholas Mitsakos
(3)
|
|
|
|
10.12
|
|
Form
of Indemnification Agreement
(5)
|
|
|
|
10.13
|
|
Form
of Independent Board of Directors Agreement
(5)
|
10.14
|
|
Joint
Development and Supply Agreement effective on November 15, 2006, by and between BASF Aktiengesellschaft and Cardax Pharmaceuticals,
Inc., as amended by Amendment No. 1 to Joint Development and Supply Agreement effective on April 15, 2007
(6)
|
|
|
|
10.15
|
|
Collaboration
Agreement, dated as of August 18, 2014, by and between Capsugel US, LLC and its affiliates and Cardax, Inc. and its affiliates
(7)
|
|
|
|
10.16
|
|
Form
of Registration Rights Agreement
(8)
|
|
|
|
10.17
|
|
Form
of Subscription Agreement
(8)
|
|
|
|
10.18
|
|
Form
of Class D Warrant
(8)
|
|
|
|
10.19
|
|
Form
of Class E Warrant
(8)
|
|
|
|
10.20
|
|
Supplement
to Agreement of the Executive Chairman
(9)
|
|
|
|
10.21
|
|
Independent
Directors’ Compensation Agreement
(9)
|
|
|
|
10.22
|
|
Supplement
to Senior Executive Employment Agreement of David G. Watumull
(9)
|
|
|
|
10.23
|
|
Payment
Deferral and Acceptance Agreement of JBR Business Solutions, LLC
(9)
|
|
|
|
10.24
|
|
Form
of Payment Deferral and Acceptance Agreement
(9)
|
|
|
|
10.25
|
|
Form
of Subscription Agreement
(10)
|
|
|
|
10.26
|
|
Form
of Equity Purchase Agreement
(11)
|
|
|
|
10.27
|
|
Form
of Subscription Agreement
(12)
|
|
|
|
10.28
|
|
Form
of Subscription Agreement
(13)
|
|
|
|
10.29
|
|
Exclusivity
Agreement, dated as of October 16, 2017, by and between Cardax, Inc. and General Nutrition Corporation
(13)
|
|
|
|
21.1
|
|
Subsidiaries
of Cardax, Inc.
(3)
|
|
|
|
23.1
|
|
Consent
of KBL, LLP*
|
|
|
|
23.2
|
|
Consent
of Herrick, Feinstein LLP (contained in the Opinion of Herrick, Feinstein, LLP under Exhibit 5.1)
|
|
|
|
99.1
|
|
Letter
to Warrant Holders*
|
|
|
|
99.2
|
|
Letter
of Transmittal*
|
101.INS
|
|
XBRL
Instance Document
|
|
|
|
101.SCH
|
|
XBRL
Taxonomy Extension Schema Document
|
|
|
|
101.CAL
|
|
XBRL
Taxonomy Extension Calculation Linkbase Document
|
|
|
|
101.DEF
|
|
XBRL
Taxonomy Extension Definition Linkbase Document
|
|
|
|
101.LAB
|
|
XBRL
Taxonomy Extension Label Linkbase Document
|
|
|
|
101.PRE
|
|
XBRL
Taxonomy Extension Presentation Linkbase Document
|
*
|
Filed
herein.
|
|
|
**
|
To
be provided by amendment.
|
|
|
(1)
|
Filed
as an exhibit to the Current Report on Form 8-K of the Company dated November 27, 2013.
|
|
|
(2)
|
Filed
as an exhibit to the Current Report on Form 8-K of the Company dated January 13, 2014.
|
|
|
(3)
|
Filed
as an exhibit to the Current Report on Form 8-K of the Company dated February 10, 2014.
|
|
|
(4)
|
Filed
as an exhibit to the Current Report on Form 8-K of the Company dated November 24, 2015.
|
|
|
(5)
|
Filed
as an exhibit to Amendment No. 1 of the Registration Statement on Form S-1 of the Company dated September 2, 2014.
|
(6)
|
Filed
as an exhibit to the Current Report on Form 8-K/A of the Company dated April 16, 2014. Confidential treatment has been requested
for this exhibit, and confidential portions have been filed separately with the SEC.
|
|
|
(7)
|
Filed
as an exhibit to the Current Report on Form 8-K/A of the Company dated December 3, 2014.
|
|
|
|
Confidential
treatment has been requested for this exhibit, and confidential portions have been filed separately with the SEC.
|
(8)
|
Filed
as an exhibit to the Current Report on Form 8-K of the Company filed March 9, 2015.
|
|
|
(9)
|
Filed
as an exhibit to the Current Report on Form 8-K of the Company filed July 7, 2015.
|
|
|
(10)
|
Filed
as an exhibit to the Quarterly Report on Form 10-Q of the Company filed May 13, 2016.
|
|
|
(11)
|
Filed
as an exhibit to the Current Report on Form 8-K of the Company dated July 13, 2016.
|
|
|
(12)
|
Filed
as an exhibit to the Annual Report on Form 10-K of the Company filed March 31, 2017.
|
|
|
(13)
|
Filed
as an exhibit to the Current Report on Form 8-K of the Company filed November 14, 2017.
|
(b)
Financial Statement Schedules
All
financial statement schedules are included in the Registrant’s consolidated financial statements and the related notes thereto,
or are inapplicable or otherwise not required.
Item
22. Undertakings
The
undersigned Registrant hereby undertakes:
(1)
To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:
(i)
to include any prospectus required by Section 10(a)(3) of the Securities Act of 1933, as amended (the “Act”);
(ii)
to reflect in the prospectus any facts or events arising after the effective date of this registration statement (or the most-recent
post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set
forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if
the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high
end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule
424(b) if, in the aggregate, the changes in volume and price represent no more than a 20 percent change in the maximum aggregate
offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement;
(iii)
to include any material information with respect to the plan of distribution not previously disclosed in the registration statement
or any material change to such information in the registration statement.
(2)
That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall
be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at
that time shall be deemed to be the initial bona fide offering thereof.
(3)
To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold
at the termination of the offering.
(4)
That, for the purpose of determining liability under the Securities Act of 1933, as amended, to any purchaser: if the registrant
is subject to Rule 430C, each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering,
other than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed
to be part of and included in the registration statement as of the date it is first used after effectiveness. Provided, however,
that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document
incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration
statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that
was made in the registration statement or prospectus that was part of the registration statement or made in any such document
immediately prior to such date of first use.
(5)
That, for the purpose of determining liability of the registrant under the Securities Act of 1933, as amended, to any purchaser
in the initial distribution of the securities, the undersigned registrant undertakes that in a primary offering of securities
of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the
securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications,
the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:
(i)
Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant
to Rule 424;
(ii)
Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred
to by the undersigned registrant;
(iii)
The portion of any other free writing prospectus relating to the offering containing material information about the undersigned
registrant or its securities provided by or on behalf of the undersigned registrant; and
(iv)
Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.
(6)
The undersigned registrant hereby undertakes as follows: that prior to any public reoffering of the securities registered hereunder
through use of a prospectus, which is a part of this Registration Statement, by any person or party who is deemed to be an underwriter
within the meaning of Rule 145(c), the issuer undertakes that such reoffering prospectus will contain the information called for
by the applicable registration form with respect to reofferings by persons who may be deemed underwriters, in addition to the
information called for by the other items of the applicable form.
(7)
The registrant undertakes that every prospectus: (i) that is filed pursuant to the immediately preceding paragraph, or (ii) that
purports to meet the requirements of Section 10(a)(3) of the Securities Act of 1933, as amended, and is used in connection with
an offering of securities subject to Rule 415, will be filed as a part of an amendment to the registration statement and will
not be used until such amendment is effective, and that, for purposes of determining any liability under the Securities Act of
1933, as amended, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities
offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
(8)
Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers or
persons controlling the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been informed that in
the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and
is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by
the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense
of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities
being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent,
submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed
in the Act and will be governed by the final adjudication of such issue.
(9)
The undersigned registrant hereby undertakes to respond to requests for information that is incorporated by reference into the
prospectus pursuant to Items 4, 10(b), 11 or 13 of this Form, within one business day of receipt of such request, and to send
the incorporated documents by first class mail or other equally prompt means. This includes information contained in documents
filed subsequent to the effective date of the registration statement through the date of responding to the request.
(10)
The undersigned registrant hereby undertakes to supply by means of a post-effective amendment all information concerning a transaction,
and the company being acquired involved therein, that was not the subject of and included in the registration statement when it
became effective.
SIGNATURES
Pursuant
to the requirements of the Securities Act of 1933, the Registrant has duly caused this registration statement to be filed on its
behalf by the undersigned, thereunto duly authorized in the City and County of Honolulu, State of Hawaii on May 2, 2018.
|
CARDAX,
INC.
|
|
|
|
|
By:
|
/s/
David G. Watumull
|
|
Name:
|
David
G. Watumull
|
|
Title:
|
President
& Chief Executive Officer
|
Pursuant
to the requirements of the Securities Act of 1933, this Registration Statement on Form S-4 has been signed by the following persons
in the capacities and on the dates indicated.
Signature
|
|
Title
|
|
Date
|
|
|
|
|
|
/s/
David G. Watumull
|
|
President,
Chief Executive Officer, and Director
|
|
May
2, 2018
|
David
G. Watumull
|
|
|
|
|
|
|
|
|
|
/s/
John B. Russell
|
|
Chief
Financial Officer and Treasurer
|
|
May
2, 2018
|
John
B. Russell
|
|
|
|
|
|
|
|
|
|
/s/
George W. Bickerstaff, III
|
|
Chairman
|
|
May
2, 2018
|
George
W. Bickerstaff, III
|
|
|
|
|
|
|
|
|
|
/s/
Terence A. Kelly
|
|
Director
|
|
May
2, 2018
|
Terence
A. Kelly, Ph.D.
|
|
|
|
|
|
|
|
|
|
/s/
Michele Galen
|
|
Director
|
|
May
2, 2018
|
Michele
Galen
|
|
|
|
|
POWER
OF ATTORNEY
KNOW
ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints David G. Watumull,
as his or her true and lawful attorney-in-fact and agent, with full power of substitution, for him in any and all capacities,
to sign this Registration Statement and any and all amendments to this Registration Statement, including post-effective amendments
or any abbreviated registration statement and any amendments thereto filed pursuant to Rule 462(b) increasing the number of securities
for which registration is sought, and to file the same, with all exhibits thereto and other documents in connection therewith,
with the SEC, granting unto said attorney-in-fact and agents, with full power of each to act alone, full power and authority to
do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents
and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or
his or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant
to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the
capacities and on the date indicated.
Signature
|
|
Title
|
|
Date
|
|
|
|
|
|
/s/
David G. Watumull
|
|
President,
Chief Executive Officer, and Director
|
|
May
2, 2018
|
David
G. Watumull
|
|
|
|
|
|
|
|
|
|
/s/
John B. Russell
|
|
Chief
Financial Officer and Treasurer
|
|
May
2, 2018
|
John
B. Russell
|
|
|
|
|
|
|
|
|
|
/s/
George W. Bickerstaff, III
|
|
Chairman
|
|
May
2, 2018
|
George
W. Bickerstaff, III
|
|
|
|
|
|
|
|
|
|
/s/
Terence A. Kelly
|
|
Director
|
|
May
2, 2018
|
Terence
A. Kelly, Ph.D.
|
|
|
|
|
|
|
|
|
|
/s/
Michele Galen
|
|
Director
|
|
May
2, 2018
|
Michele
Galen
|
|
|
|
|
Cardax (CE) (USOTC:CDXI)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
Cardax (CE) (USOTC:CDXI)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024